



(86) Date de dépôt PCT/PCT Filing Date: 2001/01/25
(87) Date publication PCT/PCT Publication Date: 2001/08/02
(85) Entrée phase nationale/National Entry: 2002/07/24
(86) N° demande PCT/PCT Application No.: US 2001/002570
(87) N° publication PCT/PCT Publication No.: 2001/055335
(30) Priorités/Priorities: 2000/01/25 (09/491,404) US;
2000/02/03 (09/496,914) US; 2000/03/07 (09/519,705) US;
2000/04/27 (09/560,875) US; 2000/05/19 (09/524,454) US;
2000/08/17 (09/642,610) US; 2000/12/29 (09/751,518) US

(51) Cl.Int.⁷/Int.Cl.⁷ C12Q 1/68, A61K 38/00, C07H 21/02

(71) Demandeur/Applicant:
HYSEQ, INC., US

(72) Inventeurs/Inventors:
BOYLE, BRYAN J., US;
KUO, CHIAUYUN, US;
MIZE, NANCY K., US;
HALEY, DANA A., US;
ARTERBURN, MATTHEW C., US;
TANG, Y. TOM, US;
ZHOU, PING, US;
...

(74) Agent: SMART & BIGGAR

(54) Titre : PROCEDES ET MATERIAUX SE RAPPORTANT A DES POLYPEPTIDES ET POLYNUCLEOTIDES
SEMBLABLES A DES RECEPTEURS DE LEUCOCYTES DE TYPE IMMUNOGLOBULINE (LIR)

(54) Title: METHODS AND MATERIALS RELATING TO LEUKOCYTE IMMUNOGLOBULIN RECEPTOR-LIKE (LIR-
LIKE) POLYPEPTIDES AND POLYNUCLEOTIDES

(57) **Abrégé/Abstract:**

The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted leukocyte immunoglobulin receptor-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA libraries prepared from a cDNA library prepared from human leukocyte mRNA (GIBCO Laboratories) (SEQ ID NO: 1, SEQ ID NO: 16); from infant brain mRNA (Columbia University) (SEQ ID NO: 35); from human mammary gland mRNA (Invitrogen) (SEQ ID NO: 47); and from bone marrow mRNA (Clontech) (SEQ ID NO: 63). Other aspects of the invention include vectors containing processes for producing novel human secreted LIR-like polypeptides, and antibodies specific for such polypeptides.



(72) **Inventeurs(suite)/Inventors(continued)**: LIU, CHENGHUA, US; ASUNDI, VINOD, US; DRMANAC, RADOJE T., US; YEUNG, GEORGE, US; PALENCIA, SERVANDO, US

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 August 2001 (02.08.2001)

PCT

(10) International Publication Number
WO 01/55335 A3

(51) International Patent Classification⁷: **C12Q 1/68**,
A61K 38/00, C07H 21/02

(21) International Application Number: PCT/US01/02570

(22) International Filing Date: 25 January 2001 (25.01.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

09/491,404	25 January 2000 (25.01.2000)	US
09/496,914	3 February 2000 (03.02.2000)	US
09/519,705	7 March 2000 (07.03.2000)	US
09/560,875	27 April 2000 (27.04.2000)	US
09/524,454	19 May 2000 (19.05.2000)	US
09/642,610	17 August 2000 (17.08.2000)	US
09/751,518	29 December 2000 (29.12.2000)	US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US	09/491,404 (CIP)
Filed on	25 January 2000 (25.01.2000)
US	09/496,914 (CIP)
Filed on	3 February 2000 (03.02.2000)
US	09/519,705 (CIP)
Filed on	7 March 2000 (07.03.2000)
US	09/560,875 (CIP)
Filed on	27 April 2000 (27.04.2000)
US	09/524,454 (CIP)
Filed on	19 May 2000 (19.05.2000)
US	09/642,610 (CIP)
Filed on	17 August 2000 (17.08.2000)
US	09/751,518 (CIP)
Filed on	29 December 2000 (29.12.2000)

(71) Applicant (for all designated States except US): **HYSEQ, INC.** [US/US]; 670 Almanor Avenue, Sunnyvale, CA 94086 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BOYLE, Bryan, J.** [US/US]; 1947 10th Avenue, San Francisco, CA 94116 (US). **KUO, Chiauyun** [US/US]; 2121 Limewood Drive,

San Jose, CA 95132 (US). **MIZE, Nancy, K.** [US/US]; 662 Mountain View Avenue, Mountain View, CA 94041 (US). **HALEY, Dana, A.** [US/US]; 1430 Glenwood Avenue, San Jose, CA 95125 (US). **ARTERBURN, Matthew, C.** [US/US]; 5910 Via Del Cielo, Pleasanton, CA 94566 (US). **TANG, Y., Tom** [US/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). **ZHOU, Ping** [CN/US]; 1461 Japaul Lane, San Jose, CA 95132 (US). **LIU, Chenghua** [CN/US]; 1125 Ranchero Way, #14, San Jose, CA 95117 (US). **ASUNDI, Vinod** [US/US]; 709 Foster City Boulevard, Foster City, CA 94404 (US). **DRMANAC, Radoje, T.** [YU/US]; 850 East Greenwich Place, Palo Alto, CA 94303 (US). **YEUNG, George** [CN/US]; 102 Magnolia Lane, Mountain View, CA 94043 (US). **PALENCIA, Servando** [MX/US]; 522 Columbia Street, Santa Cruz, CA 95060 (US).

(74) Agent: **ELRIFI, Ivor, R.**; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
7 March 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS AND MATERIALS RELATING TO LEUKOCYTE IMMUNOGLOBULIN RECEPTOR-LIKE (LIR-LIKE) POLYPEPTIDES AND POLYNUCLEOTIDES

(57) Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted leukocyte immunoglobulin receptor-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA libraries prepared from a cDNA library prepared from human leukocyte mRNA (GIBCO Laboratories) (SEQ ID NO: 1, SEQ ID NO: 16); from infant brain mRNA (Columbia University) (SEQ ID NO: 35); from human mammary gland mRNA (Invitrogen) (SEQ ID NO: 47); and from bone marrow mRNA (Clontech) (SEQ ID NO: 63). Other aspects of the invention include vectors containing processes for producing novel human secreted LIR-like polypeptides, and antibodies specific for such polypeptides.



WO 01/55335 A3

**METHODS AND MATERIALS RELATING TO
LEUKOCYTE IMMUNOGLOBULIN RECEPTOR-LIKE (LIR-LIKE)
POLYPEPTIDES AND POLYNUCLEOTIDES**

1 TECHNICAL FIELD

The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with uses for these polynucleotides and proteins, for example in therapeutic, diagnostic and research methods. In particular, the invention relates to a novel leukocyte immunoglobulin receptor-like polypeptide (LIR-like).

2 BACKGROUND ART

Identified polynucleotide and polypeptide sequences have numerous applications in, for example, diagnostics, forensics, gene mapping; identification of mutations responsible for genetic disorders or other traits, to assess biodiversity, and to produce many other types of data and products dependent on DNA and amino acid sequences. Proteins are known to have biological activity, for example, by virtue of their secreted nature in the case of leader sequence cloning, by virtue of their cell or tissue source in the case of PCR-based techniques, or by virtue of structural similarity to other genes of known biological activity. It is to these polypeptides and the polynucleotides encoding them that the present invention is directed. In particular, this invention is directed to a novel soluble LIR-like polypeptides and polynucleotides.

Immune system functions are governed by a complex network of cell surface interactions and associated signaling processes. When a cell surface receptor is activated by its ligand a signal is sent into the cell; depending upon the signal transduction pathway that is engaged, the signal can be inhibitory or activatory. For many receptor systems cellular activity is regulated by a balance between activatory signals and inhibitory signals.

The biochemical mechanisms of these positive and negative signaling pathways are being analyzed for a number of known immune system receptor and ligand interactions. Many activating receptors (ARs) that mediate positive signaling have cytoplasmic tails containing sites of tyrosine phosphorylation known as immunoreceptor tyrosine-based activation motifs (ITAM). The inhibitory pathways involve receptors having immunoreceptor tyrosine based inhibitory motifs (ITIM) which, like the ITAMs, are phosphorylated by tyrosine kinases. Receptors having these motifs are involved in inhibitory signaling because these motifs

provided binding sites for tyrosine phosphatases which block signaling by removing phosphate from activated receptors or signal transduction molecules.

The cytolytic activity of Natural Killer (NK) cells is an example of immune system activity which is regulated by a balance between positive signals that initiate cell function and inhibitory signals which prevent the activity. The receptors that activate NK cytotoxicity are not fully understood. If the target cell expresses cell surface MHC class I antigens for which the NK cell has a specific receptor, the NK cell is inhibited from killing the target cell. These specific NK cell receptors, known as Killer Inhibitory Receptors (KIRs) send a negative signal when engaged by their MHC ligand, downregulating NK cell cytotoxic activity. A cytoplasmic domain amino acid sequence common to many of the KIRs is an ITIM motif having the sequence I/L/VxYxxL/V, where "x" is any amino acid (SEQ ID NO: 77).

KIRs belong to either the immunoglobulin superfamily or the C-type lectin family. Immunoglobulin (Ig) superfamily genes encode for diverse proteins characterized by a common Ig fold. The Ig superfamily proteins include antibodies, T cell receptors, B cell receptors, NK, myeloid and leukocyte immunoglobulin receptors like killer inhibitory receptors (KIRs) and activating receptors (ARs). (Hawke, NA, Yoder, JA, Litman, GW Immunogenetics 1999 Nov; 50(3-4): 124-33. Soluble forms of some of these membrane receptors, like FDF03 and CD54, are described and may serve as markers for pathologic conditions (Borges and Cosman (2000). Cytokine and Growth Factor Reviews, 11, 209-217). Ig Variable domains are utilized to create a specific binding site while Ig Constant domains may serve as more conserved counter receptor binding module. Recently, CMRF-35 and PIGR-1 immunoglobulin members have been cloned that have only one Ig-variable domain (Shujian et al (1999). EP 0897981A1, incorporated herein by reference).

It is becoming apparent that inhibitory receptors are present on most of the haemopoietic cells, including dendritic cells, monocytes, CD19+ B cells; and CD3+ T cells (Borges and Cosman (2000). Cytokine and Growth Factor Reviews, 11, 209-217; De Maria, AD et al, (1997) Proc. Natl. Acad. Sci. USA, 94, 10285-88). An immunoreceptor expressed by mast cells is also known to downregulate cell activation signals (International Patent Application No. WO98/48017). These receptors can be classified into three groups according to their cytoplasmic domain characteristics. Transmembrane molecules with immunoreceptor tyrosine activation motifs (ITAMs) (YxxL where x is any amino acid, SEQ ID NO: 78) are activating receptors. Those with immunoreceptor tyrosine inhibition motifs (ITIMs) (I/L/VxxYxxL/V where x is any amino acid, SEQ ID NO: 77) are inhibitory in nature. A third class of transmembrane receptors, like LIR-4, lack a cytoplasmic tail with an activation

or an inhibition motif. Rather, these proteins contain a positively charged arginine residue within their transmembrane domain, which allows them to interact with transducer molecules such as CD3 ζ , Fc ϵ RI γ , or KARAP/DAP12. These proteins contain a negatively charged aspartic acid residue in their transmembrane region, allowing them to interact with the immunoglobulin receptor and have an ITAM, or possibly ITIM, motif within their cytoplasmic tail to initiate signal transduction.

The receptors on NK and T cells have been shown to mediate innate immunity and play a major role in bone marrow graft rejection as well as in killing certain virus-infected and melanoma cells. Immunoglobulin receptors have also been implicated in mediating autoimmune reactions. More recently, they have also been shown to be required for development and maturation of dendritic cells (Fournier et al, (2000). J. Immunol. 165, 1197-1209). It has been shown that addition of anti Ig receptor monoclonal antibody to T cells induced their cytolytic activity for HIV infected target cells. It is apparent that the down regulation of an inhibitory receptor could lead to generalized activation of NK/T cells, which may cause autoimmune disorders like rheumatoid arthritis, multiple sclerosis (MS), systemic lupus erythematosus (SLE), psoriasis, and inflammatory bowel disease (IBD) among others.

Clearly, the immune systems activatory and inhibitory signals mediated by opposing kinases and phosphatases are very important for maintaining balance in the immune systems. Systems with a predominance of activatory signals will lead to autoimmunity and inflammation. Immune systems with a predominance of inhibitory signals are less able to challenge infected cells or cancer cells. Isolating new activatory or inhibitory receptors is highly desirable for studying the biological signal(s) transduced via the receptor. Additionally, identifying such molecules provides a means of regulating and treating diseased states associated with autoimmunity, inflammation and infection.

For example, engaging a newly discovered cell surface receptor having ITIM motifs with an agonistic antibody or ligand can be used to downregulate a cell function in disease states in which the immune system is overactive and excessive inflammation or immunopathology is present. On the other hand, using an antagonistic antibody specific to the receptor or a soluble form of the receptor can be used to block the interaction of the cell surface receptor with the receptor's ligand to activate the specific immune function in disease states associated with suppressed immune function. Conversely, since receptors lacking the ITIM motifs, or containing the ITAM motifs, send activatory signals once bound to the appropriate ligand, the effect of the administration of antibodies and soluble receptors is the

opposite of that just described and could be used to effect killing of cancer, or virus-infected cells.

3. SUMMARY OF THE INVENTION

5 This invention is based on the discovery of novel LIR-like polypeptides, novel isolated polynucleotides encoding such polypeptides, including recombinant DNA molecules, cloned genes or degenerate variants thereof, especially naturally occurring variants such as allelic variants, antisense polynucleotide molecules, and antibodies that specifically recognize one or more epitopes present on such polypeptides, as well as hybridomas producing such antibodies.

10 Specifically, the polynucleotides of the present invention are based on an LIR-like polynucleotide isolated from a cDNA library prepared from human leukocyte mRNA (GIBCO Laboratories) (SEQ ID NO: 1, SEQ ID NO: 16); from infant brain mRNA (Columbia University) (SEQ ID NO: 35); from human mammary gland mRNA (Invitrogen) (SEQ ID NO: 47); and from bone marrow mRNA (Clontech) (SEQ ID NO: 63).

15 The compositions of the present invention additionally include vectors such as expression vectors containing the polynucleotides of the invention, cells genetically engineered to contain such polynucleotides and cells genetically engineered to express such polynucleotides.

The compositions of the invention provide isolated polynucleotides that include, but are not limited to, a polynucleotide comprising the nucleotide sequence set forth in the SEQ ID NO: 20 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67; or a fragment of SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67; a polynucleotide comprising the full length protein coding sequence of the SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67 (for example, SEQ ID NO: 3, 6, 19, 25 22, 37, 40, 50, or 66); and a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of any of SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67. The polynucleotides of the present invention also include, but are not limited to, a polynucleotide that hybridizes under stringent hybridization conditions to (a) the complement of any of the nucleotide sequences set forth in SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67; (b) a nucleotide sequence encoding any of 30 SEQ ID NO: 3, 6, 8-13, 19, 22, 24-28, 33-34, 37, 40, 42-45, 50, 52-58, 66, or 68-74; a polynucleotide which is an allelic variant of any polynucleotides recited above having at least 70% polynucleotide sequence identity to the polynucleotides; a polynucleotide which encodes a species homolog (e.g. orthologs) of any of the peptides recited above; or a polynucleotide that encodes a

polypeptide comprising a specific domain or truncation of the polypeptide comprising SEQ ID NO: 3, 6, 19, 22, 37, 40, 50, or 66.

A collection as used in this application can be a collection of only one polynucleotide. The collection of sequence information or unique identifying information of each sequence can be provided on a nucleic acid array. In one embodiment, segments of sequence information are provided on a nucleic acid array to detect the polynucleotide that contains the segment. The array can be designed to detect full-match or mismatch to the polynucleotide that contains the segment. The collection can also be provided in a computer-readable format.

This invention further provides cloning or expression vectors comprising at least a fragment of the polynucleotides set forth above and host cells or organisms transformed with these expression vectors. Useful vectors include plasmids, cosmids, lambda phage derivatives, phagemids, and the like, that are well known in the art. Accordingly, the invention also provides a vector including a polynucleotide of the invention and a host cell containing the polynucleotide. In general, the vector contains an origin of replication functional in at least one organism, convenient restriction endonuclease sites, and a selectable marker for the host cell. Vectors according to the invention include expression vectors, replication vectors, probe generation vectors, and sequencing vectors. A host cell according to the invention can be a prokaryotic or eukaryotic cell and can be a unicellular organism or part of a multicellular organism.

The compositions of the present invention include polypeptides comprising, but not limited to, an isolated polypeptide selected from the group comprising the amino acid sequence of SEQ ID NO: 3, 6, 8-13, 19, 22, 24-28, 33-34, 37, 40, 42-45, 50, 52-58, 66, or 68-74; or the corresponding full length or mature protein. Polypeptides of the invention also include polypeptides with biological activity that are encoded by (a) any of the polynucleotides having a nucleotide sequence set forth in the SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67; or (b) polynucleotides that hybridize to the complement of the polynucleotides of (a) under stringent hybridization conditions. Biologically or immunologically active variants of any of the protein sequences listed as SEQ ID NO: 3, 6, 8-13, 19, 22, 24-28, 33-34, 37, 40, 42-45, 50, 52-58, 66, or 68-74, and substantial equivalents thereof that retain biological or immunological activity are also contemplated. The polypeptides of the invention may be wholly or partially chemically synthesized but are preferably produced by recombinant means using the genetically engineered cells (e.g. host cells) of the invention.

The invention also provides compositions comprising a polypeptide of the invention. Pharmaceutical compositions of the invention may comprise a polypeptide of the invention and an acceptable carrier, such as a hydrophilic, e.g., pharmaceutically acceptable, carrier.

The invention also relates to methods for producing a polypeptide of the invention comprising culturing host cells comprising an expression vector containing at least a fragment of a polynucleotide encoding the polypeptide of the invention in a suitable culture medium under conditions permitting expression of the desired polypeptide, and purifying the protein or peptide from the culture or from the host cells. Preferred embodiments include those in which the protein produced by such a process is a mature form of the protein.

Polynucleotides according to the invention have numerous applications in a variety of techniques known to those skilled in the art of molecular biology. These techniques include use as hybridization probes, use as oligomers, or primers, for PCR, use in an array, use in computer-readable media, use for chromosome and gene mapping, use in the recombinant production of protein, and use in generation of antisense DNA or RNA, their chemical analogs and the like. For example, when the expression of an mRNA is largely restricted to a particular cell or tissue type, polynucleotides of the invention can be used as hybridization probes to detect the presence of the particular cell or tissue mRNA in a sample using, *e.g.*, *in situ* hybridization.

In other exemplary embodiments, the polynucleotides are used in diagnostics as expressed sequence tags for identifying expressed genes or, as well known in the art and exemplified by Vollrath et al., Science 258:52-59 (1992), as expressed sequence tags for physical mapping of the human genome.

The polypeptides according to the invention can be used in a variety of conventional procedures and methods that are currently applied to other proteins. For example, a polypeptide of the invention can be used to generate an antibody that specifically binds the polypeptide. Such antibodies, particularly monoclonal antibodies, are useful for detecting or quantitating the polypeptide in tissue. The polypeptides of the invention can also be used as molecular weight markers, and as a food supplement.

Methods are also provided for preventing, treating, or ameliorating a medical condition which comprises the step of administering to a mammalian subject a therapeutically effective amount of a composition comprising a peptide of the present invention and a pharmaceutically acceptable carrier.

In particular, the polypeptides and polynucleotides of the invention can be utilized, for example, as part of methods for the prevention and/or treatment of immunological diseases such as rheumatoid arthritis, multiple sclerosis, psoriasis, systemic lupus erythematosus and inflammatory bowel disease. The polynucleotides and polypeptides may also be beneficial in the treatment of viral infections and in the treatment of some forms of cancer.

The methods of the invention also provides methods for the treatment of disorders as recited herein which comprise the administration of a therapeutically effective amount of a composition comprising a polynucleotide or polypeptide of the invention and a pharmaceutically acceptable carrier to a mammalian subject exhibiting symptoms or tendencies related to disorders as recited herein. In addition, the invention encompasses methods for treating diseases or disorders as recited herein comprising the step of administering a composition comprising compounds and other substances that modulate the overall activity of the target gene products and a pharmaceutically acceptable carrier. Compounds and other substances can effect such modulation either on the level of target gene/protein expression or target protein activity. Specifically, methods are provided for preventing, treating or ameliorating a medical condition, including viral diseases, which comprises administering to a mammalian subject, including but not limited to humans, a therapeutically effective amount of a composition comprising a polypeptide of the invention or a therapeutically effective amount of a composition comprising a binding partner of (e.g., antibody specifically reactive for) LIR-like polypeptides of the invention. The mechanics of the particular condition or pathology will dictate whether the polypeptides of the invention or binding partners (or inhibitors) of these would be beneficial to the individual in need of treatment.

According to this method, polypeptides of the invention can be administered to produce an *in vitro* or *in vivo* inhibition of cellular function. A polypeptide of the invention can be administered *in vivo* alone or as an adjunct to other therapies. Conversely, protein or other active ingredients of the present invention may be included in formulations of a particular agent to minimize side effects of such an agent.

The invention further provides methods for manufacturing medicaments useful in the above-described methods.

The present invention further relates to methods for detecting the presence of the polynucleotides or polypeptides of the invention in a sample (e.g., tissue or sample). Such methods can, for example, be utilized as part of prognostic and diagnostic evaluation of disorders as recited herein and for the identification of subjects exhibiting a predisposition to such conditions.

The invention provides a method for detecting a polypeptide of the invention in a sample comprising contacting the sample with a compound that binds to and forms a complex with the polypeptide under conditions and for a period sufficient to form the complex and detecting formation of the complex, so that if a complex is formed, the polypeptide is detected.

The invention also provides kits comprising polynucleotide probes and/or monoclonal antibodies, and optionally quantitative standards, for carrying out methods of the invention. Furthermore, the invention provides methods for evaluating the efficacy of drugs, and monitoring the progress of patients, involved in clinical trials for the treatment of disorders as recited above.

The invention also provides methods for the identification of compounds that modulate (i.e., increase or decrease) the expression or activity of the polynucleotides and/or polypeptides of the invention. Such methods can be utilized, for example, for the identification of compounds that can ameliorate symptoms of disorders as recited herein. Such methods can include, but are not limited to, assays for identifying compounds and other substances that interact with (*e.g.*, bind to) the polypeptides of the invention.

The invention provides a method for identifying a compound that binds to the polypeptide of the present invention comprising contacting the compound with the polypeptide under conditions and for a time sufficient to form a polypeptide/compound complex and detecting the complex, so that if the polypeptide/compound complex is detected, a compound that binds to the polypeptide is identified.

Also provided is a method for identifying a compound that binds to the polypeptide comprising contacting the compound with the polypeptide in a cell for a time sufficient to form a polypeptide/compound complex wherein the complex drives expression of a reporter gene sequence in the cell and detecting the complex by detecting reporter gene sequence expression so that if the polypeptide/compound complex is detected a compound that binds to the polypeptide is identified.

4. BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 2 (i.e. SEQ ID NO: 3) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human IRC1a protein SEQ ID NO: 14, indicating that the two sequences share 55% similarity over 297 amino acid residues and 37% identity over the same 297 amino acid residues, wherein A = Alanine, C = Cysteine, D = Aspartic Acid, E = Glutamic Acid, F = Phenylalanine, G = Glycine, H = Histidine, I = Isoleucine, K = Lysine, L = Leucine, M = Methionine, N = Asparagine, P = Proline, Q = Glutamine, R = Arginine, S = Serine, T = Threonine, V = Valine, W = Tryptophan, Y = Tyrosine. Gaps are presented as dashes.

Figure 2 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID: 2 (i.e. SEQ ID NO: 3) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human PIGR-1 (Patent Application No. EP897981) SEQ ID NO: 15, indicating that the two sequences share 63% similarity over 176 amino acid residues and 53% identity over the same 176 amino acid residues, wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine. Gaps are presented as dashes.

Figure 3 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID: 5 (i.e. SEQ ID NO: 6) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human IRC1a protein SEQ ID NO: 14, indicating that the two sequences share 57% similarity over 135 amino acid residues and 38% identity over the same 135 amino acid residues, wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine. Gaps are presented as dashes.

Figure 4 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 5 (i.e. SEQ ID NO: 6) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human PIGR-1 (Patent Application No. EP897981) SEQ ID NO: 15, indicating that the two sequences share 67% similarity over 145 amino acid residues and 59% identity over the same 145 amino acid residues, wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine. Gaps are presented as dashes.

Figure 5 shows the BLASTP amino acid sequence alignment between the protein encoded by SEQ ID NO: 18 (i.e. SEQ ID NO: 19) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and putative inhibitory receptor (Rojo et al, (1997) J. Immunol., 158, 9-12) SEQ ID NO: 29, indicating that the two sequences share 51% similarity over 145 amino acid residues and 33% identity over the same 145 amino acid residues, wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine,

M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine. Gaps are presented as dashes.

Figure 6 shows the BLASTP amino acid sequence alignment between the protein encoded by SEQ ID NO: 18 (i.e. SEQ ID NO: 19) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human GP49 HM18 polypeptide (Patent Application No. WO9809638) SEQ ID NO: 30, indicating that the two sequences share 50% similarity over 123 amino acid residues and 34% identity over the same 123 amino acid residues, wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine. Gaps are presented as dashes.

Figure 7 shows the BLASTP amino acid sequence alignment between the protein encoded by SEQ ID NO: 21 (i.e. SEQ ID NO: 22) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and immunoglobulin-like protein IGSF1 (Mazzarella et al, (1998) Genomics 48, 157-162) SEQ ID NO: 31, indicating that the two sequences share 53% similarity over 209 amino acid residues and 38% identity over the same 209 amino acid residues, wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine. Gaps are presented as dashes.

Figure 8 shows the BLASTP amino acid sequence alignment between the protein encoded by SEQ ID NO: 21 (i.e. SEQ ID NO: 22) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human LIR-pbm36-2 protein (Patent Application No. WO9848017) SEQ ID NO: 32, indicating that the two sequences share 46% similarity over 236 amino acid residues and 32% identity over the same 236 amino acid residues, wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine. Gaps are presented as dashes.

Figure 9 shows the GeneAtlas amino acid sequence alignment between the protein encoded by SEQ ID NO: 36 and 39 (i.e. SEQ ID NO: 37 and 40, respectively) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human P58 killer cell inhibitory receptor protein, pdb Identification No. 1b6u, SEQ ID NO: 46, indicating that the two sequences share 33% similarity over 103 amino acid residues and 19.4% identity over

WO 01/55335

PCT/US01/02570

the same 103 amino acid residues, wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E=Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine. Gaps are presented as dashes.

Figure 10 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 49 (i.e. SEQ ID NO: 50) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human CMRF 35 protein (Jackson et al, (1992) Eur. J. Immunol., 22, 1157-1163) SEQ ID NO: 60, indicating that the two sequences share 62% similarity over 217 amino acid residues and 48% identity over the same 217 amino acid residues, wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine. Gaps are presented as dashes.

Figure 11 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 49 (i.e. SEQ ID NO: 50) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human Natural Killer inhibitory receptor protein SEQ ID NO: 61, indicating that the two sequences share 64% similarity over 145 amino acid residues and 51% identity over the same 145 amino acid residues, wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine. Gaps are presented as dashes.

Figure 12 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 49 (i.e. SEQ ID NO: 50) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human PIGR-2 protein (Patent Application No. EP905237) SEQ ID NO: 62, indicating that the two sequences share 58% similarity over 205 amino acid residues and 47% identity over the same 205 amino acid residues, wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine. Gaps are presented as dashes.

Figure 13 shows the GeneAtlas amino acid sequence alignment between the protein encoded by SEQ ID NO: 49 (i.e. SEQ ID NO: 50) leukocyte immunoglobulin receptor-like

polypeptide (also identified as "LIR-like") and T cell receptor, pdb Identification No. 1b88, SEQ ID NO: 59, indicating that the two sequences share 29.5% similarity over 112 amino acid residues and 11.6% identity over the same 112 amino acid residues, wherein A = Alanine,

C = Cysteine, D = Aspartic Acid, E = Glutamic Acid, F = Phenylalanine, G = Glycine,

5 H = Histidine, I = Isoleucine, K = Lysine, L = Leucine, M = Methionine, N = Asparagine,

P = Proline, Q = Glutamine, R = Arginine, S = Serine, T = Threonine, V = Valine,

W = Tryptophan, Y = Tyrosine. Gaps are presented as dashes.

Figure 14 shows the BLASTP amino acid sequence alignment between the protein encoded by SEQ ID NO: 65 (i.e. SEQ ID NO: 66) leukocyte immunoglobulin receptor-like

10 polypeptide (also identified as "LIR-like") and human platelet glycoprotein VI-2 protein (Ezumi et al, (2000) Biochem. Biophys. Res. Commun. 277, 27-36) SEQ ID NO: 75, indicating that the two sequences share 50% similarity over residues 1-219 of SEQ ID NO: 66, and 37% identity over the same residues 1-219 of SEQ ID NO: 66, wherein A = Alanine,

C = Cysteine, D = Aspartic Acid, E = Glutamic Acid, F = Phenylalanine, G = Glycine,

15 H = Histidine, I = Isoleucine, K = Lysine, L = Leucine, M = Methionine, N = Asparagine,

P = Proline, Q = Glutamine, R = Arginine, S = Serine, T = Threonine, V = Valine,

W = Tryptophan, Y = Tyrosine. Gaps are presented as dashes.

Figure 15 shows the BLASTP amino acid sequence alignment between the protein encoded by SEQ ID NO: 65 (i.e. SEQ ID NO: 66) leukocyte immunoglobulin receptor-like

20 polypeptide (also identified as "LIR-like") and human FcR-II protein (Patent Application No. WO9831806), SEQ ID NO: 76, indicating that the two sequences share 51% similarity over residues 27-262 of SEQ ID NO: 66 and 37% identity over the same amino acid residues 27-

262 of SEQ ID NO: 66, wherein A = Alanine, C = Cysteine, D = Aspartic Acid, E = Glutamic Acid, F = Phenylalanine, G = Glycine, H = Histidine, I = Isoleucine, K = Lysine, L = Leucine,

25 M = Methionine, N = Asparagine, P = Proline, Q = Glutamine, R = Arginine, S = Serine,

T = Threonine, V = Valine, W = Tryptophan, Y = Tyrosine. Gaps are presented as dashes.

5. DETAILED DESCRIPTION OF THE INVENTION

30 The leukocyte immunoglobulin receptor-like polypeptide of SEQ ID NO: 3 is an approximately 305-amino acid protein with a predicted molecular mass of approximately 34 kDa unglycosylated. Protein database searches with the BLASTX algorithm (Altschul S.F. et al., J. Mol. Evol. 36:290-300 (1993) and Altschul S.F. et al., J. Mol. Biol. 21:403-10 (1990), herein incorporated by reference) indicate that SEQ ID NO: 3 is homologous to leukocyte

immunoglobulin receptors like IRC1a and NK cell inhibitory receptors like PIGR-1. Protein database search with eMATRIX software (Stanford University, Stanford CA) further show that a portion of SEQ ID NO: 3 (i.e. SEQ ID NO: 8) is homologous to poly Ig receptors.

Figure 1 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 2 (i.e. SEQ ID NO: 3) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human IRC1a protein SEQ ID NO: 14, indicating that the two sequences share 55% similarity over 297 amino acid residues and 37% identity over the same 297 amino acid residues.

Figure 2 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID: 2 (i.e. SEQ ID NO: 3) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human PIGR-1 (Patent Application No. EP897981) SEQ ID NO: 15, indicating that the two sequences share 63% similarity over 176 amino acid residues and 53% identity over the same 176 amino acid residues.

A predicted soluble, secreted splice variant of SEQ ID NO: 3 is SEQ ID NO: 6. It is an approximately 162 amino acid protein with a predicted molecular mass of approximately 18 kDa unglycosylated. Protein database searches with the BLASTX algorithm (Altschul S.F. et al., J. Mol. Evol. 36:290-300 (1993) and Altschul S.F. et al., J. Mol. Biol. 21:403-10 (1990), herein incorporated by reference) indicate that SEQ ID NO: 6 is homologous to leukocyte immunoglobulin receptors like IRC1a and NK cell inhibitory receptor like PIGR-1. Protein database search with eMATRIX software (Stanford University, Stanford CA) further show that a portion of SEQ ID NO: 7 (i.e. SEQ ID NO: 9) is homologous to poly Ig receptors.

Figure 3 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID: 5 (i.e. SEQ ID NO: 6) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human IRC1a protein SEQ ID NO: 14, indicating that the two sequences share 57% similarity over 135 amino acid residues and 38% identity over the same 135 amino acid residues.

Figure 4 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 5 (i.e. SEQ ID NO: 6) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human PIGR-1 (Patent Application No. EP897981) SEQ ID NO: 15, indicating that the two sequences share 67% similarity over 145 amino acid residues and 59% identity over the same 145 amino acid residues.

A predicted approximately thirty residue signal peptide is encoded from approximately residue 1 to residue 30 of both SEQ ID NO: 3 and SEQ ID NO: 6 (SEQ ID NO: 10). The extracellular portion is useful on its own. This can be confirmed by expression in mammalian

cells and sequencing of the cleaved product. The signal peptide region was predicted using the Kyte-Doolittle hydrophobicity prediction algorithm (J. Mol Biol, 157, pp. 105-31 (1982), incorporated herein by reference). One of skill in the art will recognize that the actual cleavage site may be different than that predicted by the computer program. SEQ ID NO: 12 is the peptide resulting when the signal peptide is removed from SEQ ID NO: 3. SEQ ID NO: 13 is the peptide resulting when the signal peptide is removed from SEQ ID NO: 6.

A predicted approximately fourteen residue transmembrane peptide is encoded from approximately residue 170 to residue 193 of SEQ ID NO: 3 (SEQ ID NO: 11). This can be confirmed by expression in mammalian cells. The transmembrane peptide region was predicted using the Kyte-Doolittle hydrophobicity prediction algorithm (J. Mol Biol, 157, pp. 105-31 (1982), incorporated herein by reference). One of skill in the art will recognize that the actual transmembrane region may be different than that predicted by the computer program.

Using eMATRIX software package (Stanford University, Stanford, CA) (Wu et al., J. Comp. Biol., vol. 6, pp. 219-235 (1999), herein incorporated by reference), both the membrane-bound and soluble LIR-like polypeptide is expected to have a poly Ig receptor domain at residues 82 - 129 of SEQ ID NO: 3 and residues 82 - 129 of SEQ ID NO: 6 (SEQ ID NO: 8 and SEQ ID NO: 9, respectively). SEQ ID NO 8 has serine in the position 129 while SEQ ID NO: 9 contains proline in the same position. The domains corresponding to SEQ ID NO: 3 and SEQ ID NO: 6 are as follows wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine:

Poly immunoglobulin receptor domain
(IKDNQKNRTFTVTMEDLMKTDADTYWCGIEKTGNDLGVTQVTIDPAS designated as SEQ ID NO: 8) p-value of 3.628e-9, DM01688B 2 (identification number correlating to signature); located at residues 82-129 of SEQ ID NO: 3 and

Poly immunoglobulin receptor domain
(IKDNQKNRTFTVTMEDLMKTDADTYWCGIEKTGNDLGVTQVTIDPAP designated as SEQ ID NO: 9) p-value of 2.5e-10, DM01688B 2 (identification number correlating to signature); located at residues 82-129 of SEQ ID NO: 6.

Another leukocyte immunoglobulin receptor-like polypeptide SEQ ID NO: 19 is an approximately 236-amino acid protein with a predicted molecular mass of approximately 26

kDa unglycosylated. Protein database searches with the BLASTP algorithm (Altschul S.F. et al., J. Mol. Evol. 36:290-300 (1993) and Altschul S.F. et al., J. Mol. Biol. 21:403-10 (1990), herein incorporated by reference) indicate that SEQ ID NO: 19 is homologous to leukocyte immunoglobulin receptors (LIRs) and immunoglobulin-like protein IGSF-1. Protein database search with Molecular Simulations Inc. GeneAtlas software (Molecular Simulations Inc., San Diego, CA) further show that SEQ ID NO: 19 is homologous to killer cell inhibitory receptors.

Figure 5 shows the BLASTP amino acid sequence alignment between the protein encoded by SEQ ID NO: 18 (i.e. SEQ ID NO: 19) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and putative inhibitory receptor (Rojo et al, (1997) J. Immunol., 158, 9-12) SEQ ID NO: 29, indicating that the two sequences share 51% similarity over 145 amino acid residues and 33% identity over the same 145 amino acid residues.

Figure 6 shows the BLASTP amino acid sequence alignment between the protein encoded by SEQ ID NO: 18 (i.e. SEQ ID NO: 19) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human GP49 HM18 polypeptide (Patent Application No. WO9809638) SEQ ID NO: 30, indicating that the two sequences share 50% similarity over 123 amino acid residues and 34% identity over the same 123 amino acid residues.

A predicted soluble, secreted splice variant of SEQ ID NO: 19 is SEQ ID NO: 22. It is an approximately 199 amino acid protein with a predicted molecular mass of approximately 22 kDa unglycosylated. Protein database searches with the BLASTP algorithm (Altschul S.F. et al., J. Mol. Evol. 36:290-300 (1993) and Altschul S.F. et al., J. Mol. Biol. 21:403-10 (1990), herein incorporated by reference) indicate that SEQ ID NO: 22 is homologous to leukocyte immunoglobulin receptors (LIRs) and immunoglobulin-like protein IGSF-1. Protein database search with Molecular Simulations Inc. GeneAtlas software (Molecular Simulations Inc., San Diego, CA) further shows that SEQ ID NO: 22 is homologous to killer cell inhibitory receptors.

Figure 7 shows the BLASTP amino acid sequence alignment between the protein encoded by SEQ ID NO: 21 (i.e. SEQ ID NO: 22) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and immunoglobulin-like protein IGSF1 (Mazzarella et al, (1998) Genomics 48, 157-162) SEQ ID NO: 31, indicating that the two sequences share 53% similarity over 209 amino acid residues and 38% identity over the same 209 amino acid residues.

Figure 8 shows the BLASTP amino acid sequence alignment between the protein encoded by SEQ ID NO: 21 (i.e. SEQ ID NO: 22) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human LIR-pbm36-2 protein (Patent Application No. WO9848017) SEQ ID NO: 32, indicating that the two sequences share 46% similarity over 236 amino acid residues and 32% identity over the same 236 amino acid residues.

A predicted approximately sixteen residue signal peptide is encoded from approximately residue 1 to residue 16 of both SEQ ID NO: 19 and SEQ ID NO: 22 (SEQ ID NO: 25). The extracellular portion is useful on its own. This can be confirmed by expression in mammalian cells and sequencing of the cleaved product. The signal peptide region was predicted using the Kyte-Doolittle hydrophobicity prediction algorithm (J. Mol Biol, 157, pp. 105-31 (1982), incorporated herein by reference). One of skill in the art will recognize that the actual cleavage site may be different than that predicted by the computer program. SEQ ID NO: 27 is the peptide resulting when the predicted signal peptide is removed from SEQ ID NO: 19. SEQ ID NO: 28 is the peptide resulting when the predicted signal peptide is removed from SEQ ID NO: 22.

A predicted approximately twenty-three residue transmembrane peptide is encoded from approximately residue 135 to residue 157 of SEQ ID NO: 19 (SEQ ID NO: 26). This can be confirmed by expression in mammalian cells. The transmembrane peptide region was predicted using the Kyte-Doolittle hydrophobicity prediction algorithm (J. Mol Biol, 157, pp. 105-31 (1982), incorporated herein by reference). One of skill in the art will recognize that the actual transmembrane region may be different than that predicted by the computer program.

Using Molecular Simulations Inc. GeneAtlas software (Molecular Simulations Inc., San Diego, CA), LIR-like polypeptides of SEQ ID NO: 19 and 22 were determined to have a region at residues 26 – 97 with characteristic motifs to the killer cell inhibitory receptor domain (SEQ ID NO: 24). The corresponding domain within SEQ ID NO: 19 and 22 is as follows wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine:

Killer cell inhibitory receptor domain

(PPKPSLHAWPSSVVEAESNVTLKCQAHSQNVTFVLRKVND SGYKQE QSSAENEAEFPF
TDLKPKDAGRYFCA

designated as SEQ ID NO: 24 with PSI-BLAST e-value of $4.2e-24$, protein database identification number entry = 1b6u (Research collaboratory for Structural Bioinformatics. <http://www.rcsb.org/pdb>), verify score = 0.26, located at residues 26-97 of SEQ ID NO: 19.

The leukocyte immunoglobulin receptor-like polypeptide of both SEQ ID NO: 37 and 40 is an approximately 230-amino acid protein with a predicted molecular mass of approximately 26 kDa unglycosylated. Protein database search with Molecular Simulations Inc. GeneAtlas software (Molecular Simulations Inc., San Diego, CA) further shows that both SEQ ID NO: 37 and 40 and are homologous to P58 killer cell inhibitory receptor.

Figure 9 shows the GeneAtlas amino acid sequence alignment between the protein encoded by SEQ ID NO: 36 and 39 (i.e SEQ ID NO: 37 and 40, respectively) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human P58 killer cell inhibitory receptor protein, pdb Identification No. 1b6u, SEQ ID NO: 46, indicating that the two sequences share 33% similarity over 103 amino acid residues and 19.4% identity over the same 103 amino acid residues.

A predicted approximately fifteen residue signal peptide is encoded from approximately residue 1 to residue 15 of both SEQ ID NO: 37 and SEQ ID NO: 40 (SEQ ID NO: 43). The extracellular portion is useful on its own. This can be confirmed by expression in mammalian cells and sequencing of the cleaved product. The signal peptide region was predicted using the Kyte-Doolittle hydrophobicity prediction algorithm (J. Mol Biol, 157, pp. 105-31 (1982), incorporated herein by reference). One of skill in the art will recognize that the actual cleavage site may be different than that predicted by the computer program. SEQ ID NO: 45 is the peptide resulting when the predicted signal peptide is removed from either SEQ ID NO: 37 or SEQ ID NO: 40.

A predicted approximately twenty-seven residue transmembrane peptide is encoded from approximately residue 116 to residue 143 of SEQ ID NO: 37 and SEQ ID NO: 40 (SEQ ID NO: 44). The transmembrane portion may be useful on its own. This can be confirmed by expression in mammalian cells. The transmembrane peptide region was predicted using the Kyte-Doolittle hydrophobicity prediction algorithm (J. Mol Biol, 157, pp. 105-31 (1982), incorporated herein by reference). One of skill in the art will recognize that the actual transmembrane region may be different than that predicted by the computer program.

The leukocyte immunoglobulin receptor-like polypeptide of SEQ ID NO: 50 is an approximately 201-amino acid protein with a predicted molecular mass of approximately 22 kDa unglycosylated. Protein database searches with the BLASTX algorithm (Altschul S.F. et al., J. Mol. Evol. 36:290-300 (1993) and Altschul S.F. et al., J. Mol. Biol. 21:403-10 (1990),

herein incorporated by reference) indicate that SEQ ID NO: 50 is homologous to leukocyte immunoglobulin receptors like CMRF35, NK cell inhibitory receptor, and human PIGR-2 receptor.

Figure 10 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 49 (i.e. SEQ ID NO: 50) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human CMRF 35 protein (Jackson et al, (1992) Eur. J. Immunol., 22, 1157-1163) SEQ ID NO: 60, indicating that the two sequences share 62% similarity over 217 amino acid residues and 48% identity over the same 217 amino acid residues.

Figure 11 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 49 (i.e. SEQ ID NO: 50) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human Natural Killer inhibitory receptor protein SEQ ID NO: 61, indicating that the two sequences share 64% similarity over 145 amino acid residues and 51% identity over the same 145 amino acid residues.

Figure 12 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 49 (i.e. SEQ ID NO: 50) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human PIGR-2 protein (Patent Application No. EP905237) SEQ ID NO: 62, indicating that the two sequences share 58% similarity over 205 amino acid residues and 47% identity over the same 205 amino acid residues.

Figure 13 shows the GeneAtlas amino acid sequence alignment between the protein encoded by SEQ ID NO: 49 (i.e. SEQ ID NO: 50) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and T cell receptor, pdb Identification No. 1b88, SEQ ID NO: 59, indicating that the two sequences share 29.5% similarity over 112 amino acid residues and 11.6% identity over the same 112 amino acid residues.

A predicted approximately twenty-residue signal peptide is encoded from approximately residue 1 through residue 20 of SEQ ID NO: 50 (SEQ ID NO: 55). The extracellular portion is useful on its own. This can be confirmed by expression in mammalian cells and sequencing of the cleaved product. The signal peptide region was predicted using the Kyte-Doolittle hydrophobicity prediction algorithm (J. Mol Biol, 157, pp. 105-31 (1982), incorporated herein by reference). One of skill in the art will recognize that the actual cleavage site may be different than that predicted by the computer program. SEQ ID NO: 57 is the peptide resulting when the predicted signal peptide is removed from SEQ ID NO: 50.

A predicted approximately twenty-four residue transmembrane peptide is encoded from approximately residue 167 to residue 191 of SEQ ID NO: 50 (SEQ ID NO: 56). The

transmembrane portion may be useful on its own. This can be confirmed by expression in mammalian cells. The transmembrane peptide region was predicted using the Kyte-Doolittle hydrophobicity prediction algorithm (J. Mol Biol, 157, pp. 105-31 (1982), incorporated herein by reference). One of skill in the art will recognize that the actual transmembrane region may be different than that predicted by the computer program.

Using eMATRIX software package (Stanford University, Stanford, CA) (Wu et al., J. Comp. Biol., vol. 6, pp. 219-235 (1999), herein incorporated by reference), SEQ ID NO: 50, LIR-like polypeptide is expected to have two poly-Ig receptor domains. The domains corresponding to SEQ ID NO: 53-54 are as follows wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine:

Poly Immunoglobulin receptor domain

ITDHPGDLTFTVTLENLTADDAGKYRCGIATILQEDGLSGFLPDPFFQ

designated as (SEQ ID NO: 53) p-value of 4.504e-9, DM01688B 2 (identification number correlating to signature); located at residues 85-132 of SEQ ID NO: 50.

Poly Immunoglobulin receptor domain

MGAVGESLSVQCRYEEKYKTFNKYWCRQPCLPIWHEM

designated as (SEQ ID NO: 54) p-value of 8.364e-9, DM01688J 2 (identification number correlating to signature); located at residues 32-68 of SEQ ID NO: 50.

The leukocyte immunoglobulin receptor-like polypeptide of SEQ ID NO: 66 is an approximately 777-amino acid protein with a predicted molecular mass of approximately 87.8 kDa unglycosylated. Protein database searches with the BLASTP algorithm (Altschul S.F. et al., J. Mol. Evol. 36:290-300 (1993) and Altschul S.F. et al., J. Mol. Biol. 21:403-10 (1990), herein incorporated by reference) indicate that SEQ ID NO: 66 is homologous to human platelet glycoprotein VI-2 and FcR-II protein.

Figure 14 shows the BLASTP amino acid sequence alignment between the protein encoded by SEQ ID NO: 65 (i.e. SEQ ID NO: 66) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human platelet glycoprotein VI-2 protein (Ezumi et al, (2000) Biochem. Biophys. Res. Commun. 277, 27-36) SEQ ID NO: 75, indicating that the two sequences share 50% similarity over residues 1-219 of SEQ ID NO: 66, and 37% identity over the same residues 1-219 of SEQ ID NO: 66.

Figure 15 shows the BLASTP amino acid sequence alignment between the protein encoded by SEQ ID NO: 65 (i.e. SEQ ID NO: 66) leukocyte immunoglobulin receptor-like

polypeptide (also identified as "LIR-like") and human FcR-II protein (Patent Application No. WO9831806), SEQ ID NO: 76, indicating that the two sequences share 51% similarity over residues 27-262 of SEQ ID NO: 66 and 37% identity over the same amino acid residues 27-262 of SEQ ID NO: 66.

5 A predicted approximately sixteen-residue signal peptide is encoded from approximately residue 1 through residue 16 of SEQ ID NO: 66 (SEQ ID NO: 71). The extracellular portion is useful on its own. This can be confirmed by expression in mammalian cells and sequencing of the cleaved product. The signal peptide region was predicted using the Kyte-Doolittle hydrophobicity prediction algorithm (J. Mol Biol, 157, pp. 105-31 (1982),
10 incorporated herein by reference). One of skill in the art will recognize that the actual cleavage site may be different than that predicted by the computer program. SEQ ID NO: 72 is the peptide resulting when the predicted signal peptide is removed from SEQ ID NO: 66.

A predicted approximately twenty four-residue transmembrane region is encoded from approximately residue 231 through residue 254 of SEQ ID NO: 66 (SEQ ID NO: 73). The
15 transmembrane portion may be useful on its own. The transmembrane region was predicted using the Kyte-Doolittle hydrophobicity prediction algorithm (J. Mol Biol, 157, pp. 105-31 (1982), incorporated herein by reference). One of skill in the art will recognize that the actual cleavage site may be different than that predicted by the computer program.

Using eMATRIX software package (Stanford University, Stanford, CA) (Wu et al., J.
20 Comp. Biol., vol. 6, pp. 219-235 (1999), herein incorporated by reference), SEQ ID NO: 66, LIR-like polypeptide is expected to have three poly-Ig receptor domains. The domains corresponding to SEQ ID NO: 68 - 70 are as follows wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine,
25 S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine:

Receptor cell NK glycoprotein immunoglobulin

GSLPKPSLSAWPSSVVPANSNVTLRCWTPARGVSFV

designated as (SEQ ID NO: 68) p-value of 6.625e-10, PD01652A (identification number correlating to signature); located at residues 24 - 59 of SEQ ID NO: 66.

30 Receptor cell NK glycoprotein immunoglobulin

CVGQGDTRGDGSLPKPSLSAWPSSVVPANSNVTLRCWTPARGVSFVLRKGGI

designated as (SEQ ID NO: 69) p-value of 1.836e-9, PD01652B (identification number correlating to signature); located at residues 14 - 65 of SEQ ID NO: 66.

RSDVLLLLVTGHLSPFLRTYQRGTVTAGGRVTLQCQKRDQLFVPIMFALLK

designated as (SEQ ID NO: 70) p-value of 4.021e-9, PD01652B (identification number correlating to signature); located at residues 111 – 162.

The sequences of the present invention are expected to have both membrane bound and soluble LIR-like activity.

5 The polypeptides and polynucleotides of the invention can be utilized, for example, as part of methods for the prevention and/or treatment of disorders mediated by loss or overexpression of LIR-like polypeptide. Such disorders include, psoriasis, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus and inflammatory bowel disease among others. The polypeptides of the inventions could also be used to treat bone marrow transplant
10 patients to inhibit graft versus host disease. The polypeptides and polynucleotides may also be used to boost the killer cell and cytolytic activity of leukocytes of human immune deficiency disease patients.

5.1 DEFINITIONS

15 It must be noted that as used herein and in the appended claims, the singular forms “a”, “an” and “the” include plural references unless the context clearly dictates otherwise.

The term "active" refers to those forms of the polypeptide which retain the biologic and/or immunologic activities of any naturally occurring polypeptide. According to the invention, the terms “biologically active” or “biological activity” refer to a protein or peptide
20 having structural, regulatory or biochemical functions of a naturally occurring molecule. The term “LIR-like” refers to biological activity that is similar to the biological activity of a leukocyte immunoglobulin receptor. Likewise “biologically active” or “biological activity” refers to the capability of the natural, recombinant or synthetic LIR-like peptide, or any peptide thereof, to induce a specific biological response in appropriate animals or cells and to
25 bind with specific antibodies.

The term "activated cells" as used in this application are those cells which are engaged in extracellular or intracellular membrane trafficking, including the export of secretory or enzymatic molecules as part of a normal or disease process.

The terms “complementary” or “complementarity” refer to the natural binding of
30 polynucleotides by base pairing. For example, the sequence 5'-AGT-3' binds to the complementary sequence 3'-TCA-5'. Complementarity between two single-stranded molecules may be “partial” such that only some of the nucleic acids bind or it may be “complete” such that total complementarity exists between the single stranded molecules. The degree of

complementarity between the nucleic acid strands has significant effects on the efficiency and strength of the hybridization between the nucleic acid strands.

The term "embryonic stem cells (ES)" refers to a cell that can give rise to many differentiated cell types in an embryo or an adult, including the germ cells. The term "germ line stem cells (GSCs)" refers to stem cells derived from primordial stem cells that provide a steady and continuous source of germ cells for the production of gametes. The term "primordial germ cells (PGCs)" refers to a small population of cells set aside from other cell lineages particularly from the yolk sac, mesenteries, or gonadal ridges during embryogenesis that have the potential to differentiate into germ cells and other cells. PGCs are the source from which GSCs and ES cells are derived. The PGCs, the GSCs and the ES cells are capable of self-renewal. Thus these cells not only populate the germ line and give rise to a plurality of terminally differentiated cells that comprise the adult specialized organs, but are able to regenerate themselves.

The term "expression modulating fragment," EMF, means a series of nucleotides which modulates the expression of an operably linked ORF or another EMF.

As used herein, a sequence is said to "modulate the expression of an operably linked sequence" when the expression of the sequence is altered by the presence of the EMF. EMFs include, but are not limited to, promoters, and promoter modulating sequences (inducible elements). One class of EMFs is nucleic acid fragments which induce the expression of an operably linked ORF in response to a specific regulatory factor or physiological event.

The terms "nucleotide sequence" or "nucleic acid" or "polynucleotide" or "oligonucleotide" are used interchangeably and refer to a heteropolymer of nucleotides or the sequence of these nucleotides. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA) or to any DNA-like or RNA-like material. In the sequences, A is adenine, C is cytosine, G is guanine and T is thymine while N is A, C, G, or T (U). It is contemplated that where the polynucleotide is RNA, the T (thymine) in the sequence may be replaced with U (uracil). Generally, nucleic acid segments provided by this invention may be assembled from fragments of the genome and short oligonucleotide linkers, or from a series of oligonucleotides, or from individual nucleotides, to provide a synthetic nucleic acid which is capable of being expressed in a recombinant transcriptional unit comprising regulatory elements derived from a microbial or viral operon, or a eukaryotic gene.

The terms "oligonucleotide fragment" or a "polynucleotide fragment", "portion," or "segment" or "probe" or "primer" are used interchangeably and refer to a sequence of nucleotide residues which are at least about 5 nucleotides, more preferably at least about 7 nucleotides, more preferably at least about 9 nucleotides, more preferably at least about 11 nucleotides and most preferably at least about 17 nucleotides. The fragment is preferably less than about 500 nucleotides, preferably less than about 200 nucleotides, more preferably less than about 100 nucleotides, more preferably less than about 50 nucleotides and most preferably less than 30 nucleotides. Preferably the probe is from about 6 nucleotides to about 200 nucleotides, preferably from about 15 to about 50 nucleotides, more preferably from about 17 to 30 nucleotides and most preferably from about 20 to 25 nucleotides. Preferably the fragments can be used in polymerase chain reaction (PCR), various hybridization procedures or microarray procedures to identify or amplify identical or related parts of mRNA or DNA molecules. A fragment or segment may uniquely identify each polynucleotide sequence of the present invention. Preferably the fragment comprises a sequence substantially similar to a portion of SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67.

Probes may, for example, be used to determine whether specific mRNA molecules are present in a cell or tissue or to isolate similar nucleic acid sequences from chromosomal DNA as described by Walsh et al. (Walsh, P.S. et al., 1992, PCR Methods Appl 1:241-250). They may be labeled by nick translation, Klenow fill-in reaction, PCR, or other methods well known in the art. Probes of the present invention, their preparation and/or labeling are elaborated in Sambrook, J. et al., 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, NY; or Ausubel, F.M. et al., 1989, Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, both of which are incorporated herein by reference in their entirety.

The nucleic acid sequences of the present invention also include the sequence information from any of the nucleic acid sequences of SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67. The sequence information can be a segment of SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67 that uniquely identifies or represents the sequence information of SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67. One such segment can be a twenty-mer nucleic acid sequence because the probability that a twenty-mer is fully matched in the human genome is 1 in 300. In the human genome, there are three billion base pairs in one set of chromosomes. Because 4^{20} possible twenty-mers exist, there are 300 times more twenty-mers

than there are base pairs in a set of human chromosome. Using the same analysis, the probability for a seventeen-mer to be fully matched in the human genome is approximately 1 in 5. When these segments are used in arrays for expression studies, fifteen-mer segments can be used. The probability that the fifteen-mer is fully matched in the expressed sequences is also approximately one in five because expressed sequences comprise less than approximately 5% of the entire genome sequence.

Similarly, when using sequence information for detecting a single mismatch, a segment can be a twenty-five mer. The probability that the twenty-five mer would appear in a human genome with a single mismatch is calculated by multiplying the probability for a full match (1÷4²⁵) times the increased probability for mismatch at each nucleotide position (3 x 25). The probability that an eighteen mer with a single mismatch can be detected in an array for expression studies is approximately one in five. The probability that a twenty-mer with a single mismatch can be detected in a human genome is approximately one in five.

The term "open reading frame," ORF, means a series of nucleotide triplets coding for amino acids without any termination codons and is a sequence translatable into protein.

The terms "operably linked" or "operably associated" refer to functionally related nucleic acid sequences. For example, a promoter is operably associated or operably linked with a coding sequence if the promoter controls the transcription of the coding sequence. While operably linked nucleic acid sequences can be contiguous and in the same reading frame, certain genetic elements e.g. repressor genes are not contiguously linked to the coding sequence but still control transcription/translation of the coding sequence.

The term "pluripotent" refers to the capability of a cell to differentiate into a number of differentiated cell types that are present in an adult organism. A pluripotent cell is restricted in its differentiation capability in comparison to a totipotent cell.

The terms "polypeptide" or "peptide" or "amino acid sequence" refer to an oligopeptide, peptide, polypeptide or protein sequence or fragment thereof and to naturally occurring or synthetic molecules. A polypeptide "fragment," "portion," or "segment" is a stretch of amino acid residues of at least about 5 amino acids, preferably at least about 7 amino acids, more preferably at least about 9 amino acids and most preferably at least about 17 or more amino acids. The peptide preferably is not greater than about 200 amino acids, more preferably less than 150 amino acids and most preferably less than 100 amino acids. Preferably the peptide is from about 5 to about 200 amino acids. To be active, any polypeptide must have sufficient length to display biological and/or immunological activity.

The term "naturally occurring polypeptide" refers to polypeptides produced by cells that have not been genetically engineered and specifically contemplates various polypeptides arising from post-translational modifications of the polypeptide including, but not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation.

5 The term "translated protein coding portion" means a sequence which encodes for the full length protein which may include any leader sequence or a processing sequence.

The term "mature protein coding sequence" refers to a sequence which encodes a peptide or protein without any leader/signal sequence. The "mature protein portion" refers to that portion of the protein without the leader/signal sequence. The peptide may have the leader
10 sequences removed during processing in the cell or the protein may have been produced synthetically or using a polynucleotide only encoding for the mature protein coding sequence. It is contemplated that the mature protein portion may or may not include an initial methionine residue. The initial methionine is often removed during processing of the peptide.

The term "derivative" refers to polypeptides chemically modified by such techniques as
15 ubiquitination, labeling (e.g., with radionuclides or various enzymes), covalent polymer attachment such as pegylation (derivatization with polyethylene glycol) and insertion or substitution by chemical synthesis of amino acids such as ornithine, which do not normally occur in human proteins.

The term "variant"(or "analog") refers to any polypeptide differing from naturally
20 occurring polypeptides by amino acid insertions, deletions, and substitutions, created using, e.g., recombinant DNA techniques. Guidance in determining which amino acid residues may be replaced, added or deleted without abolishing activities of interest, may be found by comparing the sequence of the particular polypeptide with that of homologous peptides and minimizing the number of amino acid sequence changes made in regions of high homology (conserved
25 regions) or by replacing amino acids with consensus sequence.

Alternatively, recombinant variants encoding these same or similar polypeptides may be synthesized or selected by making use of the "redundancy" in the genetic code. Various codon substitutions, such as the silent changes which produce various restriction sites, may be introduced to optimize cloning into a plasmid or viral vector or expression in a particular
30 prokaryotic or eukaryotic system. Mutations in the polynucleotide sequence may be reflected in the polypeptide or domains of other peptides added to the polypeptide to modify the properties of any part of the polypeptide, to change characteristics such as ligand-binding affinities, interchain affinities, or degradation/turnover rate.

Preferably, amino acid "substitutions" are the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, *i.e.*, conservative amino acid replacements. "Conservative" amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the

5 amphipathic nature of the residues involved. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

10 "Insertions" or "deletions" are preferably in the range of about 1 to 20 amino acids, more preferably 1 to 10 amino acids. The variation allowed may be experimentally determined by systematically making insertions, deletions, or substitutions of amino acids in a polypeptide molecule using recombinant DNA techniques and assaying the resulting recombinant variants for activity.

15 Alternatively, where alteration of function is desired, insertions, deletions or non-conservative alterations can be engineered to produce altered polypeptides. Such alterations can, for example, alter one or more of the biological functions or biochemical characteristics of the polypeptides of the invention. For example, such alterations may change polypeptide characteristics such as ligand-binding affinities, interchain affinities, or degradation/turnover

20 rate. Further, such alterations can be selected so as to generate polypeptides that are better suited for expression, scale up and the like in the host cells chosen for expression. For example, cysteine residues can be deleted or substituted with another amino acid residue in order to eliminate disulfide bridges.

The terms "purified" or "substantially purified" as used herein denotes that the

25 indicated nucleic acid or polypeptide is present in the substantial absence of other biological macromolecules, *e.g.*, polynucleotides, proteins, and the like. In one embodiment, the polynucleotide or polypeptide is purified such that it constitutes at least 95% by weight, more preferably at least 99% by weight, of the indicated biological macromolecules present (but water, buffers, and other small molecules, especially molecules having a molecular weight of

30 less than 1000 daltons, can be present).

The term "isolated" as used herein refers to a nucleic acid or polypeptide separated from at least one other component (*e.g.*, nucleic acid or polypeptide) present with the nucleic acid or polypeptide in its natural source. In one embodiment, the nucleic acid or polypeptide is found in the presence of (if anything) only a solvent, buffer, ion, or other components

normally present in a solution of the same. The terms "isolated" and "purified" do not encompass nucleic acids or polypeptides present in their natural source.

The term "recombinant," when used herein to refer to a polypeptide or protein, means that a polypeptide or protein is derived from recombinant (*e.g.*, microbial, insect, or mammalian) expression systems. "Microbial" refers to recombinant polypeptides or proteins made in bacterial or fungal (*e.g.*, yeast) expression systems. As a product, "recombinant microbial" defines a polypeptide or protein essentially free of native endogenous substances and unaccompanied by associated native glycosylation. Polypeptides or proteins expressed in most bacterial cultures, *e.g.*, *E. coli*, will be free of glycosylation modifications; polypeptides or proteins expressed in yeast will have a glycosylation pattern in general different from those expressed in mammalian cells.

The term "recombinant expression vehicle or vector" refers to a plasmid or phage or virus or vector, for expressing a polypeptide from a DNA (RNA) sequence. An expression vehicle can comprise a transcriptional unit comprising an assembly of (1) a genetic element or elements having a regulatory role in gene expression, for example, promoters or enhancers, (2) a structural or coding sequence which is transcribed into mRNA and translated into protein, and (3) appropriate transcription initiation and termination sequences. Structural units intended for use in yeast or eukaryotic expression systems preferably include a leader sequence enabling extracellular secretion of translated protein by a host cell. Alternatively, where recombinant protein is expressed without a leader or transport sequence, it may include an amino terminal methionine residue. This residue may or may not be subsequently cleaved from the expressed recombinant protein to provide a final product.

The term "recombinant expression system" means host cells which have stably integrated a recombinant transcriptional unit into chromosomal DNA or carry the recombinant transcriptional unit extrachromosomally. Recombinant expression systems as defined herein will express heterologous polypeptides or proteins upon induction of the regulatory elements linked to the DNA segment or synthetic gene to be expressed. This term also means host cells which have stably integrated a recombinant genetic element or elements having a regulatory role in gene expression, for example, promoters or enhancers. Recombinant expression systems as defined herein will express polypeptides or proteins endogenous to the cell upon induction of the regulatory elements linked to the endogenous DNA segment or gene to be expressed. The cells can be prokaryotic or eukaryotic.

The term "secreted" includes a protein that is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence when

it is expressed in a suitable host cell. "Secreted" proteins include without limitation proteins secreted wholly (*e.g.*, soluble proteins) or partially (*e.g.*, receptors) from the cell in which they are expressed. "Secreted" proteins also include without limitation proteins that are transported across the membrane of the endoplasmic reticulum. "Secreted" proteins are also intended to include proteins containing non-typical signal sequences (*e.g.* Interleukin-1 Beta, see Krasney, P.A. and Young, P.R. (1992) Cytokine 4(2):134 -143) and factors released from damaged cells (*e.g.* Interleukin-1 Receptor Antagonist, see Arend, W.P. et. al. (1998) Annu. Rev. Immunol. 16:27-55)

Where desired, an expression vector may be designed to contain a "signal or leader sequence" which will direct the polypeptide through the membrane of a cell. Such a sequence may be naturally present on the polypeptides of the present invention or provided from heterologous protein sources by recombinant DNA techniques.

The term "stringent" is used to refer to conditions that are commonly understood in the art as stringent. Stringent conditions can include highly stringent conditions (*i.e.*, hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.1X SSC/0.1% SDS at 68°C), and moderately stringent conditions (*i.e.*, washing in 0.2X SSC/0.1% SDS at 42°C). Other exemplary hybridization conditions are described herein in the examples.

In instances of hybridization of deoxyoligonucleotides, additional exemplary stringent hybridization conditions include washing in 6X SSC/0.05% sodium pyrophosphate at 37°C (for 14-base oligonucleotides), 48°C (for 17-base oligonucleotides), 55°C (for 20-base oligonucleotides), and 60°C (for 23-base oligonucleotides).

As used herein, "substantially equivalent" can refer both to nucleotide and amino acid sequences, for example a mutant sequence, that varies from a reference sequence by one or more substitutions, deletions, or additions, the net effect of which does not result in an adverse functional dissimilarity between the reference and subject sequences. Typically, such a substantially equivalent sequence varies from one of those listed herein by no more than about 35% (*i.e.*, the number of individual residue substitutions, additions, and/or deletions in a substantially equivalent sequence, as compared to the corresponding reference sequence, divided by the total number of residues in the substantially equivalent sequence is about 0.35 or less). Such a sequence is said to have 65% sequence identity to the listed sequence. In one embodiment, a substantially equivalent, *e.g.*, mutant, sequence of the invention varies from a listed sequence by no more than 30% (70% sequence identity); in a variation of this

embodiment, by no more than 25% (75% sequence identity); and in a further variation of this embodiment, by no more than 20% (80% sequence identity) and in a further variation of this embodiment, by no more than 10% (90% sequence identity) and in a further variation of this embodiment, by no more than 5% (95% sequence identity). Substantially equivalent, *e.g.*,

5 mutant, amino acid sequences according to the invention preferably have at least 80% sequence identity with a listed amino acid sequence, more preferably at least 85% sequence identity, more preferably at least 90% sequence identity, more preferably at least 95% sequence identity, more preferably at least 98% sequence identity, and most preferably at least 99% sequence identity. Substantially equivalent nucleotide sequence of the invention can have
10 lower percent sequence identities, taking into account, for example, the redundancy or degeneracy of the genetic code. Preferably, the nucleotide sequence has at least about 65% identity, more preferably at least about 75% identity, more preferably at least about 80% sequence identity, more preferably at least 85% sequence identity, more preferably at least 90% sequence identity, more preferably at least about 95% sequence identity, more preferably
15 at least 98% sequence identity, and most preferably at least 99% sequence identity. For the purposes of the present invention, sequences having substantially equivalent biological activity and substantially equivalent expression characteristics are considered substantially equivalent. For the purposes of determining equivalence, truncation of the mature sequence (*e.g.*, via a mutation which creates a spurious stop codon) should be disregarded. Sequence identity may
20 be determined, *e.g.*, using the Jotun Hein method (Hein, J. (1990) *Methods Enzymol.* 183:626-645). Identity between sequences can also be determined by other methods known in the art, *e.g.* by varying hybridization conditions.

The term "totipotent" refers to the capability of a cell to differentiate into all of the cell types of an adult organism.

25 The term "transformation" means introducing DNA into a suitable host cell so that the DNA is replicable, either as an extrachromosomal element, or by chromosomal integration. The term "transfection" refers to the taking up of an expression vector by a suitable host cell, whether or not any coding sequences are in fact expressed. The term "infection" refers to the introduction of nucleic acids into a suitable host cell by use of a virus or viral vector.

30 As used herein, an "uptake modulating fragment," UMF, means a series of nucleotides which mediate the uptake of a linked DNA fragment into a cell. UMFs can be readily identified using known UMFs as a target sequence or target motif with the computer-based systems described below. The presence and activity of a UMF can be confirmed by attaching the suspected UMF to a marker sequence. The resulting nucleic acid molecule is then

incubated with an appropriate host under appropriate conditions and the uptake of the marker sequence is determined. As described above, a UMF will increase the frequency of uptake of a linked marker sequence.

Each of the above terms is meant to encompass all that is described for each, unless the context dictates otherwise.

5.2 NUCLEIC ACIDS OF THE INVENTION

The invention is based on the discovery of a novel secreted LIR-like polypeptide, the polynucleotides encoding the LIR-like polypeptide and the use of these compositions for the diagnosis, treatment or prevention of neurological conditions and disorders.

The isolated polynucleotides of the invention include, but are not limited to a polynucleotide comprising any of the nucleotide sequences of SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67; a fragment of SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67; a polynucleotide comprising the full length protein coding sequence of SEQ ID NO: 2, 5, 18, 21, 36, 39, 49, or 65 (for example SEQ ID NO: 3, 6, 19, 22, 37, 40, 50, or 66); and a polynucleotide comprising the nucleotide sequence encoding the mature protein coding sequence of the polynucleotides of any one of SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67.

The polynucleotides of the present invention also include, but are not limited to, a

polynucleotide that hybridizes under stringent conditions to (a) the complement of any of the nucleotides sequences of the SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67; (b) a polynucleotide encoding any one of the polypeptides of SEQ ID NO: 3, 6, 8-13, 19, 22, 24-28; 33-34, 37, 40, 42-45, 50, 52-58, 66, or 68-74 (c) a polynucleotide which is an allelic variant of any polynucleotides recited above; (d) a polynucleotide which encodes a species homolog of any of the proteins recited above; or (e) a polynucleotide that encodes a polypeptide comprising a specific domain or truncation of the polypeptides of SEQ ID NO: 3, 6, 8-13, 19, 22, 24-28, 33-34, 37, 40, 42-45, 50 52-58, 66, or 68-74. Domains of interest may depend on the nature of the encoded polypeptide; e.g., domains in receptor-like polypeptides include ligand-binding, extracellular, transmembrane, or cytoplasmic domains, or combinations thereof; domains in immunoglobulin-like proteins include the variable immunoglobulin-like domains; domains in enzyme-like polypeptides include catalytic and substrate binding domains; and domains in ligand polypeptides include receptor-binding domains.

The polynucleotides of the invention include naturally occurring or wholly or partially synthetic DNA, e.g., cDNA and genomic DNA, and RNA, e.g., mRNA. The polynucleotides may include all of the coding region of the cDNA or may represent a portion of the coding region of the cDNA.

5 The present invention also provides genes corresponding to the cDNA sequences disclosed herein. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials. Further 5' and 3'

10 sequence can be obtained using methods known in the art. For example, full length cDNA or genomic DNA that corresponds to any of the polynucleotides of the SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67 can be obtained by screening appropriate cDNA or genomic DNA libraries under suitable hybridization conditions using any of the polynucleotides of the SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49,

15 51, 63-65, or 67 or a portion thereof as a probe. Alternatively, the polynucleotides of the SEQ ID NO: SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67 may be used as the basis for suitable primer(s) that allow identification and/or amplification of genes in appropriate genomic DNA or cDNA libraries.

The nucleic acid sequences of the invention can be assembled from ESTs and sequences

20 (including cDNA and genomic sequences) obtained from one or more public databases, such as dbEST, gbpri, and UniGene. The EST sequences can provide identifying sequence information, representative fragment or segment information, or novel segment information for the full-length gene.

The polynucleotides of the invention also provide polynucleotides including nucleotide

25 sequences that are substantially equivalent to the polynucleotides recited above. Polynucleotides according to the invention can have, *e.g.*, at least about 65%, at least about 70%, at least about 75%, at least about 80%, 81%, 82%, 83%, 84%, more typically at least about 85%, 86%, 87%, 88%, 89%, more typically at least about 90%, 91%, 92%, 93%, 94%, and even more typically at least about 95%, 96%, 97%, 98%, 99% sequence identity to

30 a polynucleotide recited above.

Included within the scope of the nucleic acid sequences of the invention are nucleic acid sequence fragments that hybridize under stringent conditions to any of the nucleotide sequences of the SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67, or complements thereof, which fragment is greater than about 5 nucleotides, preferably 7

nucleotides, more preferably greater than 9 nucleotides and most preferably greater than 17 nucleotides. Fragments of, e.g. 15, 17, or 20 nucleotides or more that are selective for (i.e. specifically hybridize to any one of the polynucleotides of the invention) are contemplated. Probes capable of specifically hybridizing to a polynucleotide can differentiate polynucleotide sequences of the invention from other polynucleotide sequences in the same family of genes or can differentiate human genes from genes of other species, and are preferably based on unique nucleotide sequences.

The sequences falling within the scope of the present invention are not limited to these specific sequences, but also include allelic and species variations thereof. Allelic and species variations can be routinely determined by comparing the sequence provided in SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67, a representative fragment thereof, or a nucleotide sequence at least 90% identical, preferably 95% identical, to SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67 with a sequence from another isolate of the same species. Furthermore, to accommodate codon variability, the invention includes nucleic acid molecules coding for the same amino acid sequences as do the specific ORFs disclosed herein. In other words, in the coding region of an ORF, substitution of one codon for another codon that encodes the same amino acid is expressly contemplated.

The nearest neighbor result for the nucleic acids of the present invention, including SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67, can be obtained by searching a database using an algorithm or a program. Preferably, a BLAST which stands for Basic Local Alignment Search Tool is used to search for local sequence alignments (Altshul, S.F. J Mol. Evol. 36 290-300 (1993) and Altschul S.F. et al. J. Mol. Biol. 21:403-410 (1990))

Species homologs (or orthologs) of the disclosed polynucleotides and proteins are also provided by the present invention. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species.

The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotide which also encode proteins which are identical, homologous or related to that encoded by the polynucleotides.

The nucleic acid sequences of the invention are further directed to sequences which encode variants of the described nucleic acids. These amino acid sequence variants may be prepared by methods known in the art by introducing appropriate nucleotide changes into a

native or variant polynucleotide. There are two variables in the construction of amino acid sequence variants: the location of the mutation and the nature of the mutation. Nucleic acids encoding the amino acid sequence variants are preferably constructed by mutating the polynucleotide to encode an amino acid sequence that does not occur in nature. These nucleic acid alterations can be made at sites that differ in the nucleic acids from different species (variable positions) or in highly conserved regions (constant regions). Sites at such locations will typically be modified in series, *e.g.*, by substituting first with conservative choices (*e.g.*, hydrophobic amino acid to a different hydrophobic amino acid) and then with more distant choices (*e.g.*, hydrophobic amino acid to a charged amino acid), and then deletions or insertions may be made at the target site. Amino acid sequence deletions generally range from about 1 to 30 residues, preferably about 1 to 10 residues, and are typically contiguous. Amino acid insertions include amino- and/or carboxyl-terminal fusions ranging in length from one to one hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Intrasequence insertions may range generally from about 1 to 10 amino residues, preferably from 1 to 5 residues. Examples of terminal insertions include the heterologous signal sequences necessary for secretion or for intracellular targeting in different host cells and sequences such as FLAG or poly-histidine sequences useful for purifying the expressed protein.

In a preferred method, polynucleotides encoding the novel amino acid sequences are changed via site-directed mutagenesis. This method uses oligonucleotide sequences to alter a polynucleotide to encode the desired amino acid variant, as well as sufficient adjacent nucleotides on both sides of the changed amino acid to form a stable duplex on either side of the site being changed. In general, the techniques of site-directed mutagenesis are well known to those of skill in the art and this technique is exemplified by publications such as, Edelman et al., *DNA* 2:183 (1983). A versatile and efficient method for producing site-specific changes in a polynucleotide sequence was published by Zoller and Smith, *Nucleic Acids Res.* 10:6487-6500 (1982). PCR may also be used to create amino acid sequence variants of the novel nucleic acids. When small amounts of template DNA are used as starting material, primer(s) that differs slightly in sequence from the corresponding region in the template DNA can generate the desired amino acid variant. PCR amplification results in a population of product DNA fragments that differ from the polynucleotide template encoding the polypeptide at the position specified by the primer. The product DNA fragments replace the corresponding region in the plasmid and this gives a polynucleotide encoding the desired amino acid variant.

A further technique for generating amino acid variants is the cassette mutagenesis technique described in Wells et al., *Gene* 34:315 (1985); and other mutagenesis techniques well known in the art, such as, for example, the techniques in Sambrook et al., supra, and *Current Protocols in Molecular Biology*, Ausubel et al. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be used in the practice of the invention for the cloning and expression of these novel nucleic acids. Such DNA sequences include those which are capable of hybridizing to the appropriate novel nucleic acid sequence under stringent conditions.

Polynucleotides encoding preferred polypeptide truncations of the invention can be used to generate polynucleotides encoding chimeric or fusion proteins comprising one or more domains of the invention and heterologous protein sequences.

The polynucleotides of the invention additionally include the complement of any of the polynucleotides recited above. The polynucleotide can be DNA (genomic, cDNA, amplified, or synthetic) or RNA. Methods and algorithms for obtaining such polynucleotides are well known to those of skill in the art and can include, for example, methods for determining hybridization conditions that can routinely isolate polynucleotides of the desired sequence identities.

In accordance with the invention, polynucleotide sequences comprising the mature protein coding sequences corresponding to any one of SEQ ID NO: 3, 6, 8-13, 19, 22, 24-28, 33-34, 37, 40, 42-45, 50, 52-58, 66, or 68-74 or functional equivalents thereof, may be used to generate recombinant DNA molecules that direct the expression of that nucleic acid, or a functional equivalent thereof, in appropriate host cells. Also included are the cDNA inserts of any of the clones identified herein.

A polynucleotide according to the invention can be joined to any of a variety of other nucleotide sequences by well-established recombinant DNA techniques (see Sambrook J et al. (1989) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, NY). Useful nucleotide sequences for joining to polynucleotides include an assortment of vectors, e.g., plasmids, cosmids, lambda phage derivatives, phagemids, and the like, that are well known in the art. Accordingly, the invention also provides a vector including a polynucleotide of the invention and a host cell containing the polynucleotide. In general, the vector contains an origin of replication functional in at least one organism, convenient restriction endonuclease sites, and a selectable marker for the host cell. Vectors according to the invention include expression vectors, replication vectors, probe generation vectors, and sequencing vectors. A

host cell according to the invention can be a prokaryotic or eukaryotic cell and can be a unicellular organism or part of a multicellular organism.

The present invention further provides recombinant constructs comprising a nucleic acid having any of the nucleotide sequences of the SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67 or a fragment thereof or any other polynucleotides of the invention. In one embodiment, the recombinant constructs of the present invention comprise a vector, such as a plasmid or viral vector, into which a nucleic acid having any of the nucleotide sequences of the SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67 or a fragment thereof is inserted, in a forward or reverse orientation. In the case of a vector comprising one of the ORFs of the present invention, the vector may further comprise regulatory sequences, including for example, a promoter, operably linked to the ORF. Large numbers of suitable vectors and promoters are known to those of skill in the art and are commercially available for generating the recombinant constructs of the present invention. The following vectors are provided by way of example. Bacterial: pBs, phagescript, PsiX174, pBluescript SK, pBs KS, pNH8a, pNH16a, pNH18a, pNH46a (Stratagene); pTrc99A, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia). Eukaryotic: pWLneo, pSV2cat, pOG44, PXTI, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia).

The isolated polynucleotide of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al., *Nucleic Acids Res.* 19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, *Methods in Enzymology* 185, 537-566 (1990). As defined herein "operably linked" means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.

Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers. Two appropriate vectors are pKK232-8 and pCM7. Particular named bacterial promoters include lacI, lacZ, T3, T7, gpt, lambda PR, and trc. Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art. Generally, recombinant expression vectors will include origins of replication and selectable

markers permitting transformation of the host cell, *e.g.*, the ampicillin resistance gene of *E. coli* and *S. cerevisiae* TRP1 gene, and a promoter derived from a highly expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), a-factor, acid phosphatase, or heat shock proteins, among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a fusion protein including an amino terminal identification peptide imparting desired characteristics, *e.g.*, stabilization or simplified purification of expressed recombinant product. Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter. The vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to, if desirable, provide amplification within the host. Suitable prokaryotic hosts for transformation include *E. coli*, *Bacillus subtilis*, *Salmonella typhimurium* and various species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*, although others may also be employed as a matter of choice.

As a representative but non-limiting example, useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and GEM 1 (Promega Biotech, Madison, WI, USA). These pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed. Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is induced or derepressed by appropriate means (*e.g.*, temperature shift or chemical induction) and cells are cultured for an additional period. Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.

Polynucleotides of the invention can also be used to induce immune responses. For example, as described in Fan et al., *Nat. Biotech.* 17, 870-872 (1999), incorporated herein by reference, nucleic acid sequences encoding a polypeptide may be used to generate antibodies against the encoded polypeptide following topical administration of naked plasmid DNA or following injection, and preferably intramuscular injection of the DNA. The nucleic acid

sequences are preferably inserted in a recombinant expression vector and may be in the form of naked DNA.

5.3 ANTISENSE NUCLEIC ACIDS

5 Another aspect of the invention pertains to isolated antisense nucleic acid molecules that can hybridize to, or are complementary to, the nucleic acid molecule comprising the LIR-like nucleotide sequence, or fragments, analogs or derivatives thereof. An "antisense" nucleic acid comprises a nucleotide sequence that is complementary to a "sense" nucleic acid encoding a protein (e.g., complementary to the coding strand of a double-stranded cDNA molecule or
10 complementary to an mRNA sequence). In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire LIR-like coding strand, or to only a portion thereof. Nucleic acid molecules encoding fragments, homologs, derivatives, and analogs of an LIR-like or antisense nucleic acids complementary to an LIR-like nucleic acid sequence of are additionally provided.

15 In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding an LIR-like protein. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues. In another embodiment, the antisense nucleic acid molecule is antisense to a "conceding region" of the coding strand of a nucleotide sequence encoding the
20 LIR-like protein. The term "conceding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (i.e., also referred to as 5' and 3' untranslated regions).

Given the coding strand sequences encoding the LIR-like protein disclosed herein, antisense nucleic acids of the invention can be designed according to the rules of Watson and
25 Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of LIR-like mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of LIR-like mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of LIR-like mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15,
30 20, 25, 30, 35, 40, 45, or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability

of the duplex formed between the antisense and sense nucleic acids (e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used).

Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following section).

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding an LIR-like protein to thereby inhibit expression of the protein (e.g., by inhibiting transcription and/or translation). The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface (e.g., by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens). The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient nucleic acid molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an alpha-anomeric nucleic acid molecule. An alpha-anomeric nucleic acid molecule forms specific

double-stranded hybrids with complementary RNA in which, contrary to the usual alpha-units, the strands run parallel to each other. See, e.g., Gaultier, et al., 1987. Nucl. Acids Res. 15, 6625-6641. The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (see, e.g., Inoue, et al. 1987. Nucl. Acids Res. 15, 6131-6148) or a chimeric RNA-DNA analogue (see, e.g., Inoue, et al., 1987. FEBS Lett. 215, 327-330).

5.4 RIBOZYMES AND PNA MOIETIES

Nucleic acid modifications include, by way of non-limiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they can be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject.

In one embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes as described in Haselhoff and Gerlach 1988. Nature 334, 585-591) can be used to catalytically cleave LIR-like mRNA transcripts to thereby inhibit translation of LIR-like mRNA. A ribozyme having specificity for an LIR-like-encoding nucleic acid can be designed based upon the nucleotide sequence of an LIR-like cDNA disclosed herein. For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in an LIR-like-encoding mRNA. See, e.g., U.S. Patent 4,987,071 to Cech, et al. and U.S. Patent 5,116,742 to Cech, et al. LIR-like mRNA can also be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel et al., (1993) Science 261, 1411-1418.

Alternatively, LIR-like gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the LIR-like nucleic acid (e.g., the LIR-like promoter and/or enhancers) to form triple helical structures that prevent transcription of the LIR-like gene in target cells. See, e.g., Helene, 1991. Anticancer Drug Des. 6, 569-84; Helene, et al. 1992. Ann. N.Y. Acad. Sci. 660, 27-36; Maher, 1992. Bioassays 14, 807-15.

In various embodiments, the LIR-like nucleic acids can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids. See, e.g., Hyrup, et al., 1996. Bioorg Med Chem 4, 5-23. As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics

(e.g., DNA mimics) in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup, et al., 1996. *supra*; Perry-O'Keefe, et al., 1996. *Proc. Natl. Acad. Sci. USA* 93, 14670-14675.

PNAs of LIR-like can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting replication. PNAs of LIR-like can also be used, for example, in the analysis of single base pair mutations in a gene (e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., S1 nucleases (see, Hyrup, et al., 1996.*supra*); or as probes or primers for DNA sequence and hybridization (see, Hyrup, et al., 1996, *supra*; Perry-O'Keefe, et al., 1996. *supra*).

In another embodiment, PNAs of LIR-like can be modified, e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of LIR-like can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes (e.g., RNase H and DNA polymerases) to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (see, Hyrup, et al., 1996. *supra*). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup, et al., 1996. *supra* and Finn, et al., 1996. *Nucl Acids Res* 24, 3357-3363. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, e.g., 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5' end of DNA. See, e.g., Mag, et al., 1989. *Nucl Acid Res* 17, 5973-5988. PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment. See, e.g., Finn, et al., 1996. *supra*. Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment. See, e.g., Petersen, et al., 1975. *Bioorg. Med. Chem. Lett.* 5, 1119-11124.

In other embodiments, the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger, et al., 1989. Proc. Natl. Acad. Sci. U.S.A. 86, 6553-6556; Lemaitre, et al., 1987. Proc. Natl. Acad. Sci. 84, 648-652; PCT Publication No. WO88/09810) or
5 the blood-brain barrier (see, e.g., PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (see, e.g., Krol, et al., 1988. BioTechniques 6, 958-976) or intercalating agents (see, e.g., Zon, 1988. Pharm. Res. 5, 539-549). To this end, the oligonucleotide can be conjugated to another molecule, e.g., a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered
10 cleavage agent, and the like.

5.5 HOSTS

The present invention further provides host cells genetically engineered to contain the polynucleotides of the invention. For example, such host cells may contain nucleic acids of the
15 invention introduced into the host cell using known transformation, transfection or infection methods. The present invention still further provides host cells genetically engineered to express the polynucleotides of the invention, wherein such polynucleotides are in operative association with a regulatory sequence heterologous to the host cell which drives expression of the polynucleotides in the cell.

20 Knowledge of LIR-like DNA sequences allows for modification of cells to permit, or increase, expression of LIR-like polypeptide. Cells can be modified (e.g., by homologous recombination) to provide increased LIR-like polypeptide expression by replacing, in whole or in part, the naturally occurring LIR-like promoter with all or part of a heterologous promoter so that the cells LIR-like polypeptide is expressed at higher levels. The heterologous promoter
25 is inserted in such a manner that it is operatively linked to LIR-like encoding sequences. See, for example, PCT International Publication No. WO94/12650, PCT International Publication No. WO92/20808, and PCT International Publication No. WO91/09955. It is also contemplated that, in addition to heterologous promoter DNA, amplifiable marker DNA (e.g., *ada*, *dhfr*, and the multifunctional CAD gene which encodes carbamyl phosphate synthase, aspartate transcarbamylase, and dihydroorotase) and/or intron DNA may be inserted along
30 with the heterologous promoter DNA. If linked to the LIR-like coding sequence, amplification of the marker DNA by standard selection methods results in co-amplification of the LIR-like coding sequences in the cells.

The host cell can be a higher eukaryotic host cell, such as a mammalian cell, a lower eukaryotic host cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the recombinant construct into the host cell can be effected by calcium phosphate transfection, DEAE, dextran mediated transfection, or electroporation (Davis, L. et al., Basic Methods in Molecular Biology (1986)). The host cells containing one of polynucleotides of the invention, can be used in conventional manners to produce the gene product encoded by the isolated fragment (in the case of an ORF) or can be used to produce a heterologous protein under the control of the EMF.

Any host/vector system can be used to express one or more of the ORFs of the present invention. These include, but are not limited to, eukaryotic hosts such as HeLa cells, Cv-1 cell, COS cells, and Sf9 cells, as well as prokaryotic host such as E. coli and B. subtilis. The most preferred cells are those which do not normally express the particular polypeptide or protein or which expresses the polypeptide or protein at low natural level. Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, et al., in Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, New York (1989), the disclosure of which is hereby incorporated by reference.

Various mammalian cell culture systems can also be employed to express recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, Cell 23:175 (1981), and other cell lines capable of expressing a compatible vector, for example, the C127, 3T3, CHO, HeLa and BHK cell lines. Mammalian expression vectors will comprise an origin of replication, a suitable promoter, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequences derived from the SV40 viral genome, for example, SV40 origin, early promoter, enhancer, splice, and polyadenylation sites may be used to provide the required nontranscribed genetic elements. Recombinant polypeptides and proteins produced in bacterial culture are usually isolated by initial extraction from cell pellets, followed by one or more salting-out, aqueous ion exchange or size exclusion chromatography steps. Protein refolding steps can be used, as necessary, in completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps. Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents.

A number of types of cells may act as suitable host cells for expression of the protein. Mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.

Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces* strains, *Candida*, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include *Escherichia coli*, *Bacillus subtilis*, *Salmonella typhimurium*, or any bacterial strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.

In another embodiment of the present invention, cells and tissues may be engineered to express an endogenous gene comprising the polynucleotides of the invention under the control of inducible regulatory elements, in which case the regulatory sequences of the endogenous gene may be replaced by homologous recombination. As described herein, gene targeting can be used to replace a gene's existing regulatory region with a regulatory sequence isolated from a different gene or a novel regulatory sequence synthesized by genetic engineering methods. Such regulatory sequences may be comprised of promoters, enhancers, scaffold-attachment regions, negative regulatory elements, transcriptional initiation sites, and regulatory protein binding sites or combinations of said sequences. Alternatively, sequences which affect the structure or stability of the RNA or protein produced may be replaced, removed, added, or otherwise modified by targeting, including polyadenylation signals, mRNA stability elements, splice sites, leader sequences for enhancing or modifying transport or secretion properties of the protein, or other sequences which alter or improve the function or stability of protein or RNA molecules.

The targeting event may be a simple insertion of the regulatory sequence, placing the gene under the control of the new regulatory sequence, e.g., inserting a new promoter or enhancer or both upstream of a gene. Alternatively, the targeting event may be a simple deletion of a regulatory element, such as the deletion of a tissue-specific negative regulatory element. Alternatively, the targeting event may replace an existing element; for example, a tissue-specific enhancer can be replaced by an enhancer that has broader or different cell-type specificity than the naturally occurring elements. Here, the naturally occurring sequences are deleted and new

sequences are added. In all cases, the identification of the targeting event may be facilitated by the use of one or more selectable marker genes that are contiguous with the targeting DNA, allowing for the selection of cells in which the exogenous DNA has integrated into the host cell genome. The identification of the targeting event may also be facilitated by the use of one or more marker genes exhibiting the property of negative selection, such that the negatively selectable marker is linked to the exogenous DNA, but configured such that the negatively selectable marker flanks the targeting sequence, and such that a correct homologous recombination event with sequences in the host cell genome does not result in the stable integration of the negatively selectable marker. Markers useful for this purpose include the Herpes Simplex Virus thymidine kinase (TK) gene or the bacterial xanthine-guanine phosphoribosyl-transferase (gpt) gene.

The gene targeting or gene activation techniques which can be used in accordance with this aspect of the invention are more particularly described in U.S. Patent No. 5,272,071 to Chappel; U.S. Patent No. 5,578,461 to Sherwin et al.; International Application No. PCT/US92/09627 (WO93/09222) by Selden et al.; and International Application No. PCT/US90/06436 (WO91/06667) by Skoultchi et al., each of which is incorporated by reference herein in its entirety.

5.6 POLYPEPTIDES OF THE INVENTION

The isolated polypeptides of the invention include, but are not limited to, a polypeptide comprising: the amino acid sequence set forth as any one of SEQ ID NO: 3, 6, 8-13, 19, 22, 24-28, 33-34, 37, 40, 42-45, 50, 52-58, 66, or 68-74 or an amino acid sequence encoded by any one of the nucleotide sequences SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67 or the corresponding full length or mature protein. Polypeptides of the invention also include polypeptides preferably with biological or immunological activity that are encoded by: (a) a polynucleotide having any one of the nucleotide sequences set forth in the SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67 or (b) polynucleotides encoding any one of the amino acid sequences set forth as SEQ ID NO: 3, 6, 8-13, 19, 22, 24-28, 33-34, 37, 40, 42-45, 50, 52-58, 66, or 68-74 or (c) polynucleotides that hybridize to the complement of the polynucleotides of either (a) or (b) under stringent hybridization conditions. The invention also provides biologically active or immunologically active variants of any of the amino acid sequences set forth as SEQ ID NO: 3, 6, 8-13, 19, 22, 24-28, 33-34, 37, 40, 42-45, 50, 52-58, 66, or 68-74 or the corresponding full length or mature protein; and "substantial equivalents" (e.g., with at least about 65%, at least about

70%, at least about 75%, at least about 80%, at least about 85%, 86%, 87%, 88%, 89%, at least about 90%, 91%, 92%, 93%, 94%, typically at least about 95%, 96%, 97%, more typically at least about 98%, or most typically at least about 99% amino acid identity) that retain biological activity. Polypeptides encoded by allelic variants may have a similar, increased, or decreased activity compared to polypeptides comprising SEQ ID NO: 3, 6, 8-13, 19, 22, 24-28, 33-34, 37, 40, 42-45, 50, 52-58, 66, or 68-74.

Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H. U. Saragovi, et al., Bio/Technology 10, 773-778 (1992) and in R. S. McDowell, et al., J. Amer. Chem. Soc. 114, 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites.

The present invention also provides both full-length and mature forms (for example, without a signal sequence or precursor sequence) of the disclosed proteins. The protein coding sequence is identified in the sequence listing by translation of the disclosed nucleotide sequences. The mature form of such protein may be obtained by expression of a full-length polynucleotide in a suitable mammalian cell or other host cell. The sequence of the mature form of the protein is also determinable from the amino acid sequence of the full-length form. Where proteins of the present invention are membrane bound, soluble forms of the proteins are also provided. In such forms, part or all of the regions causing the proteins to be membrane bound are deleted so that the proteins are fully secreted from the cell in which it is expressed.

Protein compositions of the present invention may further comprise an acceptable carrier, such as a hydrophilic, *e.g.*, pharmaceutically acceptable, carrier.

The present invention further provides isolated polypeptides encoded by the nucleic acid fragments of the present invention or by degenerate variants of the nucleic acid fragments of the present invention. By "degenerate variant" is intended nucleotide fragments which differ from a nucleic acid fragment of the present invention (*e.g.*, an ORF) by nucleotide sequence but, due to the degeneracy of the genetic code, encode an identical polypeptide sequence. Preferred nucleic acid fragments of the present invention are the ORFs that encode proteins.

A variety of methodologies known in the art can be utilized to obtain any one of the isolated polypeptides or proteins of the present invention. At the simplest level, the amino acid sequence can be synthesized using commercially available peptide synthesizers. The

synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. This technique is particularly useful in producing small peptides and fragments of larger polypeptides. Fragments are useful, for example, in generating antibodies against the native polypeptide. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.

The polypeptides and proteins of the present invention can alternatively be purified from cells which have been altered to express the desired polypeptide or protein. As used herein, a cell is said to be altered to express a desired polypeptide or protein when the cell, through genetic manipulation, is made to produce a polypeptide or protein which it normally does not produce or which the cell normally produces at a lower level. One skilled in the art can readily adapt procedures for introducing and expressing either recombinant or synthetic sequences into eukaryotic or prokaryotic cells in order to generate a cell which produces one of the polypeptides or proteins of the present invention.

The invention also relates to methods for producing a polypeptide comprising growing a culture of host cells of the invention in a suitable culture medium, and purifying the protein from the cells or the culture in which the cells are grown. For example, the methods of the invention include a process for producing a polypeptide in which a host cell containing a suitable expression vector that includes a polynucleotide of the invention is cultured under conditions that allow expression of the encoded polypeptide. The polypeptide can be recovered from the culture, conveniently from the culture medium, or from a lysate prepared from the host cells and further purified. Preferred embodiments include those in which the protein produced by such process is a full length or mature form of the protein.

In an alternative method, the polypeptide or protein is purified from bacterial cells which naturally produce the polypeptide or protein. One skilled in the art can readily follow known methods for isolating polypeptides and proteins in order to obtain one of the isolated polypeptides or proteins of the present invention. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-exchange chromatography, and immuno-affinity chromatography. See, *e.g.*, Scopes, *Protein Purification: Principles and Practice*, Springer-Verlag (1994); Sambrook, et al., in *Molecular Cloning: A Laboratory Manual*; Ausubel et al., *Current Protocols in Molecular Biology*. Polypeptide fragments that retain biological/immunological activity include fragments

comprising greater than about 100 amino acids, or greater than about 200 amino acids, and fragments that encode specific protein domains.

The purified polypeptides can be used in *in vitro* binding assays which are well known in the art to identify molecules which bind to the polypeptides. These molecules include but
5 are not limited to, for e.g., small molecules, molecules from combinatorial libraries, antibodies or other proteins. The molecules identified in the binding assay are then tested for antagonist or agonist activity in *in vivo* tissue culture or animal models that are well known in the art. In brief, the molecules are titrated into a plurality of cell cultures or animals and then tested for either cell/animal death or prolonged survival of the animal/cells.

10 In addition, the peptides of the invention or molecules capable of binding to the peptides may be complexed with toxins, e.g., ricin or cholera, or with other compounds that are toxic to cells. The toxin-binding molecule complex is then targeted to a tumor or other cell by the specificity of the binding molecule for SEQ ID NO: 3, 6, 8-13, 19, 22, 24-28, 33-34, 37, 40, 42-45, 50, 52-58, 66, or 68-74.

15 The protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.

The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally
20 provided or deliberately engineered. For example, modifications, in the peptide or DNA sequence, can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the
25 conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Pat. No. 4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein. Regions of the protein that are important for the protein function can be determined by various methods known in the art including the alanine-scanning
30 method which involved systematic substitution of single or strings of amino acids with alanine, followed by testing the resulting alanine-containing variant for biological activity. This type of analysis determines the importance of the substituted amino acid(s) in biological activity. Regions of the protein that are important for protein function may be determined by the eMATRIX program.

Other fragments and derivatives of the sequences of proteins which would be expected to retain protein activity in whole or in part and are useful for screening or other immunological methodologies may also be easily made by those skilled in the art given the disclosures herein. Such modifications are encompassed by the present invention.

5 The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, *e.g.*, Invitrogen, San Diego, Calif., U.S.A. (the MaxBat™ kit), and such methods are well known in the art, as described in
10 Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed."

The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein
15 may then be purified from such culture (*i.e.*, from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl™ or Cibacrom blue 3GA Sepharose™; one or more steps involving
20 hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.

Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX), or as a
25 His tag. Kits for expression and purification of such fusion proteins are commercially available from New England BioLab (Beverly, Mass.), Pharmacia (Piscataway, N.J.) and Invitrogen, respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("FLAG®") is commercially available from Kodak (New Haven, Conn.).

30 Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, *e.g.*, silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein. The protein thus purified is

substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein."

The polypeptides of the invention include analogs (variants). The polypeptides of the invention include LIR-like analogs. This embraces fragments of LIR-like polypeptide of the invention, as well LIR-like polypeptides which comprise one or more amino acids deleted, inserted, or substituted. Also, analogs of the LIR-like polypeptide of the invention embrace fusions of the LIR-like polypeptides or modifications of the LIR-like polypeptides, wherein the LIR-like polypeptide or analog is fused to another moiety or moieties, e.g., targeting moiety or another therapeutic agent. Such analogs may exhibit improved properties such as activity and/or stability. Examples of moieties which may be fused to the LIR-like polypeptide or an analog include, for example, targeting moieties which provide for the delivery of polypeptide to neurons, e.g., antibodies to central nervous system, or antibodies to receptor and ligands expressed on neuronal cells. Other moieties which may be fused to LIR-like polypeptide include therapeutic agents which are used for treatment, for example anti-depressant drugs or other medications for neurological disorders. Also, LIR-like polypeptides may be fused to neuron growth modulators, and other chemokines for targeted delivery.

5.6.1 DETERMINING POLYPEPTIDE AND POLYNUCLEOTIDE IDENTITY AND SIMILARITY

Preferred identity and/or similarity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in computer programs including, but are not limited to, the GCG program package, including GAP (Devereux, J., et al., Nucleic Acids Research 12(1): 387 (1984); Genetics Computer Group, University of Wisconsin, Madison, WI), BLASTP, BLASTN, BLASTX, FASTA (Altschul, S.F. et al., J. Molec. Biol. 215:403-410 (1990), PSI-BLAST (Altschul S.F. et al., Nucleic Acids Res. vol. 25, pp. 3389-3402, herein incorporated by reference), the eMatrix software (Wu et al., J. Comp. Biol., vol. 6, pp. 219-235 (1999), herein incorporated by reference), eMotif software (Nevill-Manning et al, ISMB-97, vol 4, pp. 202-209, herein incorporated by reference), the GeneAtlas software (Molecular Simulations Inc. (MSI), San Diego, CA) (Sanchez and Sali (1998) Proc. Natl. Acad. Sci., 95, 13597-13602; Kitson DH et al, (2000) "Remote homology detection using structural modeling – an evaluation" Submitted; Fischer and Eisenberg (1996) Protein Sci. 5, 947-955), Neural Network SignalP V1.1 program (from Center for Biological Sequence Analysis, The Technical University of Denmark).and the Kyte-

Doolittle hydrophobicity prediction algorithm (J. Mol Biol, 157, pp. 105-31 (1982), incorporated herein by reference). The BLAST programs are publicly available from the National Center for Biotechnology Information (NCBI) and other sources (BLAST Manual, Altschul, S., et al. NCB NLM NIH Bethesda, MD 20894; Altschul, S., et al., J. Mol. Biol. 215:403-410 (1990).

5.7 CHIMERIC AND FUSION PROTEINS

The invention also provides LIR-like chimeric or fusion proteins. As used herein, an LIR-like "chimeric protein" or "fusion protein" comprises an LIR-like polypeptide operatively linked to either a different LIR-like polypeptide or a non-LIR-like polypeptide. An "LIR-like polypeptide" refers to a polypeptide having an amino acid sequence corresponding to an LIR-like protein, whereas a "non-LIR-like polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein that is not substantially homologous to the LIR-like protein, e.g., a protein that is different from the LIR-like protein and that is derived from the same or a different organism. Within an LIR-like fusion protein the LIR-like polypeptide can correspond to all or a portion of an LIR-like protein. In one embodiment, an LIR-like fusion protein comprises at least one biologically active portion of an LIR-like protein. In another embodiment, an LIR-like fusion protein comprises at least two biologically active portions of an LIR-like protein. In yet another embodiment, an LIR-like fusion protein comprises at least three biologically active portions of an LIR-like protein. Within the fusion protein, the term "operatively-linked" is intended to indicate that the LIR-like polypeptide(s) and/or the non-LIR-like polypeptide are fused in-frame with one another. The non-LIR-like polypeptide can be fused to the N-terminus or C-terminus of the LIR-like polypeptide.

In one embodiment, the fusion protein is a GST-LIR-like fusion protein in which the LIR-like sequences are fused to the C-terminus of the GST (glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of recombinant LIR-like polypeptides.

In another embodiment, the fusion protein is an LIR-like protein containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian host cells), expression and/or secretion of LIR-like can be increased through use of a heterologous signal sequence.

In yet another embodiment, the fusion protein is an LIR-like-immunoglobulin fusion protein in which the LIR-like sequences are fused to sequences derived from a member of the immunoglobulin protein family. The LIR-like-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an

interaction between an LIR-like ligand and an LIR-like protein on the surface of a cell, to thereby suppress LIR-like-mediated signal transduction *in vivo*. The LIR-like-immunoglobulin fusion proteins can be used to affect the bioavailability of an LIR-like cognate ligand. Inhibition of the LIR-like ligand/LIR-like interaction can be useful therapeutically for both the treatment of proliferative and differentiative disorders, as well as modulating (e.g. promoting or inhibiting) cell survival. Moreover, the LIR-like-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-LIR-like antibodies in a subject, to purify LIR-like ligands, and in screening assays to identify molecules that inhibit the interaction of LIR-like with an LIR-like ligand.

An LIR-like chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, e.g., by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, e.g., Ausubel, et al. (eds.) *Current Protocols in Molecular Biology*, John Wiley & Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). An LIR-like-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the LIR-like protein.

5.8 GENE THERAPY

Mutations in the polynucleotides of the invention gene may result in loss of normal function of the encoded protein. The invention thus provides gene therapy to restore normal activity of the polypeptides of the invention; or to treat disease states involving polypeptides of the invention. Delivery of a functional gene encoding polypeptides of the invention to appropriate cells is effected *ex vivo*, *in situ*, or *in vivo* by use of vectors, and more particularly viral vectors (e.g., adenovirus, adeno-associated virus, or a retrovirus), or *ex vivo* by use of physical DNA transfer methods (e.g., liposomes or chemical treatments). See, for example, Anderson, *Nature*, supplement to vol. 392, no. 6679, pp.25-20 (1998). For additional reviews of gene therapy technology see Friedmann, *Science*, 244: 1275-1281 (1989); Verma, *Scientific*

American: 68-84 (1990); and Miller, Nature, 357: 455-460 (1992). Introduction of any one of the nucleotides of the present invention or a gene encoding the polypeptides of the present invention can also be accomplished with extrachromosomal substrates (transient expression) or artificial chromosomes (stable expression). Cells may also be cultured *ex vivo* in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced *in vivo* for therapeutic purposes. Alternatively, it is contemplated that in other human disease states, preventing the expression of or inhibiting the activity of polypeptides of the invention will be useful in treating the disease states. It is contemplated that antisense therapy or gene therapy could be applied to negatively regulate the expression of polypeptides of the invention.

Other methods inhibiting expression of a protein include the introduction of antisense molecules to the nucleic acids of the present invention, their complements, or their translated RNA sequences, by methods known in the art. Further, the polypeptides of the present invention can be inhibited by using targeted deletion methods, or the insertion of a negative regulatory element such as a silencer, which is tissue specific.

The present invention still further provides cells genetically engineered *in vivo* to express the polynucleotides of the invention, wherein such polynucleotides are in operative association with a regulatory sequence heterologous to the host cell which drives expression of the polynucleotides in the cell. These methods can be used to increase or decrease the expression of the polynucleotides of the present invention.

Knowledge of DNA sequences provided by the invention allows for modification of cells to permit, increase, or decrease, expression of endogenous polypeptide. Cells can be modified (e.g., by homologous recombination) to provide increased polypeptide expression by replacing, in whole or in part, the naturally occurring promoter with all or part of a heterologous promoter so that the cells express the protein at higher levels. The heterologous promoter is inserted in such a manner that it is operatively linked to the desired protein encoding sequences. See, for example, PCT International Publication No. WO 94/12650, PCT International Publication No. WO 92/20808, and PCT International Publication No. WO 91/09955. It is also contemplated that, in addition to heterologous promoter DNA, amplifiable marker DNA (e.g., *ada*, *dhfr*, and the multifunctional CAD gene which encodes carbamyl phosphate synthase, aspartate transcarbamylase, and dihydroorotase) and/or intron DNA may be inserted along with the heterologous promoter DNA. If linked to the desired protein coding sequence, amplification of the marker DNA by standard selection methods results in co-amplification of the desired protein coding sequences in the cells.

In another embodiment of the present invention, cells and tissues may be engineered to express an endogenous gene comprising the polynucleotides of the invention under the control of inducible regulatory elements, in which case the regulatory sequences of the endogenous gene may be replaced by homologous recombination. As described herein, gene targeting can be used to replace a gene's existing regulatory region with a regulatory sequence isolated from a different gene or a novel regulatory sequence synthesized by genetic engineering methods. Such regulatory sequences may be comprised of promoters, enhancers, scaffold-attachment regions, negative regulatory elements, transcriptional initiation sites, regulatory protein binding sites or combinations of said sequences. Alternatively, sequences which affect the structure or stability of the RNA or protein produced may be replaced, removed, added, or otherwise modified by targeting. These sequences include polyadenylation signals, mRNA stability elements, splice sites, leader sequences for enhancing or modifying transport or secretion properties of the protein, or other sequences which alter or improve the function or stability of protein or RNA molecules.

The targeting event may be a simple insertion of the regulatory sequence, placing the gene under the control of the new regulatory sequence, *e.g.*, inserting a new promoter or enhancer or both upstream of a gene. Alternatively, the targeting event may be a simple deletion of a regulatory element, such as the deletion of a tissue-specific negative regulatory element. Alternatively, the targeting event may replace an existing element; for example, a tissue-specific enhancer can be replaced by an enhancer that has broader or different cell-type specificity than the naturally occurring elements. Here, the naturally occurring sequences are deleted and new sequences are added. In all cases, the identification of the targeting event may be facilitated by the use of one or more selectable marker genes that are contiguous with the targeting DNA, allowing for the selection of cells in which the exogenous DNA has integrated into the cell genome. The identification of the targeting event may also be facilitated by the use of one or more marker genes exhibiting the property of negative selection, such that the negatively selectable marker is linked to the exogenous DNA, but configured such that the negatively selectable marker flanks the targeting sequence, and such that a correct homologous recombination event with sequences in the host cell genome does not result in the stable integration of the negatively selectable marker. Markers useful for this purpose include the Herpes Simplex Virus thymidine kinase (TK) gene or the bacterial xanthine-guanine phosphoribosyl-transferase (gpt) gene.

The gene targeting or gene activation techniques which can be used in accordance with this aspect of the invention are more particularly described in U.S. Patent No. 5,272,071 to Chappel; U.S. Patent No. 5,578,461 to Sherwin et al.; International Application No.

PCT/US92/09627 (WO93/09222) by Selden et al.; and International Application No.

PCT/US90/06436 (WO91/06667) by Skoultchi et al., each of which is incorporated by reference herein in its entirety.

5.9 TRANSGENIC ANIMALS

In preferred methods to determine biological functions of the polypeptides of the invention *in vivo*, one or more genes provided by the invention are either over expressed or inactivated in the germ line of animals using homologous recombination [Capecchi, Science 244:1288-1292 (1989)]. Animals in which the gene is over expressed, under the regulatory control of exogenous or endogenous promoter elements, are known as transgenic animals. Animals in which an endogenous gene has been inactivated by homologous recombination are referred to as "knockout" animals. Knockout animals, preferably non-human mammals, can be prepared as described in U.S. Patent No. 5,557,032, incorporated herein by reference. Transgenic animals are useful to determine the roles polypeptides of the invention play in biological processes, and preferably in disease states. Transgenic animals are useful as model systems to identify compounds that modulate lipid metabolism. Transgenic animals, preferably non-human mammals, are produced using methods as described in U.S. Patent No 5,489,743 and PCT Publication No. WO94/28122, incorporated herein by reference.

Transgenic animals can be prepared wherein all or part of a promoter of the polynucleotides of the invention is either activated or inactivated to alter the level of expression of the polypeptides of the invention. Inactivation can be carried out using homologous recombination methods described above. Activation can be achieved by supplementing or even replacing the homologous promoter to provide for increased protein expression. The homologous promoter can be supplemented by insertion of one or more heterologous enhancer elements known to confer promoter activation in a particular tissue.

The polynucleotides of the present invention also make possible the development, through, e.g., homologous recombination or knock out strategies, of animals that fail to express functional LIR-like polypeptide or that express a variant of LIR-like polypeptide. Such animals are useful as models for studying the *in vivo* activities of LIR-like polypeptide as well as for studying modulators of the LIR-like polypeptide.

In preferred methods to determine biological functions of the polypeptides of the invention *in vivo*, one or more genes provided by the invention are either over expressed or inactivated in the germ line of animals using homologous recombination [Capecchi, Science 244:1288-1292 (1989)]. Animals in which the gene is over expressed, under the regulatory

control of exogenous or endogenous promoter elements, are known as transgenic animals.

Animals in which an endogenous gene has been inactivated by homologous recombination are referred to as "knockout" animals. Knockout animals, preferably non-human mammals, can be prepared as described in U.S. Patent No. 5,557,032, incorporated herein by reference.

5 Transgenic animals are useful to determine the roles polypeptides of the invention play in biological processes, and preferably in disease states. Transgenic animals are useful as model systems to identify compounds that modulate lipid metabolism. Transgenic animals, preferably non-human mammals, are produced using methods as described in U.S. Patent No 5,489,743 and PCT Publication No. WO94/28122, incorporated herein by reference.

10 Transgenic animals can be prepared wherein all or part of the polynucleotides of the invention promoter is either activated or inactivated to alter the level of expression of the polypeptides of the invention. Inactivation can be carried out using homologous recombination methods described above. Activation can be achieved by supplementing or even replacing the homologous promoter to provide for increased protein expression. The homologous promoter
15 can be supplemented by insertion of one or more heterologous enhancer elements known to confer promoter activation in a particular tissue.

5.10 USES AND BIOLOGICAL ACTIVITY OF HUMAN LIR-LIKE POLYPEPTIDE

The polynucleotides and proteins of the present invention are expected to exhibit one or
20 more of the uses or biological activities (including those associated with assays cited herein) identified herein. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA). The mechanism underlying the particular condition or pathology will dictate whether the
25 polypeptides of the invention, the polynucleotides of the invention or modulators (activators or inhibitors) thereof would be beneficial to the subject in need of treatment. Thus, "therapeutic compositions of the invention" include compositions comprising isolated polynucleotides (including recombinant DNA molecules, cloned genes and degenerate variants thereof) or polypeptides of the invention (including full length protein, mature protein and truncations or
30 domains thereof), or compounds and other substances that modulate the overall activity of the target gene products, either at the level of target gene/protein expression or target protein activity. Such modulators include polypeptides, analogs, (variants), including fragments and fusion proteins, antibodies and other binding proteins; chemical compounds that directly or indirectly activate or inhibit the polypeptides of the invention (identified, e.g., via drug

screening assays as described herein); antisense polynucleotides and polynucleotides suitable for triple helix formation; and in particular antibodies or other binding partners that specifically recognize one or more epitopes of the polypeptides of the invention.

5 The polypeptides of the present invention may likewise be involved in cellular activation or in one of the other physiological pathways described herein.

5.10.1 RESEARCH USES AND UTILITIES

The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the
10 corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify
15 potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip" or other support, including for examination of expression patterns; to raise anti-protein antibodies using
20 DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, that described in Gyuris et al., Cell 75:791-803 (1993)) to identify polynucleotides encoding the other protein
25 with which binding occurs or to identify inhibitors of the binding interaction.

The polypeptides provided by the present invention can similarly be used in assays to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its
30 receptor) in biological fluids; as markers for tissues in which the corresponding polypeptide is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.

The polypeptides of the invention are also useful for making antibody substances that are specifically immunoreactive with LIR-like proteins. Antibodies and portions thereof (e.g., Fab fragments) which bind to the polypeptides of the invention can be used to identify the presence of such polypeptides in a sample. Such determinations are carried out using any suitable immunoassay format, and any polypeptide of the invention that is specifically bound by the antibody can be employed as a positive control.

Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products.

Methods for performing the uses listed above are well known to those skilled in the art.

References disclosing such methods include without limitation "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987.

5.10.2 NUTRITIONAL USES

Polynucleotides and polypeptides of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the polypeptide or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the polypeptide or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured.

Additionally, the polypeptides of the invention can be used as molecular weight markers, and as a food supplement. A polypeptide consisting of SEQ ID NO: 3, for example, has a molecular mass of approximately 34 kDa in its unprocessed and unglycosylated state. Protein food supplements are well known and the formulation of suitable food supplements including polypeptides of the invention is within the level of skill in the food preparation art.

5.10.3 CYTOKINE AND CELL PROLIFERATION/DIFFERENTIATION ACTIVITY

A polypeptide of the present invention may exhibit activity relating to cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. A polynucleotide of the invention can encode a polypeptide exhibiting such attributes. Many

protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor-dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of therapeutic compositions of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+(preB M+), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e, CMK, HUVEC, and Caco. Therapeutic compositions of the invention can be used in the following:

Assays for T-cell or thymocyte proliferation include without limitation those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H.

Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, *In Vitro* assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Bertagnolli et al., J. Immunol. 145:1706-1712, 1990; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Bertagnolli, et al., I. Immunol. 149:3778-3783, 1992; Bowman et al., I. Immunol. 152:1756-1761, 1994.

Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A. M. and Shevach, E. M. In Current Protocols in Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human interleukin- γ , Schreiber, R. D. In Current Protocols in Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.

Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L. S. and Lipsky, P. E. In Current Protocols in Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., J. Exp. Med. 173:1205-1211, 1991; Moreau et al., Nature 336:690-692, 1988; Greenberger et al., Proc. Natl. Acad. Sci. U.S.A. 80:2931-2938, 1983; Measurement of mouse and human interleukin 6--Nordan, R. In Current Protocols in Immunology. J. E. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al., Proc. Natl. Acad. Sci. U.S.A. 83:1857-1861, 1986; Measurement of human Interleukin 11--Bennett, F., Giannotti, J., Clark, S. C. and Turner, K. J. In Current Protocols in Immunology. J. E. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991; Measurement of mouse and human Interleukin 9-Ciarletta, A., Giannotti, J., Clark, S. C. and Turner, K. J. In Current

Protocols in Immunology. J. E. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.

Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, *In Vitro* assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988.

5.10.4 STEM CELL GROWTH FACTOR ACTIVITY

A polypeptide of the present invention may exhibit stem cell growth factor activity and be involved in the proliferation, differentiation and survival of pluripotent and totipotent stem cells including primordial germ cells, embryonic stem cells, hematopoietic stem cells and/or germ line stem cells. Administration of the polypeptide of the invention to stem cells *in vivo* or *ex vivo* may maintain and expand cell populations in a totipotent or pluripotent state which would be useful for re-engineering damaged or diseased tissues, transplantation, manufacture of bio-pharmaceuticals and the development of bio-sensors. The ability to produce large quantities of human cells has important working applications for the production of human proteins which currently must be obtained from non-human sources or donors, implantation of cells to treat diseases such as Parkinson's, Alzheimer's and other neurodegenerative diseases; tissues for grafting such as bone marrow, skin, cartilage, tendons, bone, muscle (including cardiac muscle), blood vessels, cornea, neural cells, gastrointestinal cells and others; and organs for transplantation such as kidney, liver, pancreas (including islet cells), heart and lung.

It is contemplated that multiple different exogenous growth factors and/or cytokines may be administered in combination with the polypeptide of the invention to achieve the desired effect, including any of the growth factors listed herein, other stem cell maintenance factors, and specifically including stem cell factor (SCF), leukemia inhibitory factor (LIF), Flt-3 ligand (Flt-3L), any of the interleukins, recombinant soluble IL-6 receptor fused to IL-6, macrophage inflammatory protein 1-alpha (MIP-1-alpha), G-CSF, GM-CSF, thrombopoietin

(TPO), platelet factor 4 (PF-4), platelet-derived growth factor (PDGF), neural growth factors and basic fibroblast growth factor (bFGF).

Since totipotent stem cells can give rise to virtually any mature cell type, expansion of these cells in culture will facilitate the production of large quantities of mature cells.

5 Techniques for culturing stem cells are known in the art and administration of polypeptides of the invention, optionally with other growth factors and/or cytokines, is expected to enhance the survival and proliferation of the stem cell populations. This can be accomplished by direct administration of the polypeptide of the invention to the culture medium. Alternatively, stroma
10 cells transfected with a polynucleotide that encodes for the polypeptide of the invention can be used as a feeder layer for the stem cell populations in culture or in vivo. Stromal support cells for feeder layers may include embryonic bone marrow fibroblasts, bone marrow stromal cells, fetal liver cells, or cultured embryonic fibroblasts (see U.S. Patent No. 5,690,926).

Stem cells themselves can be transfected with a polynucleotide of the invention to induce autocrine expression of the polypeptide of the invention. This will allow for generation
15 of undifferentiated totipotent/pluripotent stem cell lines that are useful as is or that can then be differentiated into the desired mature cell types. These stable cell lines can also serve as a source of undifferentiated totipotent/pluripotent mRNA to create cDNA libraries and templates for polymerase chain reaction experiments. These studies would allow for the isolation and identification of differentially expressed genes in stem cell populations that
20 regulate stem cell proliferation and/or maintenance.

Expansion and maintenance of totipotent stem cell populations will be useful in the treatment of many pathological conditions. For example, polypeptides of the present invention may be used to manipulate stem cells in culture to give rise to neuroepithelial cells that can be used to augment or replace cells damaged by illness, autoimmune disease, accidental damage
25 or genetic disorders. The polypeptide of the invention may be useful for inducing the proliferation of neural cells and for the regeneration of nerve and brain tissue, i.e. for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders which involve degeneration, death or trauma to neural cells or nerve tissue. In addition, the expanded stem cell populations can also be genetically altered
30 for gene therapy purposes and to decrease host rejection of replacement tissues after grafting or implantation.

Expression of the polypeptide of the invention and its effect on stem cells can also be manipulated to achieve controlled differentiation of the stem cells into more differentiated cell types. A broadly applicable method of obtaining pure populations of a specific differentiated

cell type from undifferentiated stem cell populations involves the use of a cell-type specific promoter driving a selectable marker. The selectable marker allows only cells of the desired type to survive. For example, stem cells can be induced to differentiate into cardiomyocytes (Wobus et al., Differentiation, 48: 173-182, (1991); Klug et al., J. Clin. Invest., 98(1): 216-224, (1998)) or skeletal muscle cells (Browder, L. W. In: *Principles of Tissue Engineering* eds. Lanza et al., Academic Press (1997)). Alternatively, directed differentiation of stem cells can be accomplished by culturing the stem cells in the presence of a differentiation factor such as retinoic acid and an antagonist of the polypeptide of the invention which would inhibit the effects of endogenous stem cell factor activity and allow differentiation to proceed.

10 *In vitro* cultures of stem cells can be used to determine if the polypeptide of the invention exhibits stem cell growth factor activity. Stem cells are isolated from any one of various cell sources (including hematopoietic stem cells and embryonic stem cells) and cultured on a feeder layer, as described by Thompson et al. Proc. Natl. Acad. Sci, U.S.A., 92: 7844-7848 (1995), in the presence of the polypeptide of the invention alone or in combination with
15 other growth factors or cytokines. The ability of the polypeptide of the invention to induce stem cells proliferation is determined by colony formation on semi-solid support e.g. as described by Bernstein et al., Blood, 77: 2316-2321 (1991).

5.10.5 HEMATOPOIESIS REGULATING ACTIVITY

20 A polypeptide of the present invention may be involved in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell disorders. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating
25 utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth
30 and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell

disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either *in-vivo* or *ex-vivo* (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation
 5 (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.

Therapeutic compositions of the invention can be used in the following:

Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.

Assays for embryonic stem cell differentiation (which will identify, among others,
 10 proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. Cellular Biology 15:141-151, 1995; Keller et al., Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood 81:2903-2915, 1993.

Assays for stem cell survival and differentiation (which will identify, among others,
 15 proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M. G. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, N.Y. 1994; Hirayama et al., Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I. K. and Briddell, R. A. In
 20 Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, N.Y. 1994; Neben et al., Experimental Hematology 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R. E. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, N.Y. 1994; Long term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and Allen, T.
 25 In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, N.Y. 1994; Long term culture initiating cell assay, Sutherland, H. J. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, N.Y. 1994.

30 5.10.6 TISSUE GROWTH ACTIVITY

A polypeptide of the present invention also may be involved in bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as in wound healing and tissue repair and replacement, and in healing of burns, incisions and ulcers.

A polypeptide of the present invention which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Compositions of a polypeptide, antibody, binding partner, or other modulator of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

A polypeptide of this invention may also be involved in attracting bone-forming cells, stimulating growth of bone-forming cells, or inducing differentiation of progenitors of bone-forming cells. Treatment of osteoporosis, osteoarthritis, bone degenerative disorders, or periodontal disease, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes may also be possible using the composition of the invention.

Another category of tissue regeneration activity that may involve the polypeptide of the present invention is tendon/ligament formation. Induction of tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors *ex vivo* for return *in vivo* to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.

The compositions of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, i.e. for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a composition may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a composition of the invention.

Compositions of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.

Compositions of the present invention may also be involved in the generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring may allow normal tissue to regenerate. A polypeptide of the present invention may also exhibit angiogenic activity.

A composition of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.

A composition of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.

Therapeutic compositions of the invention can be used in the following:

Assays for tissue generation activity include, without limitation, those described in: International Patent Publication No. WO95/16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium).

Assays for wound healing activity include, without limitation, those described in: Winter, Epidermal Wound Healing, pp. 71-112 (Maibach, H. I. and Rovee, D. T., eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J. Invest. Dermatol 71:382-84 (1978).

5

5.10.7 IMMUNE STIMULATING OR SUPPRESSING ACTIVITY

A polypeptide of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A polynucleotide of the invention can encode a polypeptide exhibiting such activities.

10 A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases caused by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpes viruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, proteins of the present invention may also be useful where a boost to the immune system generally may be desirable, 15 i.e., in the treatment of cancer.

Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus, myasthenia gravis, 25 graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein (or antagonists thereof, including antibodies) of the present invention may also be useful in the treatment of allergic reactions and conditions (e.g., anaphylaxis, serum sickness, drug reactions, food allergies, insect venom allergies, mastocytosis, allergic rhinitis, hypersensitivity pneumonitis, urticaria, angioedema, eczema, atopic dermatitis, allergic contact dermatitis, erythema multiforme, Stevens-Johnson syndrome, allergic conjunctivitis, atopic 30 keratoconjunctivitis, venereal keratoconjunctivitis, giant papillary conjunctivitis and contact allergies), such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein (or antagonists thereof) of the present

invention. The therapeutic effects of the polypeptides or antagonists thereof on allergic reactions can be evaluated by in vivo animals models such as the cumulative contact enhancement test (Lastbom et al., Toxicology 125: 59-66, 1998), skin prick test (Hoffmann et al., Allergy 54: 446-54, 1999), guinea pig skin sensitization test (Vohr et al., Arch. Toxicol. 73: 501-9), and murine local lymph node assay (Kimber et al., J. Toxicol. Environ. Health 53: 563-79).

Using the proteins of the invention it may also be possible to modulate immune responses, in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.

Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as, for example, B7)), e.g., preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a therapeutic composition of the invention may prevent cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, a lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.

The efficacy of particular therapeutic compositions in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts

in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins in vivo as described in Lenschow et al., Science 257:789-792 (1992) and Turka et al., Proc. Natl. Acad. Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of therapeutic compositions of the invention on the development of that disease.

Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block stimulation of T cells can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythematosus in MRL/lpr/lpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).

Upregulation of an antigen function (e.g., a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response may be useful in cases of viral infection, including systemic viral diseases such as influenza, the common cold, and encephalitis.

Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells in vitro with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the in vitro activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein

on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells in vivo.

A polypeptide of the present invention may provide the necessary stimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient mounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class I alpha chain protein and β_2 microglobulin protein or an MHC class II alpha chain protein and an MHC class II beta chain protein to thereby express MHC class I or MHC class II proteins on the cell surface. Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., I. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bowman et al., J. Virology 61:1992-1998; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Brown et al., J. Immunol. 153:3079-3092, 1994.

Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function: In vitro antibody production,

Mond, J. J. and Brunswick, M. In Current Protocols in Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.

Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.

Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.

Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993; Gorczyca et al., International Journal of Oncology 1:639-648, 1992.

Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad Sci. USA 88:7548-7551, 1991.

5.10.8 ACTIVIN/INHIBIN ACTIVITY

A polypeptide of the present invention may also exhibit activin- or inhibin-related activities. A polynucleotide of the invention may encode a polypeptide exhibiting such characteristics. Inhibins are characterized by their ability to inhibit the release of follicle

stimulating hormone (FSH), while activins and are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a polypeptide of the present invention, alone or in heterodimers with a member of the inhibin family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the polypeptide of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, U.S. Pat. No. 4,798,885. A polypeptide of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as, but not limited to, cows, sheep and pigs.

The activity of a polypeptide of the invention may, among other means, be measured by the following methods.

Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., *Endocrinology* 91:562-572, 1972; Ling et al., *Nature* 321:779-782, 1986; Vale et al., *Nature* 321:776-779, 1986; Mason et al., *Nature* 318:659-663, 1985; Forage et al., *Proc. Natl. Acad. Sci. USA* 83:3091-3095, 1986.

5.10.9 CHEMOTACTIC/CHEMOKINETIC ACTIVITY

A polypeptide of the present invention may be involved in chemotactic or chemokinetic activity for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells. A polynucleotide of the invention can encode a polypeptide exhibiting such attributes. Chemotactic and chemokinetic receptor activation can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic compositions (e.g. proteins, antibodies, binding partners, or modulators of the invention) provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.

A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of

cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.

Therapeutic compositions of the invention can be used in the following:

- 5 Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, 10 A. M. Kruisbeek, D. H. Marguiles, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95:1370-1376, 1995; Lind et al. APMIS 103:140-146, 1995; Muller et al Eur. J. Immunol. 25:1744-1748; Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnston et al. J. of Immunol. 153:1762-1768, 1994.

15

5.10.10 HEMOSTATIC AND THROMBOLYTIC ACTIVITY

- A polypeptide of the invention may also be involved in hemostasis or thrombolysis or thrombosis. A polynucleotide of the invention can encode a polypeptide exhibiting such attributes. Compositions may be useful in treatment of various coagulation disorders 20 (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A composition of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke).

- 25 Therapeutic compositions of the invention can be used in the following:

Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis Res. 45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467-474, 1988.

30

5.10.11 CANCER DIAGNOSIS AND THERAPY

Polypeptides of the invention may be involved in cancer cell generation, proliferation or metastasis. Detection of the presence or amount of polynucleotides or polypeptides of the invention may be useful for the diagnosis and/or prognosis of one or more types of cancer.

For example, the presence or increased expression of a polynucleotide/polypeptide of the invention may indicate a hereditary risk of cancer, a precancerous condition, or an ongoing malignancy. Conversely, a defect in the gene or absence of the polypeptide may be associated with a cancer condition. Identification of single nucleotide polymorphisms associated with cancer or a predisposition to cancer may also be useful for diagnosis or prognosis.

Cancer treatments promote tumor regression by inhibiting tumor cell proliferation, inhibiting angiogenesis (growth of new blood vessels that is necessary to support tumor growth) and/or prohibiting metastasis by reducing tumor cell motility or invasiveness. Therapeutic compositions of the invention may be effective in adult and pediatric oncology including in solid phase tumors/malignancies, locally advanced tumors, human soft tissue sarcomas, metastatic cancer, including lymphatic metastases, blood cell malignancies including multiple myeloma, acute and chronic leukemias, and lymphomas, head and neck cancers including mouth cancer, larynx cancer and thyroid cancer, lung cancers including small cell carcinoma and non-small cell cancers, breast cancers including small cell carcinoma and ductal carcinoma, gastrointestinal cancers including esophageal cancer, stomach cancer, colon cancer, colorectal cancer and polyps associated with colorectal neoplasia, pancreatic cancers, liver cancer, urologic cancers including bladder cancer and prostate cancer, malignancies of the female genital tract including ovarian carcinoma, uterine (including endometrial) cancers, and solid tumor in the ovarian follicle, kidney cancers including renal cell carcinoma, brain cancers including intrinsic brain tumors, neuroblastoma, astrocytic brain tumors, gliomas, metastatic tumor cell invasion in the central nervous system, bone cancers including osteomas, skin cancers including malignant melanoma, tumor progression of human skin keratinocytes, squamous cell carcinoma, basal cell carcinoma, hemangiopericytoma and Kaposi's sarcoma.

Polypeptides, polynucleotides, or modulators of polypeptides of the invention (including inhibitors and stimulators of the biological activity of the polypeptide of the invention) may be administered to treat cancer. Therapeutic compositions can be administered in therapeutically effective dosages alone or in combination with adjuvant cancer therapy such as surgery, chemotherapy, radiotherapy, thermotherapy, and laser therapy, and may provide a beneficial effect, e.g. reducing tumor size, slowing rate of tumor growth, inhibiting metastasis, or otherwise improving overall clinical condition, without necessarily eradicating the cancer.

The composition can also be administered in therapeutically effective amounts as a portion of an anti-cancer cocktail. An anti-cancer cocktail is a mixture of the polypeptide or modulator of the invention with one or more anti-cancer drugs in addition to a pharmaceutically acceptable carrier for delivery. The use of anti-cancer cocktails as a cancer

treatment is routine. Anti-cancer drugs that are well known in the art and can be used as a treatment in combination with the polypeptide or modulator of the invention include:

Actinomycin D, Aminoglutethimide, Asparaginase, Bleomycin, Busulfan, Carboplatin, Carmustine, Chlorambucil, Cisplatin (cis-DDP), Cyclophosphamide, Cytarabine HCl
 5 (Cytosine arabinoside), Dacarbazine, Dactinomycin, Daunorubicin HCl, Doxorubicin HCl, Estramustine phosphate sodium, Etoposide (V16-213), Floxuridine, 5-Fluorouracil (5-Fu), Flutamide, Hydroxyurea (hydroxycarbamide), Ifosfamide, Interferon Alpha-2a, Interferon Alpha-2b, Leuprolide acetate (LHRH-releasing factor analog), Lomustine, Mechlorethamine HCl (nitrogen mustard), Melphalan, Mercaptopurine, Mesna, Methotrexate (MTX),
 10 Mitomycin, Mitoxantrone HCl, Octreotide, Plicamycin, Procarbazine HCl, Streptozocin, Tamoxifen citrate, Thioguanine, Thiotepa, Vinblastine sulfate, Vincristine sulfate, Amsacrine, Azacitidine, Hexamethylmelamine, Interleukin-2, Mitoguazone, Pentostatin, Semustine, Teniposide, and Vindesine sulfate.

In addition, therapeutic compositions of the invention may be used for prophylactic
 15 treatment of cancer. There are hereditary conditions and/or environmental situations (e.g. exposure to carcinogens) known in the art that predispose an individual to developing cancers. Under these circumstances, it may be beneficial to treat these individuals with therapeutically effective doses of the polypeptide of the invention to reduce the risk of developing cancers.

In vitro models can be used to determine the effective doses of the polypeptide of the
 20 invention as a potential cancer treatment. These *in vitro* models include proliferation assays of cultured tumor cells, growth of cultured tumor cells in soft agar (see Freshney, (1987) Culture of Animal Cells: A Manual of Basic Technique, Wiley-Liss, New York, NY Ch 18 and Ch 21), tumor systems in nude mice as described in Giovanella et al., J. Natl. Can. Inst., 52: 921-30 (1974), mobility and invasive potential of tumor cells in Boyden Chamber assays as described
 25 in Pilkington et al., Anticancer Res., 17: 4107-9 (1997), and angiogenesis assays such as induction of vascularization of the chick chorioallantoic membrane or induction of vascular endothelial cell migration as described in Ribatta et al., Intl. J. Dev. Biol., 40: 1189-97 (1999) and Li et al., Clin. Exp. Metastasis, 17:423-9 (1999), respectively. Suitable tumor cells lines are available, e.g. from American Type Tissue Culture Collection catalogs.

30

5.10.12 RECEPTOR/LIGAND ACTIVITY

A polypeptide of the present invention may also demonstrate activity as receptor, receptor ligand or inhibitor or agonist of receptor/ligand interactions. A polynucleotide of the invention can encode a polypeptide exhibiting such characteristics. Examples of such receptors

and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses. Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.

10 The activity of a polypeptide of the invention may, among other means, be measured by the following methods:

Suitable assays for receptor-ligand activity include without limitation those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al., Cell 80:661-670, 1995.

20 By way of example, the polypeptides of the invention may be used as a receptor for a ligand(s) thereby transmitting the biological activity of that ligand(s). Ligands may be identified through binding assays, affinity chromatography, dihybrid screening assays, BIAcore assays, gel overlay assays, or other methods known in the art.

25 Studies characterizing drugs or proteins as agonist or antagonist or partial agonists or a partial antagonist require the use of other proteins as competing ligands. The polypeptides of the present invention or ligand(s) thereof may be labeled by being coupled to radioisotopes, colorimetric molecules or a toxin molecules by conventional methods. ("Guide to Protein Purification" Murray P. Deutscher (ed) Methods in Enzymology Vol. 182 (1990) Academic Press, Inc. San Diego). Examples of radioisotopes include, but are not limited to, tritium and carbon-14 . Examples of colorimetric molecules include, but are not limited to, fluorescent molecules such as fluorescamine, or rhodamine or other colorimetric molecules. Examples of toxins include, but are not limited, to ricin.

30

5.10.13 DRUG SCREENING

This invention is particularly useful for screening chemical compounds by using the novel polypeptides or binding fragments thereof in any of a variety of drug screening techniques. The polypeptides or fragments employed in such a test may either be free in solution, affixed to a solid support, borne on a cell surface or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or a fragment thereof. Drugs are screened against such transformed cells in competitive binding assays. Such cells, either in viable or fixed form, can be used for standard binding assays. One may measure, for example, the formation of complexes between polypeptides of the invention or fragments and the agent being tested or examine the diminution in complex formation between the novel polypeptides and an appropriate cell line, which are well known in the art.

Sources for test compounds that may be screened for ability to bind to or modulate (i.e., increase or decrease) the activity of polypeptides of the invention include (1) inorganic and organic chemical libraries, (2) natural product libraries, and (3) combinatorial libraries comprised of either random or mimetic peptides, oligonucleotides or organic molecules.

Chemical libraries may be readily synthesized or purchased from a number of commercial sources, and may include structural analogs of known compounds or compounds that are identified as "hits" or "leads" via natural product screening.

The sources of natural product libraries are microorganisms (including bacteria and fungi), animals, plants or other vegetation, or marine organisms, and libraries of mixtures for screening may be created by: (1) fermentation and extraction of broths from soil, plant or marine microorganisms or (2) extraction of the organisms themselves. Natural product libraries include polyketides, non-ribosomal peptides, and (non-naturally occurring) variants thereof. For a review, see *Science* 282:63-68 (1998).

Combinatorial libraries are composed of large numbers of peptides, oligonucleotides or organic compounds and can be readily prepared by traditional automated synthesis methods, PCR, cloning or proprietary synthetic methods. Of particular interest are peptide and oligonucleotide combinatorial libraries. Still other libraries of interest include peptide, protein, peptidomimetic, multiparallel synthetic collection, recombinatorial, and polypeptide libraries. For a review of combinatorial chemistry and libraries created therefrom, see Myers, *Curr. Opin. Biotechnol.* 8:701-707 (1997). For reviews and examples of peptidomimetic libraries, see Al-Obeidi et al., *Mol. Biotechnol.* 9(3):205-23 (1998); Hruby et al., *Curr Opin Chem Biol*, 1(1):114-19 (1997); Dorner et al., *Bioorg Med Chem*, 4(5):709-15 (1996) (alkylated dipeptides).

Identification of modulators through use of the various libraries described herein permits modification of the candidate "hit" (or "lead") to optimize the capacity of the "hit" to bind a polypeptide of the invention. The molecules identified in the binding assay are then tested for antagonist or agonist activity in *in vivo* tissue culture or animal models that are well known in the art. In brief, the molecules are titrated into a plurality of cell cultures or animals and then tested for either cell/animal death or prolonged survival of the animal/cells.

The binding molecules thus identified may be complexed with toxins, e.g., ricin or cholera, or with other compounds that are toxic to cells such as radioisotopes. The toxin-binding molecule complex is then targeted to a tumor or other cell by the specificity of the binding molecule for a polypeptide of the invention. Alternatively, the binding molecules may be complexed with imaging agents for targeting and imaging purposes.

5.10.14 ASSAY FOR RECEPTOR ACTIVITY

The invention also provides methods to detect specific binding of a polypeptide e.g. a ligand or a receptor. The art provides numerous assays particularly useful for identifying previously unknown binding partners for receptor polypeptides of the invention. For example, expression cloning using mammalian or bacterial cells, or dihybrid screening assays can be used to identify polynucleotides encoding binding partners. As another example, affinity chromatography with the appropriate immobilized polypeptide of the invention can be used to isolate polypeptides that recognize and bind polypeptides of the invention. There are a number of different libraries used for the identification of compounds, and in particular small molecules that modulate (*i.e.*, increase or decrease) biological activity of a polypeptide of the invention. Ligands for receptor polypeptides of the invention can also be identified by adding exogenous ligands, or cocktails of ligands to two cells populations that are genetically identical except for the expression of the receptor of the invention: one cell population expresses the receptor of the invention whereas the other does not. The response of the two cell populations to the addition of ligands(s) are then compared. Alternatively, an expression library can be co-expressed with the polypeptide of the invention in cells and assayed for an autocrine response to identify potential ligand(s). As still another example, BIAcore assays, gel overlay assays, or other methods known in the art can be used to identify binding partner polypeptides, including, (1) organic and inorganic chemical libraries, (2) natural product libraries, and (3) combinatorial libraries comprised of random peptides, oligonucleotides or organic molecules.

The role of downstream intracellular signaling molecules in the signaling cascade of the polypeptide of the invention can be determined. For example, a chimeric protein in which the

cytoplasmic domain of the polypeptide of the invention is fused to the extracellular portion of a protein, whose ligand has been identified, is produced in a host cell. The cell is then incubated with the ligand specific for the extracellular portion of the chimeric protein, thereby activating the chimeric receptor. Known downstream proteins involved in intracellular signaling can then be assayed for expected modifications i.e. phosphorylation. Other methods known to those in the art can also be used to identify signaling molecules involved in receptor activity.

5.10.15 ANTI-INFLAMMATORY ACTIVITY

Compositions of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response.

Compositions with such activities can be used to treat inflammatory conditions including chronic or acute conditions, including without limitation intimation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Compositions of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material. Compositions of this invention may be utilized to prevent or treat conditions such as, but not limited to, sepsis, acute pancreatitis, endotoxin shock, cytokine induced shock, rheumatoid arthritis, chronic inflammatory arthritis, pancreatic cell damage from diabetes mellitus type 1, graft versus host disease, inflammatory bowel disease, inflammation associated with pulmonary disease, other autoimmune disease or inflammatory disease, an antiproliferative agent such as for acute or chronic myelogenous leukemia or in the prevention of premature labor secondary to intrauterine infections.

5.10.16 LEUKEMIAS

Leukemias and related disorders may be treated or prevented by administration of a therapeutic that promotes or inhibits function of the polynucleotides and/or polypeptides of the invention. Such leukemias and related disorders include but are not limited to acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, myeloblastic, promyelocytic,

myelomonocytic, monocytic, erythroleukemia, chronic leukemia, chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia (for a review of such disorders, see Fishman et al., 1985, Medicine, 2d Ed., J.B. Lippincott Co., Philadelphia).

5 5.10.17 NERVOUS SYSTEM DISORDERS

Nervous system disorders, involving cell types which can be tested for efficacy of intervention with compounds that modulate the activity of the polynucleotides and/or polypeptides of the invention, and which can be treated upon thus observing an indication of therapeutic utility, include but are not limited to nervous system injuries, and diseases or disorders which result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated in a patient (including human and non-human mammalian patients) according to the invention include but are not limited to the following lesions of either the central (including spinal cord, brain) or peripheral nervous systems:

- 15 (i) traumatic lesions, including lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the nervous system, or compression injuries;
- (ii) ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord
20 infarction or ischemia;
- (iii) infectious lesions, in which a portion of the nervous system is destroyed or injured as a result of infection, for example, by an abscess or associated with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, syphilis;
- 25 (iv) degenerative lesions, in which a portion of the nervous system is destroyed or injured as a result of a degenerative process including but not limited to degeneration associated with Parkinson's disease, Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis;
- 30 (v) lesions associated with nutritional diseases or disorders, in which a portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including but not limited to, vitamin B12 deficiency, folic acid deficiency, Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primary degeneration of the corpus callosum), and alcoholic cerebellar degeneration;

(vi) neurological lesions associated with systemic diseases including but not limited to diabetes (diabetic neuropathy, Bell's palsy), systemic lupus erythematosus, carcinoma, or sarcoidosis;

(vii) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and

(viii) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating disease including but not limited to multiple sclerosis, human immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis.

Therapeutics which are useful according to the invention for treatment of a nervous system disorder may be selected by testing for biological activity in promoting the survival or differentiation of neurons. For example, and not by way of limitation, therapeutics which elicit any of the following effects may be useful according to the invention:

(i) increased survival time of neurons in culture;

(ii) increased sprouting of neurons in culture or *in vivo*;

(iii) increased production of a neuron-associated molecule in culture or *in vivo*, *e.g.*, choline acetyltransferase or acetylcholinesterase with respect to motor neurons; or

(iv) decreased symptoms of neuron dysfunction *in vivo*.

Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may be measured by the method set forth in Arakawa et al. (1990, J. Neurosci. 10:3507-3515); increased sprouting of neurons may be detected by methods set forth in Pestronk et al. (1980, Exp. Neurol. 70:65-82) or Brown et al. (1981, Ann. Rev. Neurosci. 4:17-42); increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, *etc.*, depending on the molecule to be measured; and motor neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, *e.g.*, weakness, motor neuron conduction velocity, or functional disability.

In specific embodiments, motor neuron disorders that may be treated according to the invention include but are not limited to disorders such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor neurons as well as other components of the nervous system, as well as disorders that selectively affect neurons such as amyotrophic lateral sclerosis, and including but not limited to progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-

Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary Motorsensory Neuropathy (Charcot-Marie-Tooth Disease).

5.10.18 OTHER ACTIVITIES

5 A polypeptide of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part
10 size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or circadian cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, co-factors or other nutritional factors or component(s); effecting behavioral characteristics,
15 including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases;
20 treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.

25 5.10.19 IDENTIFICATION OF POLYMORPHISMS

The demonstration of polymorphisms makes possible the identification of such polymorphisms in human subjects and the pharmacogenetic use of this information for diagnosis and treatment. Such polymorphisms may be associated with, e.g., differential predisposition or susceptibility to various disease states (such as disorders involving
30 inflammation or immune response) or a differential response to drug administration, and this genetic information can be used to tailor preventive or therapeutic treatment appropriately. For example, the existence of a polymorphism associated with a predisposition to inflammation or autoimmune disease makes possible the diagnosis of this condition in humans by identifying the presence of the polymorphism.

Polymorphisms can be identified in a variety of ways known in the art which all generally involve obtaining a sample from a patient, analyzing DNA from the sample, optionally involving isolation or amplification of the DNA, and identifying the presence of the polymorphism in the DNA. For example, PCR may be used to amplify an appropriate
5 fragment of genomic DNA which may then be sequenced. Alternatively, the DNA may be subjected to allele-specific oligonucleotide hybridization (in which appropriate oligonucleotides are hybridized to the DNA under conditions permitting detection of a single base mismatch) or to a single nucleotide extension assay (in which an oligonucleotide that hybridizes immediately adjacent to the position of the polymorphism is extended with one or more labeled
10 nucleotides). In addition, traditional restriction fragment length polymorphism analysis (using restriction enzymes that provide differential digestion of the genomic DNA depending on the presence or absence of the polymorphism) may be performed. Arrays with nucleotide sequences of the present invention can be used to detect polymorphisms. The array can comprise modified nucleotide sequences of the present invention in order to detect the
15 nucleotide sequences of the present invention. In the alternative, any one of the nucleotide sequences of the present invention can be placed on the array to detect changes from those sequences.

Alternatively a polymorphism resulting in a change in the amino acid sequence could also be detected by detecting a corresponding change in amino acid sequence of the protein,
20 e.g., by an antibody specific to the variant sequence.

5.10.20 ARTHRITIS AND INFLAMMATION

The immunosuppressive effects of the compositions of the invention against rheumatoid arthritis is determined in an experimental animal model system. The experimental model
25 system is adjuvant induced arthritis in rats, and the protocol is described by J. Holoshitz, et al., 1983, Science, 219:56, or by B. Waksman et al., 1963, Int. Arch. Allergy Appl. Immunol., 23:129. Induction of the disease can be caused by a single injection, generally intradermally, of a suspension of killed Mycobacterium tuberculosis in complete Freund's adjuvant (CFA). The route of injection can vary, but rats may be injected at the base of the tail
30 with an adjuvant mixture. The polypeptide is administered in phosphate buffered solution (PBS) at a dose of about 1-5 mg/kg. The control consists of administering PBS only.

The procedure for testing the effects of the test compound would consist of intradermally injecting killed Mycobacterium tuberculosis in CFA followed by immediately administering the test compound and subsequent treatment every other day until day 24. At 14,

15, 18, 20, 22, and 24 days after injection of Mycobacterium CFA, an overall arthritis score may be obtained as described by J. Holoskitz above. An analysis of the data would reveal that the test compound would have a dramatic affect on the swelling of the joints as measured by a decrease of the arthritis score.

5

5.11 THERAPEUTIC METHODS

The compositions (including polypeptide fragments, analogs, variants and antibodies or other binding partners or modulators including antisense polynucleotides) of the invention have numerous applications in a variety of therapeutic methods. Examples of therapeutic applications include, but are not limited to, those exemplified herein.

10

5.11.1 EXAMPLE

One embodiment of the invention is the administration of an effective amount of the LIR-like polypeptides or other composition of the invention to individuals affected by a disease or disorder that can be modulated by regulating the soluble immunoglobulin receptor of the invention. While the mode of administration is not particularly important, parenteral administration is preferred. An exemplary mode of administration is to deliver an intravenous bolus. The dosage of LIR-like polypeptides or other composition of the invention will normally be determined by the prescribing physician. It is to be expected that the dosage will vary according to the age, weight, condition and response of the individual patient. Typically, the amount of polypeptide administered per dose will be in the range of about 0.01 μ g/kg to 100 mg/kg of body weight, with the preferred dose being about 0.1 μ g/kg to 10 mg/kg of patient body weight. For parenteral administration, LIR-like polypeptides of the invention will be formulated in an injectable form combined with a pharmaceutically acceptable parenteral vehicle. Such vehicles are well known in the art and examples include water, saline, Ringer's solution, dextrose solution, and solutions consisting of small amounts of the human serum albumin. The vehicle may contain minor amounts of additives that maintain the isotonicity and stability of the polypeptide or other active ingredient. The preparation of such solutions is within the skill of the art.

25
30

5.12 PHARMACEUTICAL FORMULATIONS AND ROUTES OF ADMINISTRATION

A protein or other composition of the present invention (from whatever source derived, including without limitation from recombinant and non-recombinant sources and including antibodies and other binding partners of the polypeptides of the invention) may be administered to a patient in need, by itself, or in pharmaceutical compositions where it is mixed with suitable carriers or excipient(s) at doses to treat or ameliorate a variety of disorders. Such a composition may optionally contain (in addition to protein or other active ingredient and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IFN, TNF0, TNF1, TNF2, G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin. In further compositions, proteins of the invention may be combined with other agents beneficial to the treatment of the disease or disorder in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet-derived growth factor (PDGF), transforming growth factors (TGF- α and TGF- β), insulin-like growth factor (IGF), as well as cytokines described herein.

The pharmaceutical composition may further contain other agents which either enhance the activity of the protein or other active ingredient or complement its activity or use in treatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein or other active ingredient of the invention, or to minimize side effects. Conversely, protein or other active ingredient of the present invention may be included in formulations of the particular clotting factor, cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the clotting factor, cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent (such as IL-1Ra, IL-1 Hy1, IL-1 Hy2, anti-TNF, corticosteroids, immunosuppressive agents). A protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins. As a result, pharmaceutical compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.

As an alternative to being included in a pharmaceutical composition of the invention including a first protein, a second protein or a therapeutic agent may be concurrently administered with the first protein (e.g., at the same time, or at differing times provided that therapeutic concentrations of the combination of agents is achieved at the treatment site).

5 Techniques for formulation and administration of the compounds of the instant application may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, latest edition. A therapeutically effective dose further refers to that amount of the compound sufficient to result in amelioration of symptoms, *e.g.*, treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing,
10 prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, a therapeutically effective dose refers to that ingredient alone. When applied to a combination, a therapeutically effective dose refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

15 In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein or other active ingredient of the present invention is administered to a mammal having a condition to be treated. Protein or other active ingredient of the present invention may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or
20 other hematopoietic factors. When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, protein or other active ingredient of the present invention may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering
25 protein or other active ingredient of the present invention in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.

5.12.1 ROUTES OF ADMINISTRATION

Suitable routes of administration may, for example, include oral, rectal, transmucosal,
30 or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections. Administration of protein or other active ingredient of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as

oral ingestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection. Intravenous administration to the patient is preferred.

Alternately, one may administer the compound in a local rather than systemic manner for example, via injection of the compound directly into a arthritic joints or in fibrotic tissue often in a depot or sustained release formulation. In order to prevent the scarring process frequently occurring as complication of glaucoma surgery, the compounds may be administered topically, for example, as eye drops. Furthermore, one may administer the drug in a targeted drug delivery system, for example, in a liposome coated with a specific antibody targeting, for example, arthritic or fibrotic tissue. The liposomes will be targeted to and taken up selectively by the afflicted tissue.

The polypeptides of the invention are administered by any route that delivers an effective dosage to the desired site of action. The determination of a suitable route of administration and an effective dosage for a particular indication is within the level of skill in the art. Preferably for wound treatment, one administers the therapeutic compound directly to the site. Suitable dosage ranges for the polypeptides of the invention can be extrapolated from these dosages or from similar studies in appropriate animal models. Dosages can then be adjusted as necessary by the clinician to provide maximal therapeutic benefit.

5.12.2 COMPOSITIONS/FORMULATIONS

Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. These pharmaceutical compositions may be manufactured in a manner that is itself known, *e.g.*, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes. Proper formulation is dependent upon the route of administration chosen. When a therapeutically effective amount of protein or other active ingredient of the present invention is administered orally, protein or other active ingredient of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% protein or other active ingredient of the present invention, and preferably from about 25 to 90% protein or other active ingredient of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant

WO 01/55335

PCT/US01/02570

origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the

5 pharmaceutical composition contains from about 0.5 to 90% by weight of protein or other active ingredient of the present invention, and preferably from about 1 to 50% protein or other active ingredient of the present invention.

When a therapeutically effective amount of protein or other active ingredient of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein

10 or other active ingredient of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein or other active ingredient solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein or other active

15 ingredient of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art. For injection, the agents of the invention may be

20 formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

For oral administration, the compounds can be formulated readily by combining the

25 active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding

30 suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents

may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide. lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration. For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, *e.g.*, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, *e.g.*, gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch. The compounds may be formulated for parenteral administration by injection, *e.g.*, by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, *e.g.*, in ampules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain

substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Alternatively, the active ingredient may be in powder form for
5 constitution with a suitable vehicle, *e.g.*, sterile pyrogen-free water, before use.

The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, *e.g.*, containing conventional suppository bases such as cocoa butter or other glycerides. In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by
10 implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

A pharmaceutical carrier for the hydrophobic compounds of the invention is a co-
15 solvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. The co-solvent system may be the VPD co-solvent system. VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant polysorbate 80, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol. The VPD co-solvent system (VPD:5W) consists of VPD diluted 1:1 with a 5% dextrose in water
20 solution. This co-solvent system dissolves hydrophobic compounds well, and itself produces low toxicity upon systemic administration. Naturally, the proportions of a co-solvent system may be varied considerably without destroying its solubility and toxicity characteristics. Furthermore, the identity of the co-solvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of polysorbate 80; the fraction size of
25 polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, *e.g.* polyvinyl pyrrolidone; and other sugars or polysaccharides may substitute for dextrose. Alternatively, other delivery systems for hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are well known examples of delivery vehicles or carriers for hydrophobic drugs. Certain organic solvents such as dimethylsulfoxide also may be
30 employed, although usually at the cost of greater toxicity. Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various types of sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few

weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein or other active ingredient stabilization may be employed.

The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols. Many of the active ingredients of the invention may be provided as salts with pharmaceutically compatible counter ions. Such pharmaceutically acceptable base addition salts are those salts which retain the biological effectiveness and properties of the free acids and which are obtained by reaction with inorganic or organic bases such as sodium hydroxide, magnesium hydroxide, ammonia, trialkylamine, dialkylamine, monoalkylamine, dibasic amino acids, sodium acetate, potassium benzoate, triethanol amine and the like.

The pharmaceutical composition of the invention may be in the form of a complex of the protein(s) or other active ingredient of present invention along with protein or peptide antigens. The protein and/or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes. B lymphocytes will respond to antigen through their surface immunoglobulin receptor. T lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes. The antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind surface immunoglobulin and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention.

The pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithins, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent Nos. 4,235,871; 4,501,728; 4,837,028; and 4,737,323, all of which are incorporated herein by reference.

The amount of protein or other active ingredient of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of protein or other active ingredient of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein or other active ingredient of the present invention and observe the patient's response. Larger doses of protein or other active ingredient of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.01 μg to about 100 mg (preferably about 0.1 μg to about 10 mg, more preferably about 0.1 μg to about 1 mg) of protein or other active ingredient of the present invention per kg body weight. For compositions of the present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device. When administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than a protein or other active ingredient of the invention which may also optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods of the invention. Preferably for bone and/or cartilage formation, the composition would include a matrix capable of delivering the protein-containing or other active ingredient-containing composition to the site of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical applications.

The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular application of the compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, tricalcium phosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides. Other potential materials are biodegradable and biologically well-defined, such as bone or dermal

collagen. Further matrices are comprised of pure proteins or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxyapatite, bioglass, aluminates, or other ceramics. Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalcium phosphate. The bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability. Presently preferred is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns. In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions from disassociating from the matrix.

A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl-methylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol). The amount of sequestering agent useful herein is 0.5-20 wt %, preferably 1-10 wt % based on total formulation weight, which represents the amount necessary to prevent desorption of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells. In further compositions, proteins or other active ingredient of the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF- α and TGF- β), and insulin-like growth factor (IGF).

The therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to humans, are desired patients for such treatment with proteins or other active ingredient of the present invention. The dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering various factors which modify the action of the proteins, *e.g.*, amount of tissue weight desired to be formed, the site

WO 01/55335

PCT/US01/02570

of damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue (*e.g.*, bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor I), to the final composition, may also effect the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometric determinations and tetracycline labeling.

Polynucleotides of the present invention can also be used for gene therapy. Such polynucleotides can be introduced either *in vivo* or *ex vivo* into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without limitation, in the form of viral vectors or naked DNA). Cells may also be cultured *ex vivo* in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced *in vivo* for therapeutic purposes.

5.12.3 EFFECTIVE DOSAGE

Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve its intended purpose. More specifically, a therapeutically effective amount means an amount effective to prevent development of or to alleviate the existing symptoms of the subject being treated. Determination of the effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from appropriate *in vitro* assays. For example, a dose can be formulated in animal models to achieve a circulating concentration range that can be used to more accurately determine useful doses in humans. For example, a dose can be formulated in animal models to achieve a circulating concentration range that includes the IC_{50} as determined in cell culture (*i.e.*, the concentration of the test compound which achieves a half-maximal inhibition of the protein's biological activity). Such information can be used to more accurately determine useful doses in humans.

A therapeutically effective dose refers to that amount of the compound that results in amelioration of symptoms or a prolongation of survival in a patient. Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the LD_{50} (the dose lethal to 50% of the

population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between LD₅₀ and ED₅₀. Compounds which exhibit high therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used in
5 formulating a range of dosage for use in human. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. See, *e.g.*,
10 Fingl et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p.1. Dosage amount and interval may be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the desired effects, or minimal effective concentration (MEC). The MEC will vary for each compound but can be estimated from *in vitro* data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of
15 administration. However, HPLC assays or bioassays can be used to determine plasma concentrations.

Dosage intervals can also be determined using MEC value. Compounds should be administered using a regimen which maintains plasma levels above the MEC for 10-90% of the time, preferably between 30-90% and most preferably between 50-90%. In cases of local
20 administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration.

An exemplary dosage regimen for polypeptides or other compositions of the invention will be in the range of about 0.01 µg/kg to 100 mg/kg of body weight daily, with the preferred dose being about 0.1 µg/kg to 25 mg/kg of patient body weight daily, varying in adults and
25 children. Dosing may be once daily, or equivalent doses may be delivered at longer or shorter intervals.

The amount of composition administered will, of course, be dependent on the subject being treated, on the subject's age and weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician.

30

5.12.4 PACKAGING

The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may,

for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. Compositions comprising a compound of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated
5 condition.

5.13 ANTIBODIES

Also included in the invention are antibodies to proteins, or fragments of proteins of the invention. The term "antibody" as used herein refers to immunoglobulin molecules and
10 immunologically active portions of immunoglobulin (Ig) molecules. i.e., molecules that contain an antigen-binding site that specifically binds (immunoreacts with) an antigen. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, F_{ab} , F_{ab}' and $F_{(ab)2}$ fragments, and an F_{ab} expression library. In general, an antibody molecule obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another
15 by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgG₁, IgG₂, and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, subclasses and types of human antibody species.

An isolated related protein of the invention may be intended to serve as an antigen, or a
20 portion or fragment thereof, and additionally can be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for polyclonal and monoclonal antibody preparation. The full-length protein can be used or, alternatively, the invention provides antigenic peptide fragments of the antigen for use as immunogens. An antigenic peptide fragment comprises at least 6 amino acid residues of the amino acid sequence
25 of the full length protein, such as an amino acid sequence shown in SEQ ID NO: 3, 6, 8-13, 19, 22, 24-28, 33-34, 37, 40, 42-45, 50, 52-58, 66, or 68-74, and encompasses an epitope thereof such that an antibody raised against the peptide forms a specific immune complex with the full length protein or with any fragment that contains the epitope. Preferably, the antigenic peptide comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20 amino
30 acid residues, or at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are hydrophilic regions.

In certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a region of LIR-like protein that is located on the surface of the protein, *e.g.*,
35 a hydrophilic region. A hydrophobicity analysis of the human related protein sequence will

indicate which regions of a related protein are particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting antibody production. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art, including, for example, the Kyte

5 Doolittle or the Hopp Woods methods, either with or without Fourier transformation. See, *e.g.*, Hopp and Woods, 1981, *Proc. Nat. Acad. Sci. USA* 78: 3824-3828; Kyte and Doolittle 1982, *J. Mol. Biol.* 157: 105-142, each of which is incorporated herein by reference in its entirety. Antibodies that are specific for one or more domains within an antigenic protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

10 A protein of the invention, or a derivative, fragment, analog, homolog or ortholog thereof, may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components.

The term "specific for" indicates that the variable regions of the antibodies of the invention recognize and bind polypeptides of the invention exclusively (*i.e.*, able to distinguish

15 the polypeptide of the invention from other similar polypeptides despite sequence identity, homology, or similarity found in the family of polypeptides), but may also interact with other proteins (for example, *S. aureus* protein A or other antibodies in ELISA techniques) through interactions with sequences outside the variable region of the antibodies, and in particular, in the constant region of the molecule. Screening assays to determine binding specificity of an

20 antibody of the invention are well known and routinely practiced in the art. For a comprehensive discussion of such assays, see Harlow et al. (Eds), *Antibodies A Laboratory Manual*; Cold Spring Harbor Laboratory; Cold Spring Harbor, NY (1988), Chapter 6. Antibodies that recognize and bind fragments of the polypeptides of the invention are also contemplated, provided that the antibodies are first and foremost specific for, as defined above, full-length

25 polypeptides of the invention. As with antibodies that are specific for full length polypeptides of the invention, antibodies of the invention that recognize fragments are those which can distinguish polypeptides from the same family of polypeptides despite inherent sequence identity, homology, or similarity found in the family of proteins.

Antibodies of the invention are useful for, for example, therapeutic purposes (by

30 modulating activity of a polypeptide of the invention), diagnostic purposes to detect or quantitate a polypeptide of the invention, as well as purification of a polypeptide of the invention. Kits comprising an antibody of the invention for any of the purposes described herein are also comprehended. In general, a kit of the invention also includes a control antigen for which the antibody is immunospecific. The invention further provides a hybridoma that produces an

antibody according to the invention. Antibodies of the invention are useful for detection and/or purification of the polypeptides of the invention.

Monoclonal antibodies binding to the protein of the invention may be useful diagnostic agents for the immunodetection of the protein. Neutralizing monoclonal antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where abnormal expression of the protein is involved. In the case of cancerous cells or leukemic cells, neutralizing monoclonal antibodies against the protein may be useful in detecting and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein.

The labeled antibodies of the present invention can be used for *in vitro*, *in vivo*, and *in situ* assays to identify cells or tissues in which a fragment of the polypeptide of interest is expressed. The antibodies may also be used directly in therapies or other diagnostics. The present invention further provides the above-described antibodies immobilized on a solid support. Examples of such solid supports include plastics such as polycarbonate, complex carbohydrates such as agarose and Sepharose®, acrylic resins and such as polyacrylamide and latex beads. Techniques for coupling antibodies to such solid supports are well known in the art (Weir, D.M. et al., "Handbook of Experimental Immunology" 4th Ed., Blackwell Scientific Publications, Oxford, England, Chapter 10 (1986); Jacoby, W.D. et al., Meth. Enzym. 34 Academic Press, N.Y. (1974)). The immobilized antibodies of the present invention can be used for *in vitro*, *in vivo*, and *in situ* assays as well as for immuno-affinity purification of the proteins of the present invention.

Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof (see, for example, Antibodies: A Laboratory Manual, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, incorporated herein by reference). Some of these antibodies are discussed below.

5.13.1 POLYCLONAL ANTIBODIES

For the production of polyclonal antibodies, various suitable host animals (e.g., rabbit, goat, mouse or other mammal) may be immunized by one or more injections with the native protein, a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, the naturally occurring immunogenic protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, the protein may be conjugated to a second protein known to be immunogenic in the mammal being immunized. Examples of such

WO 01/55335

PCT/US01/02570

immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (e.g., aluminum hydroxide),
5 surface-active substances (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), adjuvants usable in humans such as Bacille Calmette-Guerin and Corynebacterium parvum, or similar immunostimulatory agents. Additional examples of adjuvants that can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).

10 The polyclonal antibody molecules directed against the immunogenic protein can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to
15 purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, Inc., Philadelphia PA, Vol. 14, No. 8 (April 17, 2000), pp. 25-28).

5.13.2 MONOCLONAL ANTIBODIES

20 The term "monoclonal antibody" (MAb) or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs thus contain an antigen-
25 binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it.

Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to
30 elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro.

The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources
35 are desired. The lymphocytes are then fused with an immortalized cell line using a suitable

fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63).

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980). Preferably, antibodies having a high degree of specificity and a high binding affinity for the target antigen are isolated.

After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal.

The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Patent No. 4,816,567; Morrison, Nature 368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

5.13.3 HUMANIZED ANTIBODIES

The antibodies directed against the protein antigens of the invention can further comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered immunoglobulin. Humanized forms of antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')₂ or other antigen-binding subsequences of antibodies) that are principally comprised of the sequence of a human immunoglobulin, and contain minimal sequence derived from a non-human immunoglobulin. Humanization can be performed following the method of Winter and co-workers (Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. (See also U.S. Patent No. 5,225,539). In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human

immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., 1986; Riechmann et al., 1988; and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)).

5

5.13.4 HUMAN ANTIBODIES

Fully human antibodies relate to antibody molecules in which essentially the entire sequences of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed "human antibodies", or "fully human antibodies" herein.

10 Human monoclonal antibodies can be prepared by the trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983 Immunol Today 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by using
15 human hybridomas (see Cote, et al., 1983. Proc Natl Acad Sci USA 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96).

In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991);
20 Marks et al., J. Mol. Biol., 222:581 (1991)). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach
25 is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al. (Bio/Technology 10, 779-783 (1992)); Lonberg et al. (Nature 368 856-859 (1994)); Morrison (Nature 368, 812-13 (1994)); Fishwild et al, (Nature Biotechnology 14, 845-51 (1996)); Neuberger (Nature Biotechnology 14, 826 (1996)); and Lonberg and Huszar (Intern. Rev. Immunol. 13 65-93 (1995)).

30 Human antibodies may additionally be produced using transgenic nonhuman animals that are modified so as to produce fully human antibodies rather than the animal's endogenous antibodies in response to challenge by an antigen. (See PCT publication WO94/02602). The endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins
35 are inserted into the host's genome. The human genes are incorporated, for example, using yeast

artificial chromosomes containing the requisite human DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full complement of the modifications. The preferred embodiment of such a nonhuman animal is a mouse, and is termed the XenomouseTM as disclosed in PCT publications WO 96/33735 and WO 96/34096. This animal produces B cells that secrete fully human immunoglobulins. The antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly, or can be further modified to obtain analogs of antibodies such as, for example, single chain Fv molecules.

An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Patent No. 5,939,598. It can be obtained by a method including deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent rearrangement of the locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker.

A method for producing an antibody of interest, such as a human antibody, is disclosed in U.S. Patent No. 5,916,771. It includes introducing an expression vector that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain.

In a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen, and a correlative method for selecting an antibody that binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO 99/53049.

5.13.5 FAB FRAGMENTS AND SINGLE CHAIN ANTIBODIES

According to the invention, techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see e.g., U.S. Patent No. 4,946,778). In addition, methods can be adapted for the construction of F_{ab} expression libraries (see e.g.,

Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and effective identification of monoclonal F_{ab} fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an F_{(ab')₂} fragment produced by pepsin digestion of an antibody molecule; (ii) an F_{ab} fragment generated by reducing the disulfide bridges of an F_{(ab')₂} fragment; (iii) an F_{ab} fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) F_v fragments.

5.13.6 BISPECIFIC ANTIBODIES

10 Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for an antigenic protein of the invention. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.

Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, Nature, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker *et al.*, 1991 *EMBO J.*, 10:3655-3659.

Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology, 121:210 (1986).

According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers that are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side

chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory “cavities” of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. $F(ab')_2$ bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., Science 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate $F(ab')_2$ fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab' -TNB derivatives is then reconverted to the Fab' -thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab' -TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

Additionally, Fab' fragments can be directly recovered from *E. coli* and chemically coupled to form bispecific antibodies. Shalaby et al., J. Exp. Med. 175:217-225 (1992) describe the production of a fully humanized bispecific antibody $F(ab')_2$ molecule. Each Fab' fragment was separately secreted from *E. coli* and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., J. Immunol. 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The “diabody” technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (V_H) connected to a light-chain variable domain (V_L) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly,

the V_H and V_L domains of one fragment are forced to pair with the complementary V_L and V_H domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al., *J. Immunol.* 152:5368 (1994).

5 Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al., *J. Immunol.* 147:60 (1991).

Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a triggering
10 molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (Fc R), such as Fc RI (CD64), Fc RII (CD32) and Fc RIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular
15 antigen. These antibodies possess an antigen-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).

5.13.7 HETEROCONJUGATE ANTIBODIES

20 Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Patent No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared in vitro using known methods in
25 synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

30 5.13.8 EFFECTOR FUNCTION ENGINEERING

It can be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, e.g., the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have

improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med., 176: 1191-1195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity can also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research, 53: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., Anti-Cancer Drug Design, 3: 219-230 (1989).

5.13.9 IMMUNOCONJUGATES

The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).

Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolacca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include ^{212}Bi , ^{131}I , ^{131}In , ^{90}Y , and ^{186}Re .

Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science, 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.

In another embodiment, the antibody can be conjugated to a "receptor" (such as streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is

WO 01/55335

PCT/US01/02570

administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g., avidin) that is in turn conjugated to a cytotoxic agent.

5 5.14 COMPUTER READABLE SEQUENCES

In one application of this embodiment, a nucleotide sequence of the present invention can be recorded on computer readable media. As used herein, "computer readable media" refers to any medium which can be read and accessed directly by a computer. Such media include, but are not limited to: magnetic storage media, such as floppy discs, hard disc storage
10 medium, and magnetic tape; optical storage media such as CD-ROM; electrical storage media such as RAM and ROM; and hybrids of these categories such as magnetic/optical storage media. A skilled artisan can readily appreciate how any of the presently known computer readable mediums can be used to create a manufacture comprising computer readable medium having recorded thereon a nucleotide sequence of the present invention. As used herein,
15 "recorded" refers to a process for storing information on computer readable medium. A skilled artisan can readily adopt any of the presently known methods for recording information on computer readable medium to generate manufactures comprising the nucleotide sequence information of the present invention.

A variety of data storage structures are available to a skilled artisan for creating a
20 computer readable medium having recorded thereon a nucleotide sequence of the present invention. The choice of the data storage structure will generally be based on the means chosen to access the stored information. In addition, a variety of data processor programs and formats can be used to store the nucleotide sequence information of the present invention on computer readable medium. The sequence information can be represented in a word
25 processing text file, formatted in commercially-available software such as WordPerfect and Microsoft Word, or represented in the form of an ASCII file, stored in a database application, such as DB2, Sybase, Oracle, or the like. A skilled artisan can readily adapt any number of data processor structuring formats (e.g. text file or database) in order to obtain computer readable medium having recorded thereon the nucleotide sequence information of the present
30 invention.

By providing any of the nucleotide sequences SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67 or a representative fragment thereof; or a nucleotide sequence at least 95% identical to any of the nucleotide sequences of the SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67 in computer

readable form, a skilled artisan can routinely access the sequence information for a variety of purposes. Computer software is publicly available which allows a skilled artisan to access sequence information provided in a computer readable medium. The examples which follow demonstrate how software which implements the BLAST (Altschul et al., J. Mol. Biol. 215:403-410 (1990)) and BLAZE (Brutlag et al., Comp. Chem. 17:203-207 (1993)) search algorithms on a Sybase system is used to identify open reading frames (ORFs) within a nucleic acid sequence. Such ORFs may be protein encoding fragments and may be useful in producing commercially important proteins such as enzymes used in fermentation reactions and in the production of commercially useful metabolites.

As used herein, "a computer-based system" refers to the hardware means, software means, and data storage means used to analyze the nucleotide sequence information of the present invention. The minimum hardware means of the computer-based systems of the present invention comprises a central processing unit (CPU), input means, output means, and data storage means. A skilled artisan can readily appreciate that any one of the currently available computer-based systems are suitable for use in the present invention. As stated above, the computer-based systems of the present invention comprise a data storage means having stored therein a nucleotide sequence of the present invention and the necessary hardware means and software means for supporting and implementing a search means. As used herein, "data storage means" refers to memory which can store nucleotide sequence information of the present invention, or a memory access means which can access manufactures having recorded thereon the nucleotide sequence information of the present invention.

As used herein, "search means" refers to one or more programs which are implemented on the computer-based system to compare a target sequence or target structural motif with the sequence information stored within the data storage means. Search means are used to identify fragments or regions of a known sequence which match a particular target sequence or target motif. A variety of known algorithms are disclosed publicly and a variety of commercially available software for conducting search means are and can be used in the computer-based systems of the present invention. Examples of such software includes, but is not limited to, Smith-Waterman, MacPattern (EMBL), BLASTN and BLASTA (NPOLYPEPTIDEIA). A skilled artisan can readily recognize that any one of the available algorithms or implementing software packages for conducting homology searches can be adapted for use in the present computer-based systems. As used herein, a "target sequence" can be any nucleic acid or amino acid sequence of six or more nucleotides or two or more amino acids. A skilled artisan

can readily recognize that the longer a target sequence is, the less likely a target sequence will be present as a random occurrence in the database. The most preferred sequence length of a target sequence is from about 10 to 100 amino acids, or from about 30 to 300 nucleotide residues. However, it is well recognized that searches for commercially important fragments, such as sequence fragments involved in gene expression and protein processing, may be of shorter length.

As used herein, "a target structural motif," or "target motif," refers to any rationally selected sequence or combination of sequences in which the sequence(s) are chosen based on a three-dimensional configuration which is formed upon the folding of the target motif. There are a variety of target motifs known in the art. Protein target motifs include, but are not limited to, enzyme active sites and signal sequences. Nucleic acid target motifs include, but are not limited to, promoter sequences, hairpin structures and inducible expression elements (protein binding sequences).

15 5.15 TRIPLE HELIX FORMATION

In addition, the fragments of the present invention, as broadly described, can be used to control gene expression through triple helix formation or antisense DNA or RNA, both of which methods are based on the binding of a polynucleotide sequence to DNA or RNA. Polynucleotides suitable for use in these methods are usually 20 to 40 bases in length and are designed to be complementary to a region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 15241:456 (1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself (antisense - Olmno, J. Neurochem. 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988)). Triple helix-formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques have been demonstrated to be effective in model systems. Information contained in the sequences of the present invention is necessary for the design of an antisense or triple helix oligonucleotide.

30 5.16 DIAGNOSTIC ASSAYS AND KITS

The present invention further provides methods to identify the presence or expression of one of the ORFs of the present invention, or homolog thereof, in a test sample, using a nucleic acid probe or antibodies of the present invention, optionally conjugated or otherwise associated with a suitable label.

In general, methods for detecting a polynucleotide of the invention can comprise contacting a sample with a compound that binds to and forms a complex with the polynucleotide for a period sufficient to form the complex, and detecting the complex, so that if a complex is detected, a polynucleotide of the invention is detected in the sample. Such
5 methods can also comprise contacting a sample under stringent hybridization conditions with nucleic acid primers that anneal to a polynucleotide of the invention under such conditions, and amplifying annealed polynucleotides, so that if a polynucleotide is amplified, a polynucleotide of the invention is detected in the sample.

In general, methods for detecting a polypeptide of the invention can comprise
10 contacting a sample with a compound that binds to and forms a complex with the polypeptide for a period sufficient to form the complex, and detecting the complex, so that if a complex is detected, a polypeptide of the invention is detected in the sample.

In detail, such methods comprise incubating a test sample with one or more of the antibodies or one or more of the nucleic acid probes of the present invention and assaying for
15 binding of the nucleic acid probes or antibodies to components within the test sample.

Conditions for incubating a nucleic acid probe or antibody with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods employed, and the type and nature of the nucleic acid probe or antibody used in the assay. One skilled in the art will recognize that any one of the commonly available hybridization,
20 amplification or immunological assay formats can readily be adapted to employ the nucleic acid probes or antibodies of the present invention. Examples of such assays can be found in Chard, T., An Introduction to Radioimmunoassay and Related Techniques, Elsevier Science Publishers, Amsterdam, The Netherlands (1986); Bullock, G.R. et al., Techniques in Immunocytochemistry, Academic Press, Orlando, FL Vol. 1 (1982), Vol. 2 (1983), Vol. 3
25 (1985); Tijssen, P., Practice and Theory of immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Publishers, Amsterdam, The Netherlands (1985). The test samples of the present invention include cells, protein or membrane extracts of cells, or biological fluids such as sputum, blood, serum, plasma, or urine. The test sample used in the above-described method will vary based on the assay
30 format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed. Methods for preparing protein extracts or membrane extracts of cells are well known in the art and can be readily be adapted in order to obtain a sample which is compatible with the system utilized.

In another embodiment of the present invention, kits are provided which contain the necessary reagents to carry out the assays of the present invention. Specifically, the invention provides a compartment kit to receive, in close confinement, one or more containers which comprises: (a) a first container comprising one of the probes or antibodies of the present invention; and (b) one or more other containers comprising one or more of the following: wash reagents, reagents capable of detecting presence of a bound probe or antibody.

In detail, a compartment kit includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers or strips of plastic or paper. Such containers allows one to efficiently transfer reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample, a container which contains the antibodies used in the assay, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, etc.), and containers which contain the reagents used to detect the bound antibody or probe. Types of detection reagents include labeled nucleic acid probes, labeled secondary antibodies, or in the alternative, if the primary antibody is labeled, the enzymatic, or antibody binding reagents which are capable of reacting with the labeled antibody. One skilled in the art will readily recognize that the disclosed probes and antibodies of the present invention can be readily incorporated into one of the established kit formats which are well known in the art.

5.17 MEDICAL IMAGING

The novel polypeptides and binding partners of the invention are useful in medical imaging of sites expressing the molecules of the invention (e.g., where the polypeptide of the invention is involved in the immune response, for imaging sites of inflammation or infection). See, e.g., Kunkel et al., U.S. Pat. No. 5,413,778. Such methods involve chemical attachment of a labeling or imaging agent, administration of the labeled polypeptide to a subject in a pharmaceutically acceptable carrier, and imaging the labeled polypeptide *in vivo* at the target site.

5.18 SCREENING ASSAYS

Using the isolated proteins and polynucleotides of the invention, the present invention further provides methods of obtaining and identifying agents which bind to a polypeptide encoded by an ORF corresponding to any of the nucleotide sequences set forth in the SEQ ID

NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67, or bind to a specific domain of the polypeptide encoded by the nucleic acid. In detail, said method comprises the steps of:

- (a) contacting an agent with an isolated protein encoded by an ORF of the present invention, or nucleic acid of the invention; and
- (b) determining whether the agent binds to said protein or said nucleic acid.

In general, therefore, such methods for identifying compounds that bind to a polynucleotide of the invention can comprise contacting a compound with a polynucleotide of the invention for a time sufficient to form a polynucleotide/compound complex, and detecting the complex, so that if a polynucleotide/compound complex is detected, a compound that binds to a polynucleotide of the invention is identified.

Likewise, in general, therefore, such methods for identifying compounds that bind to a polypeptide of the invention can comprise contacting a compound with a polypeptide of the invention for a time sufficient to form a polypeptide/compound complex, and detecting the complex, so that if a polypeptide/compound complex is detected, a compound that binds to a polynucleotide of the invention is identified.

Methods for identifying compounds that bind to a polypeptide of the invention can also comprise contacting a compound with a polypeptide of the invention in a cell for a time sufficient to form a polypeptide/compound complex, wherein the complex drives expression of a receptor gene sequence in the cell, and detecting the complex by detecting reporter gene sequence expression, so that if a polypeptide/compound complex is detected, a compound that binds a polypeptide of the invention is identified.

Compounds identified via such methods can include compounds which modulate the activity of a polypeptide of the invention (that is, increase or decrease its activity, relative to activity observed in the absence of the compound). Alternatively, compounds identified via such methods can include compounds which modulate the expression of a polynucleotide of the invention (that is, increase or decrease expression relative to expression levels observed in the absence of the compound). Compounds, such as compounds identified via the methods of the invention, can be tested using standard assays well known to those of skill in the art for their ability to modulate activity/expression.

The agents screened in the above assay can be, but are not limited to, peptides, carbohydrates, vitamin derivatives, or other pharmaceutical agents. The agents can be selected and screened at random or rationally selected or designed using protein modeling techniques.

For random screening, agents such as peptides, carbohydrates, pharmaceutical agents and the like are selected at random and are assayed for their ability to bind to the protein encoded by the ORF of the present invention. Alternatively, agents may be rationally selected or designed. As used herein, an agent is said to be "rationally selected or designed" when the agent is chosen based on the configuration of the particular protein. For example, one skilled in the art can readily adapt currently available procedures to generate peptides, pharmaceutical agents and the like, capable of binding to a specific peptide sequence, in order to generate rationally designed antipeptide peptides, for example see Hurby et al., Application of Synthetic Peptides: Antisense Peptides," In Synthetic Peptides, A User's Guide, W.H. Freeman, NY (1992), pp. 289-307, and Kaspczak et al., Biochemistry 28:9230-8 (1989), or pharmaceutical agents, or the like.

In addition to the foregoing, one class of agents of the present invention, as broadly described, can be used to control gene expression through binding to one of the ORFs or EMFs of the present invention. As described above, such agents can be randomly screened or rationally designed/selected. Targeting the ORF or EMF allows a skilled artisan to design sequence specific or element specific agents, modulating the expression of either a single ORF or multiple ORFs which rely on the same EMF for expression control. One class of DNA binding agents are agents which contain base residues which hybridize or form a triple helix formation by binding to DNA or RNA. Such agents can be based on the classic phosphodiester, ribonucleic acid backbone, or can be a variety of sulfhydryl or polymeric derivatives which have base attachment capacity.

Agents suitable for use in these methods usually contain 20 to 40 bases and are designed to be complementary to a region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988)). Triple helix-formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques have been demonstrated to be effective in model systems. Information contained in the sequences of the present invention is necessary for the design of an antisense or triple helix oligonucleotide and other DNA binding agents.

Agents which bind to a protein encoded by one of the ORFs of the present invention can be used as a diagnostic agent. Agents which bind to a protein encoded by one of the ORFs

of the present invention can be formulated using known techniques to generate a pharmaceutical composition.

5.19 USE OF NUCLEIC ACIDS AS PROBES

5 Another aspect of the subject invention is to provide for polypeptide-specific nucleic acid hybridization probes capable of hybridizing with naturally occurring nucleotide sequences. The hybridization probes of the subject invention may be derived from any of the nucleotide sequences SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67. Because the corresponding gene is only expressed in a limited number of tissues, a
10 hybridization probe derived from any of the nucleotide sequences SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67 can be used as an indicator of the presence of RNA of cell type of such a tissue in a sample.

Any suitable hybridization technique can be employed, such as, for example, *in situ* hybridization. PCR as described in US Patents Nos. 4,683,195 and 4,965,188 provides
15 additional uses for oligonucleotides based upon the nucleotide sequences. Such probes used in PCR may be of recombinant origin, may be chemically synthesized, or a mixture of both. The probe will comprise a discrete nucleotide sequence for the detection of identical sequences or a degenerate pool of possible sequences for identification of closely related genomic sequences.

Other means for producing specific hybridization probes for nucleic acids include the
20 cloning of nucleic acid sequences into vectors for the production of mRNA probes. Such vectors are known in the art and are commercially available and may be used to synthesize RNA probes *in vitro* by means of the addition of the appropriate RNA polymerase as T7 or SP6 RNA polymerase and the appropriate radioactively labeled nucleotides. The nucleotide sequences may be used to construct hybridization probes for mapping their respective genomic
25 sequences. The nucleotide sequence provided herein may be mapped to a chromosome or specific regions of a chromosome using well known genetic and/or chromosomal mapping techniques. These techniques include *in situ* hybridization, linkage analysis against known chromosomal markers, hybridization screening with libraries or flow-sorted chromosomal preparations specific to known chromosomes, and the like. The technique of fluorescent *in situ* hybridization of chromosome spreads has been described, among other places, in Verma et
30 al (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York NY.

Fluorescent *in situ* hybridization of chromosomal preparations and other physical chromosome mapping techniques may be correlated with additional genetic map data.

Examples of genetic map data can be found in the 1994 Genome Issue of Science (265:1981f). Correlation between the location of a nucleic acid on a physical chromosomal map and a specific disease (or predisposition to a specific disease) may help delimit the region of DNA associated with that genetic disease. The nucleotide sequences of the subject invention may be used to detect differences in gene sequences between normal, carrier or affected individuals.

5.20 PREPARATION OF SUPPORT BOUND OLIGONUCLEOTIDES

Oligonucleotides, i.e., small nucleic acid segments, may be readily prepared by, for example, directly synthesizing the oligonucleotide by chemical means, as is commonly practiced using an automated oligonucleotide synthesizer.

Support bound oligonucleotides may be prepared by any of the methods known to those of skill in the art using any suitable support such as glass, polystyrene or Teflon. One strategy is to precisely spot oligonucleotides synthesized by standard synthesizers. Immobilization can be achieved using passive adsorption (Inouye & Hondo, 1990 J. Clin Microbiol 28(6) 1462-72); using UV light (Nagata *et al.*, 1985; Dahlen *et al.*, 1987; Morrissey & Collins, Mol. Cell Probes 1989 3(2) 189-207) or by covalent binding of base modified DNA (Keller *et al.*, 1988; 1989); all references being specifically incorporated herein.

Another strategy that may be employed is the use of the strong biotin-streptavidin interaction as a linker. For example, Broude *et al.* (1994) Proc. Natl. Acad. Sci USA 91(8) 3072-6 describe the use of biotinylated probes, although these are duplex probes, that are immobilized on streptavidin-coated magnetic beads. Streptavidin-coated beads may be purchased from Dynal, Oslo. Of course, this same linking chemistry is applicable to coating any surface with streptavidin. Biotinylated probes may be purchased from various sources, such as, e.g., Operon Technologies (Alameda, CA).

Nunc Laboratories (Naperville, IL) is also selling suitable material that could be used. Nunc Laboratories have developed a method by which DNA can be covalently bound to the microwell surface termed CovaLink NH. CovaLink NH is a polystyrene surface grafted with secondary amino groups ($>NH$) that serve as bridge-heads for further covalent coupling. CovaLink Modules may be purchased from Nunc Laboratories. DNA molecules may be bound to CovaLink exclusively at the 5'-end by a phosphoramidate bond, allowing immobilization of more than 1 pmol of DNA (Rasmussen *et al.*, (1991) Anal Biochem 198(1) 138-42).

The use of CovaLink NH strips for covalent binding of DNA molecules at the 5'-end has been described (Rasmussen *et al.*, 1991). In this technology, a phosphoramidate bond is employed (Chu *et al.*, 1983 Nucleic Acids 11(18) 6513-29). This is beneficial as immobilization

using only a single covalent bond is preferred. The phosphoramidate bond joins the DNA to the CovaLink NH secondary amino groups that are positioned at the end of spacer arms covalently grafted onto the polystyrene surface through a 2 nm long spacer arm. To link an oligonucleotide to CovaLink NH via an phosphoramidate bond, the oligonucleotide terminus must have a 5'-end phosphate group. It is, perhaps, even possible for biotin to be covalently bound to CovaLink and then streptavidin used to bind the probes.

More specifically, the linkage method includes dissolving DNA in water (7.5 ng/ul) and denaturing for 10 min. at 95°C and cooling on ice for 10 min. Ice-cold 0.1 M 1-methylimidazole, pH 7.0 (1-MeIm₇), is then added to a final concentration of 10 mM 1-MeIm₇. A ss DNA solution is then dispensed into CovaLink NH strips (75 ul/well) standing on ice.

Carbodiimide 0.2 M 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide(EDC), dissolved in 10 mM 1-MeIm₇, is made fresh and 25 ul added per well. The strips are incubated for 5 hours at 50°C. After incubation the strips are washed using, e.g., Nunc-Immuno Wash; first the wells are washed 3 times, then they are soaked with washing solution for 5 min., and finally they are washed 3 times (where in the washing solution is 0.4 N NaOH, 0.25% SDS heated to 50°C).

It is contemplated that a further suitable method for use with the present invention is that described in PCT Patent Application WO 90/03382 (Southern & Maskos), incorporated herein by reference. This method of preparing an oligonucleotide bound to a support involves attaching a nucleoside 3'-reagent through the phosphate group by a covalent phosphodiester link to aliphatic hydroxyl groups carried by the support. The oligonucleotide is then synthesized on the supported nucleoside and protecting groups removed from the synthetic oligonucleotide chain under standard conditions that do not cleave the oligonucleotide from the support. Suitable reagents include nucleoside phosphoramidite and nucleoside hydrogen phosphorate.

An on-chip strategy for the preparation of DNA probe for the preparation of DNA probe arrays may be employed. For example, addressable laser-activated photodeprotection may be employed in the chemical synthesis of oligonucleotides directly on a glass surface, as described by Fodor *et al.* (1991) Science 251(4995) 767-73, incorporated herein by reference. Probes may also be immobilized on nylon supports as described by Van Ness *et al.* (1991) Nucleic Acids Res. 19(12) 3345-50; or linked to Teflon using the method of Duncan & Cavalier (1988) Anal Biochem 169(1) 104-8; all references being specifically incorporated herein.

To link an oligonucleotide to a nylon support, as described by Van Ness *et al.* (1991), requires activation of the nylon surface via alkylation and selective activation of the 5'-amine of oligonucleotides with cyanuric chloride.

One particular way to prepare support bound oligonucleotides is to utilize the light-generated synthesis described by Pease *et al.*, (1994) Proc. Natl. Acad. Sci USA 91(11) 5022-6. These authors used current photolithographic techniques to generate arrays of immobilized oligonucleotide probes (DNA chips). These methods, in which light is used to direct the synthesis
5 of oligonucleotide probes in high-density, miniaturized arrays, utilize photolabile 5'-protected *N*-acyl-deoxynucleoside phosphoramidites, surface linker chemistry and versatile combinatorial synthesis strategies. A matrix of 256 spatially defined oligonucleotide probes may be generated in this manner.

5.21 PREPARATION OF NUCLEIC ACID FRAGMENTS

10 The nucleic acids may be obtained from any appropriate source, such as cDNAs, genomic DNA, chromosomal DNA, microdissected chromosome bands, cosmid or YAC inserts, and RNA, including mRNA without any amplification steps. For example, Sambrook *et al.* (1989) describes three protocols for the isolation of high molecular weight DNA from mammalian cells (p. 9.14-9.23).

15 DNA fragments may be prepared as clones in M13, plasmid or lambda vectors and/or prepared directly from genomic DNA or cDNA by PCR or other amplification methods. Samples may be prepared or dispensed in multiwell plates. About 100-1000 ng of DNA samples may be prepared in 2-500 ml of final volume.

The nucleic acids would then be fragmented by any of the methods known to those of skill
20 in the art including, for example, using restriction enzymes as described at 9.24-9.28 of Sambrook *et al.* (1989), shearing by ultrasound and NaOH treatment.

Low pressure shearing is also appropriate, as described by Schrieffer *et al.* (1990) Nucleic Acids Res. 18(24) 7455-6. In this method, DNA samples are passed through a small French pressure cell at a variety of low to intermediate pressures. A lever device allows controlled
25 application of low to intermediate pressures to the cell. The results of these studies indicate that low-pressure shearing is a useful alternative to sonic and enzymatic DNA fragmentation methods.

One particularly suitable way for fragmenting DNA is contemplated to be that using the two base recognition endonuclease, *Cvi*II, described by Fitzgerald *et al.* (1992) Nucleic Acids Res. 20(14) 3753-62. These authors described an approach for the rapid fragmentation and
30 fractionation of DNA into particular sizes that they contemplated to be suitable for shotgun cloning and sequencing.

The restriction endonuclease *Cvi*II normally cleaves the recognition sequence PuGCPy between the G and C to leave blunt ends. Atypical reaction conditions, which alter the specificity

of this enzyme (*Cvi*JI**), yield a quasi-random distribution of DNA fragments from the small molecule pUC19 (2688 base pairs). Fitzgerald *et al.* (1992) quantitatively evaluated the randomness of this fragmentation strategy, using a *Cvi*JI** digest of pUC19 that was size fractionated by a rapid gel filtration method and directly ligated, without end repair, to a lac Z minus M13 cloning vector. Sequence analysis of 76 clones showed that *Cvi*JI** restricts pyGCPy and PuGCPu, in addition to PuGCPy sites, and that new sequence data is accumulated at a rate consistent with random fragmentation.

As reported in the literature, advantages of this approach compared to sonication and agarose gel fractionation include: smaller amounts of DNA are required (0.2-0.5 ug instead of 2-5 ug); and fewer steps are involved (no preligation, end repair, chemical extraction, or agarose gel electrophoresis and elution are needed).

Irrespective of the manner in which the nucleic acid fragments are obtained or prepared, it is important to denature the DNA to give single stranded pieces available for hybridization. This is achieved by incubating the DNA solution for 2-5 minutes at 80-90°C. The solution is then cooled quickly to 2°C to prevent renaturation of the DNA fragments before they are contacted with the chip. Phosphate groups must also be removed from genomic DNA by methods known in the art.

5.22 PREPARATION OF DNA ARRAYS

Arrays may be prepared by spotting DNA samples on a support such as a nylon membrane. Spotting may be performed by using arrays of metal pins (the positions of which correspond to an array of wells in a microtiter plate) to repeated by transfer of about 20 nl of a DNA solution to a nylon membrane. By offset printing, a density of dots higher than the density of the wells is achieved. One to 25 dots may be accommodated in 1 mm², depending on the type of label used. By avoiding spotting in some preselected number of rows and columns, separate subsets (subarrays) may be formed. Samples in one subarray may be the same genomic segment of DNA (or the same gene) from different individuals, or may be different, overlapped genomic clones. Each of the subarrays may represent replica spotting of the same samples. In one example, a selected gene segment may be amplified from 64 patients. For each patient, the amplified gene segment may be in one 96-well plate (all 96 wells containing the same sample). A plate for each of the 64 patients is prepared. By using a 96-pin device, all samples may be spotted on one 8 x 12 cm membrane. Subarrays may contain 64 samples, one from each patient. Where the 96 subarrays are identical, the dot span may be 1 mm² and there may be a 1 mm space between subarrays.

Another approach is to use membranes or plates (available from NUNC, Naperville, Illinois) which may be partitioned by physical spacers e.g. a plastic grid molded over the membrane, the grid being similar to the sort of membrane applied to the bottom of multiwell plates, or hydrophobic strips. A fixed physical spacer is not preferred for imaging by exposure to
5 flat phosphor-storage screens or x-ray films.

The present invention is illustrated in the following examples. Upon consideration of the present disclosure, one of skill in the art will appreciate that many other embodiments and variations may be made in the scope of the present invention. Accordingly, it is intended that the broader aspects of the present invention not be limited to the disclosure of the following
10 examples. The present invention is not to be limited in scope by the exemplified embodiments which are intended as illustrations of single aspects of the invention, and compositions and methods which are functionally equivalent are within the scope of the invention. Indeed, numerous modifications and variations in the practice of the invention are expected to occur to those skilled in the art upon consideration of the present preferred embodiments. Consequently,
15 the only limitations which should be placed upon the scope of the invention are those which appear in the appended claims.

All references cited within the body of the instant specification are hereby incorporated by reference in their entirety.

6.0 EXAMPLES

20

EXAMPLE 1

Isolation of SEQ ID NO: 1, 16, 35, 47, and 63 from human cDNA Libraries

A plurality of novel nucleic acids were obtained from cDNA libraries prepared from human leukocyte mRNA (GIBCO Laboratories) (SEQ ID NO: 1, SEQ ID NO: 16); from infant
25 brain mRNA (Columbia University) (SEQ ID NO: 35); from human mammary gland mRNA (Invitrogen) (SEQ ID NO: 47); and from bone marrow mRNA (Clontech) (SEQ ID NO: 63) using standard PCR, sequencing by hybridization sequence signature analysis, and Sanger sequencing techniques. The inserts of the library were amplified with PCR using primers specific for vector sequences flanking the inserts. These samples were spotted onto nylon
30 membranes and interrogated with oligonucleotide probes to give sequence signatures. The clones were clustered into groups of similar or identical sequences, and single representative clones were selected from each group for gel sequencing. The 5' sequence of the amplified inserts was then deduced using the reverse M13 sequencing primer in a typical Sanger sequencing protocol. PCR products were purified and subjected to fluorescent dye terminator

WO 01/55335

PCT/US01/02570

cycle sequencing. Single-pass gel sequencing was done using a 377 Applied Biosystems (ABI) sequencer. The insert was identified as a novel sequence not previously obtained from this library and not previously reported in public databases. The sequences were designated as SEQ ID NO: 1, 16, 35, 47, and 63.

5

EXAMPLE 2

ASSEMBLAGE OF SEQ ID NO: 2, 17, 48, and 64

The nucleic acids of the present invention, designated as SEQ ID NO: 2, 17, 48, and 64 were assembled using SEQ ID NO: 1, 16, 47, or 63 as a seed, respectively. Then a recursive algorithm was used to extend the seed into an extended assemblage, by pulling additional sequences from different databases (i.e., Hyseq's database containing EST sequences, dbEST version 114, gb pri 114, and UniGene version 101) that belong to this assemblage. The algorithm terminated when there was no additional sequences from the above databases that would extend the assemblage. Inclusion of component sequences into the assemblage was based on a BLASTN hit to the extending assemblage with BLAST scores greater than 300 and percent identities greater than 95%.

The nearest neighbor result for the assembled contigs were obtained by a FASTA version 3 search against Genpept release 114, using FASTXY algorithm. FASTXY is an improved version of FASTA alignment which allows in-codon frame shifts. The nearest neighbor result showed the closest homologue for each assemblage from Genpept (and contains the translated amino acid sequences for which the assemblage encodes). The nearest neighbor results is set forth below:

SEQ ID NO:	Accession No.	Description	Smith-Waterman Score	% Identity
2	AJ010101	Homo sapiens IRC1a	407	33.968
17	U70665	Homo sapiens putative inhibitory receptor	211	32.432
48	AJ010101	Homo sapiens IRC1a	350	48.780
64	AB002362	Homo sapiens KIAA0364	199	39.423

25

The nucleotide sequence within the assembled contigs that codes for signal peptide sequences and their cleavage sites can be determined from using Neural Network SignalP V1.1 program (from Center for Biological Sequence Analysis, The Technical University of Denmark). The process for identifying prokaryotic and eukaryotic signal peptides and their cleavage sites are also disclosed by Henrik Nielson, Jacob Engelbrecht, Soren Brunak, and Gunnar von Heijne in the publication " Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites" Protein Engineering, vol. 10, no. 1, pp. 1-6 (1997), incorporated herein by reference. A maximum S score and a mean S score, as described in the Nielson et al reference, are obtained for each assembled contig. Starting from the first amino acid of the predicted signal sequence, a sequence of 45 amino acids is described. Not all forty-five amino acids in the sequence may comprise the signal peptide.

For SEQ ID NO: 2:

Beginning and end nucleotide location corresponding to amino acid segment	Maximum S score	mean S score	Amino acid segment containing signal peptide (A = Alanine, C = Cysteine, D = Aspartic Acid, E = Glutamic Acid, F = Phenylalanine, G = Glycine, H = Histidine, I = Isoleucine, K = Lysine, L = Leucine, M = Methionine, N = Asparagine, P = Proline, Q = Glutamine, R = Arginine, S = Serine, T = Threonine, V = Valine, W = Tryptophan, Y = Tyrosine, X = Unknown, * = Stop Codon, / = possible nucleotide deletion, \ = possible nucleotide insertion)
114: 249	0.982	0.959	MPLLTLYLLLFWLSGYSIATQITGPT TVNGLERGS�TVQCVYRSG (SEQ ID NO: 33)

The predicted amino acid sequences for SEQ ID NO: 17, 48, and 64 were obtained by using a software program called FASTY (available from <http://fasta.bioch.virginia.edu>) which selects a polypeptide based on a comparison of translated novel polynucleotide to known polynucleotides (W.R. Pearson, Methods in Enzymology, 183:63-98 (1990), incorporated herein by reference).

For SEQ ID NO: 17, 48, and 64:

SEQ ID NO:	Predicted beginning nucleotide location corresponding to first amino acid residue of amino acid sequence	Predicted end nucleotide location corresponding to first amino acid residue of amino acid sequence	Amino acid segment containing signal peptide (A = Alanine, C = Cysteine, D = Aspartic Acid, E = Glutamic Acid, F = Phenylalanine, G = Glycine, H = Histidine, I = Isoleucine, K = Lysine, L = Leucine, M = Methionine, N = Asparagine, P = Proline, Q = Glutamine, R = Arginine, S = Serine, T = Threonine, V = Valine, W = Tryptophan, Y = Tyrosine, X = Unknown, * = Stop Codon. / = possible nucleotide deletion, \ = possible nucleotide insertion)
17	130	876	NPRRGLGSGRRDAMTAEFLSLLCLGLCLGYE DEKKNEKPPKPSLHAWPSSVVEAESNVTLKC QAHSQNVTFVLRKVNDSGYKQEQAENEA EFPFTDLKPKDAGRYFCAYKTTASHEWSESS EHLQLVVTDKHDELEAPSMKTDTRTIFVAIFS CISILLFLSVFIIYRCSQHSSSSEESTKRTSHS KLPEQEAAEADLSNMERVSLSTADPQGVTY AELSTSALSEAASDTTQEPPGSHEYAALKV(S EQ ID NO: 34)
48	14	383	VGSFQIGFLLLLWLRDSTGEIVKTQSPSTLSG SPGERATLSCRASQRVSIILAWDQQKPGQAP MLLMYRACTRAIDIPARFSGGGSGTEFTLTIS SLQSGDCAVYFWQHYNNWPPWTFGQGTR (SEQ ID NO: 58)
64	32	428	GAIMIPKLLSLLCFRLRVGQGDTRGDGSLPK PSLIAWPTSVVPANSNVTLRCWTPARGVSCV LRKGGIILESPKPLDSTEGADECHLYNLKVR NAGEYTCEYYRKACPHILSQSSDLLLLMVT GHLCKPLLR (SEQ ID NO: 64)

EXAMPLE 3

ASSEMBLAGE OF SEQ ID NO: 5, 21, 36, and 49

5

Assembly of novel nucleotide sequences of SEQ ID NO: 5, 21, 36, and 49 was accomplished by using EST sequences SEQ ID NO: 1, 16, 35, and 47 as seeds, respectively. The seeds were extended at both the 3' and 5' end by gel sequencing (377 Applied Biosystems (ABI) Sequencer) with new primers (primer extension). Some of the seeds were also extended using nested primers and RACE (Rapid Amplification of cDNA Ends) using Marathon RACE kit from Clontech.

10

EXAMPLE 4

ASSEMBLAGE OF SEQ ID NO: 18, 39, and 65

15

Using PHRAP (Univ. of Washington) or CAP4 (Paracel), a full-length gene cDNA sequences and its corresponding protein sequences were generated from the assemblage of SEQ ID NO: 17, 35, and 63. Any frame shifts and incorrect stop codons were corrected by hand editing. During editing, the sequence was checked using FASTY and/or BLAST against Genbank. (i.e. Genepept release 119). Other computer programs, which may have been used in the editing process, were phredPhrap and Consed (University of Washington) and ed_ready, ed_ext and cg_zip-2 (Hyseq, Inc.).

10

EXAMPLE 5

ASSEMBLAGE OF SEQ ID NO: 3, 6, 19, 22, 37, 40, 50, and 66

15

A polypeptide (SEQ ID NO: 3) was predicted to be encoded by SEQ ID NO: 2 as set forth below. The polypeptide was predicted using a software program called BLASTX which selects a polypeptide based on a comparison of translated novel polynucleotide to known polynucleotides. The initial methionine starts at position 114 of SEQ ID NO: 2 and the putative stop codon, TAG, begins at position 1029 of the nucleotide sequence.

20

A polypeptide (SEQ ID NO: 6) was predicted to be encoded by SEQ ID NO: 5 as set forth below. The polypeptide was predicted using a software program called BLASTX which selects a polypeptide based on a comparison of translated novel polynucleotide to known polynucleotides. The initial methionine starts at position 280 of SEQ ID NO: 5 and the putative stop codon, TAG, begins at position 766 of the nucleotide sequence.

25

The leukocyte immunoglobulin receptor-like polypeptide of SEQ ID NO: 3 is an approximately 305-amino acid protein with a predicted molecular mass of approximately 34 kDa unglycosylated. Protein database searches with the BLASTX algorithm (Altschul S.F. et al., J. Mol. Evol. 36:290-300 (1993) and Altschul S.F. et al., J. Mol. Biol. 21:403-10 (1990), herein incorporated by reference) indicate that SEQ ID NO: 3 is homologous to leukocyte immunoglobulin receptors like IRC1a and NK cell inhibitory receptors like PIGR-1. Protein database search with eMATRIX software (Stanford University, Stanford CA) further show that a portion of SEQ ID NO: 3 (i.e. SEQ ID NO: 8) is homologous to poly Ig receptors.

30

Figure 1 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 2 (i.e. SEQ ID NO: 3) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human IRC1a protein SEQ ID NO: 14,

indicating that the two sequences share 55% similarity over 297 amino acid residues and 37% identity over the same 297 amino acid residues.

Figure 2 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID: 2 (i.e. SEQ ID NO: 3) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human PIGR-1 (Patent Application No. EP897981) SEQ ID NO: 15, indicating that the two sequences share 63% similarity over 176 amino acid residues and 53% identity over the same 176 amino acid residues.

A predicted soluble, secreted splice variant of SEQ ID NO: 3 is SEQ ID NO: 6. It is an approximately 162 amino acid protein with a predicted molecular mass of approximately 18 kDa unglycosylated. Protein database searches with the BLASTX algorithm (Altschul S.F. et al., J. Mol. Evol. 36:290-300 (1993) and Altschul S.F. et al., J. Mol. Biol. 21:403-10 (1990), herein incorporated by reference) indicate that SEQ ID NO: 6 is homologous to leukocyte immunoglobulin receptors like IRC1a and NK cell inhibitory receptor like PIGR-1. Protein database search with eMATRIX software (Stanford University, Stanford CA) further show that a portion of SEQ ID NO: 7 (i.e. SEQ ID NO: 9) is homologous to poly Ig receptors.

Figure 3 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID: 5 (i.e. SEQ ID NO: 6) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human IRC1a protein SEQ ID NO: 14, indicating that the two sequences share 57% similarity over 135 amino acid residues and 38% identity over the same 135 amino acid residues.

Figure 4 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 5 (i.e. SEQ ID NO: 6) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human PIGR-1 (Patent Application No. EP897981) SEQ ID NO: 15, indicating that the two sequences share 67% similarity over 145 amino acid residues and 59% identity over the same 145 amino acid residues.

A predicted approximately thirty residue signal peptide is encoded from approximately residue 1 to residue 30 of both SEQ ID NO: 3 and SEQ ID NO: 6 (SEQ ID NO: 10). The extracellular portion is useful on its own. This can be confirmed by expression in mammalian cells and sequencing of the cleaved product. The signal peptide region was predicted using the Kyte-Doolittle hydrophobicity prediction algorithm (J. Mol Biol, 157, pp. 105-31 (1982), incorporated herein by reference). One of skill in the art will recognize that the actual cleavage site may be different than that predicted by the computer program. SEQ ID NO: 12 is the peptide resulting when the signal peptide is removed from SEQ ID NO: 3. SEQ ID NO: 13 is the peptide resulting when the signal peptide is removed from SEQ ID NO: 6.

A predicted approximately fourteen residue transmembrane peptide is encoded from approximately residue 170 to residue 193 of SEQ ID NO: 3 (SEQ ID NO: 11). This can be confirmed by expression in mammalian cells. The transmembrane peptide region was predicted using the Kyte-Doolittle hydrophobicity prediction algorithm (J. Mol Biol, 157, pp. 105-31 (1982), incorporated herein by reference). One of skill in the art will recognize that the actual transmembrane region may be different than that predicted by the computer program.

Using eMATRIX software package (Stanford University, Stanford, CA) (Wu et al., J. Comp. Biol., vol. 6, pp. 219-235 (1999), herein incorporated by reference), both the membrane-bound and soluble LIR-like polypeptide is expected to have a poly Ig receptor domain at residues 82 - 129 of SEQ ID NO: 3 and residues 82 - 129 of SEQ ID NO: 6 (SEQ ID NO: 8 and SEQ ID NO: 9, respectively). SEQ ID NO 8 has serine in the position 129 while SEQ ID NO: 9 contains proline in the same position. The domains corresponding to SEQ ID NO: 3 and SEQ ID NO: 6 are as follows wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine:

Poly immunoglobulin receptor domain

(IKDNQKNRTFTVTMEDLMKTDADTYWCGIEKTGNDLGVTQVTIDPAS designated as SEQ ID NO: 8) p-value of 3.628e-9, DM01688B 2 (identification number correlating to signature); located at residues 82-129 of SEQ ID NO: 3 and

Poly immunoglobulin receptor domain

(IKDNQKNRTFTVTMEDLMKTDADTYWCGIEKTGNDLGVTQVTIDPAP designated as SEQ ID NO: 9) p-value of 2.5e-10, DM01688B 2 (identification number correlating to signature); located at residues 82-129 of SEQ ID NO: 6.

A polypeptide (SEQ ID NO: 19) was predicted to be encoded by SEQ ID NO: 18 as set forth below. The polypeptide was predicted using software programs called BLASTX/FASTY which selects a polypeptide based on a comparison of translated novel polynucleotide to known polypeptides. The initial methionine ATG starts at position 169 of the nucleotide sequence and the putative stop codon, TAG, ends the coding region at position 879.

Leukocyte immunoglobulin receptor-like polypeptide SEQ ID NO: 19 is an approximately 236-amino acid protein with a predicted molecular mass of approximately 26 kDa unglycosylated. Protein database searches with the BLASTP algorithm (Altschul S.F. et

al., J. Mol. Evol. 36:290-300 (1993) and Altschul S.F. et al., J. Mol. Biol. 21:403-10 (1990), herein incorporated by reference) indicate that SEQ ID NO: 19 is homologous to leukocyte immunoglobulin receptors (LIRs) and immunoglobulin-like protein IGSF-1. Protein database search with Molecular Simulations Inc. GeneAtlas software (Molecular Simulations Inc., San
5 Diego, CA) further show that SEQ ID NO: 19 is homologous to killer cell inhibitory receptors.

Figure 5 shows the BLASTP amino acid sequence alignment between the protein encoded by SEQ ID NO: 18 (i.e. SEQ ID NO: 19) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and putative inhibitory receptor (Rojo et al, (1997)
10 J. Immunol., 158, 9-12) SEQ ID NO: 29, indicating that the two sequences share 51 % similarity over 145 amino acid residues and 33 % identity over the same 145 amino acid residues.

Figure 6 shows the BLASTP amino acid sequence alignment between the protein encoded by SEQ ID NO: 18 (i.e. SEQ ID NO: 19) leukocyte immunoglobulin receptor-like
15 polypeptide (also identified as "LIR-like") and human GP49 HM18 polypeptide (Patent Application No. WO9809638) SEQ ID NO: 30, indicating that the two sequences share 50% similarity over 123 amino acid residues and 34 % identity over the same 123 amino acid residues.

A polypeptide (SEQ ID NO: 22) was predicted to be encoded by SEQ ID NO: 21 as set
20 forth below. The polypeptide was predicted using a software program called BLASTX which selects a polypeptide based on a comparison of translated novel polynucleotide to known polynucleotides. The initial methionine starts at position 176 of SEQ ID NO: 21 and the putative stop codon, TAA, begins at position 773 of the nucleotide sequence.

SEQ ID NO 22 is a soluble, secreted splice variant of SEQ ID NO: 19. It is an
25 approximately 199 amino acid protein with a predicted molecular mass of approximately 22 kDa unglycosylated. Protein database searches with the BLASTP algorithm (Altschul S.F. et al., J. Mol. Evol. 36:290-300 (1993) and Altschul S.F. et al., J. Mol. Biol. 21:403-10 (1990), herein incorporated by reference) indicate that SEQ ID NO: 22 is homologous to leukocyte immunoglobulin receptors (LIRs) and immunoglobulin-like protein IGSF-1. Protein database
30 search with Molecular Simulations Inc. GeneAtlas software (Molecular Simulations Inc., San Diego, CA) further shows that SEQ ID NO: 22 is homologous to killer cell inhibitory receptors.

Figure 7 shows the BLASTP amino acid sequence alignment between the protein encoded by SEQ ID NO: 21 (i.e SEQ ID NO: 22) leukocyte immunoglobulin receptor-like

polypeptide (also identified as "LIR-like") and immunoglobulin-like protein IGSF1 (Mazzarella et al, (1998) Genomics 48, 157-162) SEQ ID NO: 31, indicating that the two sequences share 53% similarity over 209 amino acid residues and 38% identity over the same 209 amino acid residues.

5 Figure 8 shows the BLASTP amino acid sequence alignment between the protein encoded by SEQ ID NO: 21 (i.e SEQ ID NO: 22) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human LIR-pbm36-2 protein (Patent Application No. WO9848017) SEQ ID NO: 32, indicating that the two sequences share 46% similarity over 236 amino acid residues and 32% identity over the same 236 amino acid
10 residues.

 A predicted approximately sixteen residue signal peptide is encoded from approximately residue 1 to residue 16 of both SEQ ID NO: 19 and SEQ ID NO: 22 (SEQ ID NO: 25). The extracellular portion is useful on its own. This can be confirmed by expression in mammalian cells and sequencing of the cleaved product. The signal peptide region was
15 predicted using the Kyte-Doolittle hydrophobicity prediction algorithm (J. Mol Biol, 157, pp. 105-31 (1982), incorporated herein by reference). One of skill in the art will recognize that the actual cleavage site may be different than that predicted by the computer program. SEQ ID NO: 27 is the peptide resulting when the predicted signal peptide is removed from SEQ ID NO: 19. SEQ ID NO: 28 is the peptide resulting when the predicted signal peptide is removed
20 from SEQ ID NO: 22.

 A predicted approximately twenty-three residue transmembrane peptide is encoded from approximately residue 135 to residue 157 of SEQ ID NO: 19 (SEQ ID NO: 26). This can be confirmed by expression in mammalian cells. The transmembrane peptide region was predicted using the Kyte-Doolittle hydrophobicity prediction algorithm (J. Mol Biol, 157, pp.
25 105-31 (1982), incorporated herein by reference). One of skill in the art will recognize that the actual transmembrane region may be different than that predicted by the computer program.

 Using Molecular Simulations Inc. GeneAtlas software (Molecular Simulations Inc., San Diego, CA), LIR-like polypeptides of SEQ ID NO: 19 and 22 were determined to have a
30 region at residues 26 – 97 with characteristic motifs to the killer cell inhibitory receptor domain (SEQ ID NO: 24). The corresponding domain within SEQ ID NO: 19 and 22 is as follows wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine,

M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine,

T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine:

Killer cell inhibitory receptor domain

PPKPSLHAWPSSVVEAESNVTLKCQAHSQNVTFVLRKVNDSGYKQEQSSAENEAEFPFT

5 DLKPKDAGRYFCA

designated as SEQ ID NO: 24 with PSI-BLAST e-value of 4.2e-24, protein database identification number entry = 1b6u (Research collaboratory for Structural Bioinformatics. <http://www.rcsb.org/pdb>), verify score = 0.26. located at residues 26-97 of SEQ ID NO: 19.

The identical leukocyte immunoglobulin receptor-like polypeptide of both SEQ ID NO: 37 and 40 is an approximately 230-amino acid protein with a predicted molecular mass of approximately 26 kDa unglycosylated. Protein database search with Molecular Simulations Inc. GeneAtlas software (Molecular Simulations Inc., San Diego, CA) further shows that both SEQ ID NO: 37 and 40 and is homologous to P58 killer cell inhibitory receptor.

Figure 9 shows the GeneAtlas amino acid sequence alignment between the protein encoded by SEQ ID NO: 36 and 39 (i.e SEQ ID NO: 37 and 40, respectively) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human P58 killer cell inhibitory receptor protein, pdb Identification No. 1b6u, SEQ ID NO: 46, indicating that the two sequences share 33% similarity over 103 amino acid residues and 19.4% identity over the same 103 amino acid residues.

A predicted approximately fifteen residue signal peptide is encoded from approximately residue 1 to residue 15 of both SEQ ID NO: 37 and SEQ ID NO: 40 (SEQ ID NO: 43). The extracellular portion is useful on its own. This can be confirmed by expression in mammalian cells and sequencing of the cleaved product. The signal peptide region was predicted using the Kyte-Doolittle hydrophobicity prediction algorithm (J. Mol Biol, 157, pp. 105-31 (1982), incorporated herein by reference). One of skill in the art will recognize that the actual cleavage site may be different than that predicted by the computer program.

A predicted approximately twenty-seven residue transmembrane peptide is encoded from approximately residue 116 to residue 143 of SEQ ID NO: 37 and SEQ ID NO: 40 (SEQ ID NO: 44). The transmembrane portion may be useful on its own. This can be confirmed by expression in mammalian cells. The transmembrane peptide region was predicted using the Kyte-Doolittle hydrophobicity prediction algorithm (J. Mol Biol, 157, pp. 105-31 (1982), incorporated herein by reference). One of skill in the art will recognize that the actual transmembrane region may be different than that predicted by the computer program.

The leukocyte immunoglobulin receptor-like polypeptide of SEQ ID NO: 50 is an approximately 201-amino acid protein with a predicted molecular mass of approximately 22 kDa unglycosylated. Protein database searches with the BLASTX algorithm (Altschul S.F. et al., J. Mol. Evol. 36:290-300 (1993) and Altschul S.F. et al., J. Mol. Biol. 21:403-10 (1990),
5 herein incorporated by reference) indicate that SEQ ID NO: 50 is homologous to leukocyte immunoglobulin receptors like CMRF35, NK cell inhibitory receptor, and human PIGR-2 receptor.

Figure 10 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 49 (i.e. SEQ ID NO: 50) leukocyte immunoglobulin receptor-like
10 polypeptide (also identified as "LIR-like") and human CMRF 35 protein (Jackson et al, (1992) Eur. J. Immunol., 22, 1157-1163) SEQ ID NO: 60, indicating that the two sequences share 62% similarity over 217 amino acid residues and 48% identity over the same 217 amino acid residues.

Figure 11 shows the BLASTX amino acid sequence alignment between the protein
15 encoded by SEQ ID NO: 49 (i.e. SEQ ID NO: 50) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human Natural Killer inhibitory receptor protein SEQ ID NO: 61, indicating that the two sequences share 64% similarity over 145 amino acid residues and 51% identity over the same 145 amino acid residues.

Figure 12 shows the BLASTX amino acid sequence alignment between the protein
20 encoded by SEQ ID NO: 49 (i.e. SEQ ID NO: 50) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human PIGR-2 protein (Patent Application No. EP905237) SEQ ID NO: 62, indicating that the two sequences share 58% similarity over 205 amino acid residues and 47% identity over the same 205 amino acid residues.

Figure 13 shows the GeneAtlas amino acid sequence alignment between the protein
25 encoded by SEQ ID NO: 49 (i.e. SEQ ID NO: 50) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and T cell receptor, pdb Identification No. 1b88, SEQ ID NO: 59, indicating that the two sequences share 29.5% similarity over 112 amino acid residues and 11.6% identity over the same 112 amino acid residues.

A predicted approximately twenty-residue signal peptide is encoded from approximately
30 residue 1 through residue 20 of SEQ ID NO: 50 (SEQ ID NO: 55). The extracellular portion is useful on its own. This can be confirmed by expression in mammalian cells and sequencing of the cleaved product. The signal peptide region was predicted using the Kyte-Doolittle hydrophobicity prediction algorithm (J. Mol Biol, 157, pp. 105-31 (1982), incorporated herein

by reference). One of skill in the art will recognize that the actual cleavage site may be different than that predicted by the computer program.

A predicted approximately twenty-four residue transmembrane peptide is encoded from approximately residue 167 to residue 191 of SEQ ID NO: 50 (SEQ ID NO: 56). The transmembrane portion may be useful on its own. This can be confirmed by expression in mammalian cells. The transmembrane peptide region was predicted using the Kyte-Doolittle hydrophobicity prediction algorithm (J. Mol Biol, 157, pp. 105-31 (1982), incorporated herein by reference). One of skill in the art will recognize that the actual transmembrane region may be different than that predicted by the computer program.

Using eMATRIX software package (Stanford University, Stanford, CA) (Wu et al., J. Comp. Biol., vol. 6, pp. 219-235 (1999), herein incorporated by reference), SEQ ID NO: 50, LIR-like polypeptide is expected to have two poly-Ig receptor domains. The domains corresponding to SEQ ID NO: 53-54 are as follows wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine:

Poly Immunoglobulin receptor domain

ITDHPGDLTFTVTLENLTADDAGKYRCGIATILQEDGLSGFLPDPFFQ

designated as (SEQ ID NO: 53) p-value of 4.504e-9, DM01688B 2 (identification

number correlating to signature); located at residues 85-132 of SEQ ID NO: 50.

Poly Immunoglobulin receptor domain

MGAVGESLSVQCRYEEKYKTFNKYWCRQPCLPIWHEM

designated as (SEQ ID NO: 54) p-value of 8.364e-9, DM01688J 2 (identification number correlating to signature); located at residues 32-68 of SEQ ID NO: 50.

A polypeptide (SEQ ID NO: 66) was predicted to be encoded by SEQ ID NO: 65 as set forth below. The polypeptide was predicted using software programs called BLASTX, which selects a polypeptide based on a comparison of translated novel polynucleotide to known polypeptides. The initial methionine ATG starts at position 35 of the nucleotide sequence and the putative stop codon, TGA, ends the coding region at position 850.

The leukocyte immunoglobulin receptor-like polypeptide of SEQ ID NO: 66 is an approximately 271-amino acid protein with a predicted molecular mass of approximately 30.4 kDa unglycosylated. Protein database searches with the BLASTP algorithm (Altschul S.F. et al., J. Mol. Evol. 36:290-300 (1993) and Altschul S.F. et al., J. Mol. Biol. 21:403-10 (1990),

herein incorporated by reference) indicate that SEQ ID NO: 66 is homologous to human platelet glycoprotein VI-2 and FcR-II protein.

Figure 14 shows the BLASTP amino acid sequence alignment between the protein encoded by SEQ ID NO: 65 (i.e. SEQ ID NO: 66) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human platelet glycoprotein VI-2 protein (Ezumi et al, (2000) Biochem. Biophys. Res. Commun. 277, 27-36) SEQ ID NO: 75, indicating that the two sequences share 50% similarity over residues 1-219 of SEQ ID NO: 66, and 37% identity over the same residues 1-219 of SEQ ID NO: 66.

Figure 15 shows the BLASTP amino acid sequence alignment between the protein encoded by SEQ ID NO: 65 (i.e. SEQ ID NO: 66) leukocyte immunoglobulin receptor-like polypeptide (also identified as "LIR-like") and human FcR-II protein (Patent Application No. WO9831806), SEQ ID NO: 76, indicating that the two sequences share 51% similarity over residues 27-262 of SEQ ID NO: 66 and 37% identity over the same amino acid residues 27-262 of SEQ ID NO: 66.

A predicted approximately sixteen-residue signal peptide is encoded from approximately residue 1 through residue 16 of SEQ ID NO: 66 (SEQ ID NO: 71). The extracellular portion is useful on its own. This can be confirmed by expression in mammalian cells and sequencing of the cleaved product. The signal peptide region was predicted using the Kyte-Doolittle hydrophobicity prediction algorithm (J. Mol Biol, 157, pp. 105-31 (1982), incorporated herein by reference) and also using the Neural Network SignalP V1.1 program (from Center for Biological Sequence Analysis, The Technical University of Denmark). One of skill in the art will recognize that the actual cleavage site may be different than that predicted by the computer program.

A predicted approximately twenty four-residue transmembrane region is encoded from approximately residue 231 through residue 254 of SEQ ID NO: 66 (SEQ ID NO: 73). The transmembrane portion may be useful on its own. The transmembrane region was predicted using the Kyte-Doolittle hydrophobicity prediction algorithm (J. Mol Biol, 157, pp. 105-31 (1982), incorporated herein by reference). One of skill in the art will recognize that the actual cleavage site may be different than that predicted by the computer program.

Using eMATRIX software package (Stanford University, Stanford, CA) (Wu et al., J. Comp. Biol., vol. 6, pp. 219-235 (1999), herein incorporated by reference), SEQ ID NO: 66, LIR-like polypeptide is expected to have three poly-Ig receptor domains. The domains corresponding to SEQ ID NO: 68 - 70 are as follows wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine.

WO 01/55335

PCT/US01/02570

K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine.
S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine:

Receptor cell NK glycoprotein immunoglobulin

GSLPKPSLSAWPSSVVPANSNVTLRCWTPARGVSFV

5 designated as (SEQ ID NO: 68) p-value of 6.625e-10, PD01652A (identification number correlating to signature); located at residues 24 - 59 of SEQ ID NO: 66.

Receptor cell NK glycoprotein immunoglobulin

CVGQGDTRGDGSLPKPSLSAWPSSVVPANSNVTLRCWTPARGVSFVLRKGGI

10 designated as (SEQ ID NO: 69) p-value of 1.836e-9, PD01652B (identification number correlating to signature); located at residues 14 - 65 of SEQ ID NO: 66.

RSDVLLLLVTGHLSKPFLRTYQRGTVTAGGRVTLQCQKRDQLFVPIMFALLK

designated as (SEQ ID NO: 70) p-value of 4.021e-9, PD01652B (identification number correlating to signature); located at residues 111 - 162 of SEQ ID NO: 66.

SEQ ID NO: 2, 5, 18, and 21 were determined to be present in the following tissues:

15 adult brain (Clontech) (Hyseq library name ABR001), adult lung (GIBCO) (Hyseq library name ALG001), adult ovary (Invitrogen) (Hyseq library name AOV001), adult spleen (GIBCO) (Hyseq library name ASP001), bone marrow (Clontech) (Hyseq library name BMD002), adult colon (Invitrogen) (Hyseq library name CLN001), fetal lung (Clontech) (Hyseq library name FLG001), fetal liver-spleen (Columbia University) (Hyseq library name
20 FLS002), macrophage (Invitrogen) (Hyseq library name HMP001), lung tumor (Invitrogen) (Hyseq library name LGT002), leukocyte (GIBCO) (Hyseq library name LUC001) and (Clontech) (Hyseq library name LUC003), small intestine (Clontech) (Hyseq library name SIN001), adult spleen (Clontech) (Hyseq library name SPLc01), thymus (Clontech) (Hyseq library name THMc02), and uterus (Clontech) (Hyseq library name UTR001). The tissue
25 expression information was determined using the tissue source of the ESTs that comprise SEQ ID NO: 2, 5, 18, and 21 and the tissue sources of the other ESTs of the cluster to which those ESTs belong. Clusters were made depending on the sequence signature of each sequence as described in Example 1.

30 SEQ ID NO: 36 and 39 were determined to be present in the following tissues: adult brain (Clontech) (Hyseq library name ABR006), adult lung (GIBCO) (Hyseq library name ALG001), adult spleen (GIBCO) (Hyseq library name ASP001), bone marrow (Clontech) (Hyseq library names BMD001 and BMD002), fetal brain (Invitrogen) (Hyseq library name FBT002), fetal lung (Clontech) (Hyseq library name FLG001), fetal liver-spleen (Columbia University) (Hyseq library name FLS001), fetal liver (Clontech) (Hyseq library name

FLV004), fetal skin (Invitrogen) (Hyseq library name FSK001), macrophage (Invitrogen) (Hyseq library name HMP001), infant brain (Columbia University) (Hyseq library names IB2002, IB2003, and IBS001), lymphocyte (ATCC) (Hyseq library name LPC001), leukocyte (GIBCO) (Hyseq library name LUC001), and skeletal muscle (Clontech) (Hyseq library name SKM001). The tissue expression information was determined using the tissue source of the ESTs that comprise SEQ ID NO: 36 and 39 and the tissue sources of the other ESTs of the cluster to which those ESTs belong. Clusters were made depending on the sequence signature of each sequence as described in Example 1.

SEQ ID NO: 49 was determined to be present in the following tissues: adult spleen (GIBCO) (Hyseq library name ASP001), fetal heart (Invitrogen) (Hyseq library name FHR001), fetal kidney (Clontech) (Hyseq library name FKD002), and mammary gland (Invitrogen) (Hyseq library name MMG001). The tissue expression information was determined using the tissue source of the ESTs that comprise SEQ ID NO: 49 and the tissue sources of the other ESTs of the cluster to which those ESTs belong. Clusters were made depending on the sequence signature of each sequence as described in Example 1.

SEQ ID NO: 65 was determined to be present in the following tissues: adult brain (Clontech) (Hyseq library names ABR006 and ABR008) and (Invitrogen) (Hyseq library name ABT004), adrenal gland (Clontech) (Hyseq library name ADR002), adult kidney (Invitrogen) (Hyseq library name AKT002), adult liver (Invitrogen) (Hyseq library name ALV002), bone marrow (Clontech) (Hyseq library names BMD001 and BMD002), adult cervix (BioChain) (Hyseq library name CVX001), endothelial cells (Stratagene) (Hyseq library name EDT001), fetal brain (Clontech) (Hyseq library name FBR006), fetal heart (Invitrogen) (Hyseq library name FHR001), fetal lung (Invitrogen) (Hyseq library name FLG003), fetal liver-spleen (Columbia University) (Hyseq library names FLS001 and FLS002), fetal liver (Invitrogen) (Hyseq library name FLV001), fetal muscle (Invitrogen) (Hyseq library names FMS001 and FMS002), fetal skin (Invitrogen) (Hyseq library name FSK001), fetal brain (GIBCO) (Hyseq library name HFB001), macrophage (Invitrogen) (Hyseq library name HMP001), infant brain (Columbia University) (Hyseq library names IB2002, IB2003, IBM002, and IBS001), lung fibroblast (Stratagene) (Hyseq library name LFB001), lung tumor (Invitrogen) (Hyseq library name LGT002), lymphocytes (ATCC) (Hyseq library name LPC001), mammary gland (Invitrogen) (Hyseq library name MMG001), retinoic acid-induced neuronal cells (Stratagene) (Hyseq library name NTR001), prostate (Clontech) (Hyseq library name PRT001), adult spleen (Clontech) (Hyseq library name SPLc01), thalamus (Clontech) (Hyseq library name THA002), thymus (Clontech) (Hyseq library name THMc02), and trachea (Clontech) (Hyseq

library name TRC001). The tissue expression information was determined using the tissue source of the ESTs that comprise SEQ ID NO: 65 and the tissue sources of the other ESTs of the cluster to which those ESTs belong. Clusters were made depending on the sequence signature of each sequence as described in Example 1.

5

EXAMPLE 6

A. Expression of SEQ ID NO: 3, 6, 19, 22, 37, 40, 50, and 66 in cells

10 Chinese Hamster Ovary (CHO) cells or other suitable cell types are grown in DMEM (ATCC) and 10% fetal bovine serum (FBS) (Gibco) to 70% confluence. Prior to transfection the media is changed to DMEM and 0.5% FCS. Cells are transfected with cDNAs for SEQ ID NO: 3, 6, 19, 22, 37, 40 50, 66, or with pBGal vector by the FuGENE-6 transfection reagent (Boehringer). In summary, 4 μ l of FuGENE-6 is diluted in 100 μ l of DMEM and
15 incubated for 5 minutes. Then, this is added to 1 μ g of DNA and incubated for 15 minutes before adding it to a 35 mm dish of CHO cells. The CHO cells are incubated at 37°C with 5% CO₂. After 24 hours, media and cell lysates are collected, centrifuged and dialyzed against assay buffer (15 mM Tris pH 7.6, 134 mM NaCl, 5 mM glucose, 3 mM CaCl₂ and MgCl₂).

20 B. Expression Study Using SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67

The expression of SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67 in various tissues is analyzed using a semi-quantitative polymerase chain reaction-based technique. Human cDNA libraries are used as sources of expressed genes from
25 tissues of interest (adult bladder, adult brain, adult heart, adult kidney, adult lymph node, adult liver, adult lung, adult ovary, adult placenta, adult rectum, adult spleen, adult testis, bone marrow, thymus, thyroid gland, fetal kidney, fetal liver, fetal liver-spleen, fetal skin, fetal brain, fetal leukocyte and macrophage). Gene-specific primers are used to amplify portions of the SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67
30 sequences from the samples. Amplified products are separated on an agarose gel, transferred and chemically linked to a nylon filter. The filter is then hybridized with a radioactively labeled (³³P-dCTP) double-stranded probe generated from SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67 using a Klenow polymerase, random-prime method. The filters are washed (high stringency) and used to expose a phosphorimaging

WO 01/55335**PCT/US01/02570**

screen for several hours. Bands indicate the presence of cDNA including SEQ ID NO: 1-2, 4-5, 7, 16-18, 20-21, 23, 35-36, 38-39, 41, 47-49, 51, 63-65, or 67 sequences in a specific library, and thus mRNA expression in the corresponding cell type or tissue.

WO 01/55335

PCT/US01/02570

SEQUENCE LISTING

<110> Hyseq, Inc.
 Boyle, Bryan J
 Kuo, Chiauyun
 Mize, Nancy K
 Haley, Dana A
 Arterburn, Matthew C
 Tang, Y. Tom
 Zhou, Ping
 Liu, Chenghua
 Asundi, Vinod
 Drmanac, Radoje T
 Yeung, George
 Palencia, Servando

<120> Methods and Materials Relating to Leukocyte
 Immunoglobulin Receptor-Like (LIR-Like) Polypeptides
 and Polynucleotides

<130> 21272-023 (HYS-19CIP)

<140> Not Yet Assigned
 <141> 2001-01-25

<150> Not Yet Assigned
 <151> 2000-12-29

<150> 09/642,610
 <151> 2000-08-17

<150> 09/560,875
 <151> 2000-04-27

<150> 09/496,914
 <151> 2000-02-03

<150> 09/491,404
 <151> 2000-01-25

<150> 09/524,454
 <151> 2000-05-19

<150> 09/519,705
 <151> 2000-03-07

<160> 78

<170> PatentIn Ver. 2.1

<210> 1
 <211> 423
 <212> DNA
 <213> Homo sapiens

<400> 1
 agagaagatg cccctgctga cactctacct gctcctcttc tggetctcat gctactccat 60
 tgtcactcaa atcgccggtc caacaacagt gaatggcttg gagcggggct ccttgaccgt 120
 gcagtgtgtt tacagatcag gctgggagac ctacttgaag tgggtggtgtc gaggagctat 180
 ttggcgtgac tgcaagatcc ttgttaaaac cagtgggtca gagcaggagg tgaagaggga 240
 ccgggtgtcc atcaaggaca atcataaaaa ccgcacgttc actgtgacca tggaggatct 300
 catgaaaact gatgctgaca cttactggtg tggaattgag aaaactggaa atgaccttgg 360
 ggtcacagtt caagtgacca ttgaccacgc accagtcact ccagaagaaa ctagcagctt 420
 ccc 423

WO 01/55335

PCT/US01/02570

<210> 2
 <211> 1821
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (114)..(1031)

<400> 2
 tttcgtgagg aagttcaagg gcgagagtga gtaccagcag aaggctggga gtctgtagtt 60

tgttcctgct gccaggctcc actgagggga acggggacct gtctgaagag aag atg 116
 Met
 1

ccc ctg ctg aca ctc tac ctg ctc ctc ttc tgg ctc tca ggc tac tcc 164
 Pro Leu Leu Thr Leu Tyr Leu Leu Leu Phe Trp Leu Ser Gly Tyr Ser
 5 10 15

att gcc act caa atc acc ggt cca aca aca gtg aat ggc ttg gag cgg 212
 Ile Ala Thr Gln Ile Thr Gly Pro Thr Thr Val Asn Gly Leu Glu Arg
 20 25 30

ggc tcc ttg acc gtg cag tgt gtt tac aga tca ggc tgg gag acc tac 260
 Gly Ser Leu Thr Val Gln Cys Val Tyr Arg Ser Gly Trp Glu Thr Tyr
 35 40 45

ttg aag tgg tgg tgt cga gga gct att tgg cgt gac tgc aag atc ctt 308
 Leu Lys Trp Trp Cys Arg Gly Ala Ile Trp Arg Asp Cys Lys Ile Leu
 50 55 60 65

gtt aaa acc agt ggg tca gag cag gag gtg aag agg gac cgg gtg tcc 356
 Val Lys Thr Ser Gly Ser Glu Gln Glu Val Lys Arg Asp Arg Val Ser
 70 75 80

atc aag gac aat cag aaa aac cgc acg ttc act gtg acc atg gag gat 404
 Ile Lys Asp Asn Gln Lys Asn Arg Thr Phe Thr Val Thr Met Glu Asp
 85 90 95

ctc atg aaa act gat gct gac act tac tgg tgt gga att gag aaa act 452
 Leu Met Lys Thr Asp Ala Asp Thr Tyr Trp Cys Gly Ile Glu Lys Thr
 100 105 110

gga aat gac ctt ggg gtc aca gtt caa gtg acc att gac cca gcg tcg 500
 Gly Asn Asp Leu Gly Val Thr Val Gln Val Thr Ile Asp Pro Ala Ser
 115 120 125

act cct gcc ccc acc acg cct acc tcc act acg ttt aca gca cca gtc 548
 Thr Pro Ala Pro Thr Thr Pro Thr Ser Thr Thr Phe Thr Ala Pro Val
 130 135 140 145

acc caa gaa gaa act agc agc tcc cca act ctg acc ggc cac cac ttg 596
 Thr Gln Glu Glu Thr Ser Ser Ser Pro Thr Leu Thr Gly His His Leu
 150 155 160

gac aac agg cac aag ctc ctg aag ctc agt gtc ctc ctg ccc ctc atc 644
 Asp Asn Arg His Lys Leu Leu Lys Leu Ser Val Leu Leu Pro Leu Ile
 165 170 175

ttc acc ata ttg ctg ctg ctt ttg gtg gcc gcc tca ctc ttg gct tgg 692
 Phe Thr Ile Leu Leu Leu Leu Leu Val Ala Ala Ser Leu Leu Ala Trp

WO 01/55335

PCT/US01/02570

180	185	190	
agg atg atg aag tac cag cag aaa gca gcc ggg atg tcc cca gag cag			740
Arg Met Met Lys Tyr Gln Gln Lys Ala Ala Gly Met Ser Pro Glu Gln			
195	200	205	
gta ctg cag ccc ctg gag ggc gac ctc tgc tat gca gac ctg acc ctg			788
Val Leu Gln Pro Leu Glu Gly Asp Leu Cys Tyr Ala Asp Leu Thr Leu			
210	215	220	225
cag ctg gcc gga acc tcc ccg caa aag gct acc acg aag ctt tcc tct			836
Gln Leu Ala Gly Thr Ser Pro Gln Lys Ala Thr Thr Lys Leu Ser Ser			
	230	235	240
gcc cag gtt gac cag gtg gaa gtg gaa tat gtc acc atg gct tcc ttg			884
Ala Gln Val Asp Gln Val Glu Val Glu Tyr Val Thr Met Ala Ser Leu			
	245	250	255
ccg aag gag gac att tcc tat gca tct ctg acc ttg ggt gct gag gat			932
Pro Lys Glu Asp Ile Ser Tyr Ala Ser Leu Thr Leu Gly Ala Glu Asp			
	260	265	270
cag gaa ccg acc tac tgc aac atg ggc cac ctc agt agc cac ctc ccc			980
Gln Glu Pro Thr Tyr Cys Asn Met Gly His Leu Ser Ser His Leu Pro			
	275	280	285
ggc agg ggc cct gag gag ccc acg gaa tac agc acc atc agc agg cct			1028
Gly Arg Gly Pro Glu Glu Pro Thr Glu Tyr Ser Thr Ile Ser Arg Pro			
290	295	300	305
tag cctgcactcc aggtccttc ttggacccca ggctgtgagc acactcctgc			1081
ctcatcgacc gtctgcccc tgctcccctc atcaggacca acccggggac tgggtgcctct			1141
gcctgatcag ccagcattgc ccctagctct gggttgggct tggggccaag tctcaggggg			1201
cttctaggag ttgggggtttt ctaaactgtcc cctcctctcc tacatagttg aggagggggc			1261
tagggatatg ctctggggct ttcattgggaa tgatgaagat gataatgaga aaaatgttat			1321
cattattatc atgaagtacc attatcataa tacaatgaac ctttatttat tgcctaccac			1381
atgttatggg ctgaataatg gcccccaaag atatctgtgt cctaactctc agaacttggtg			1441
actgttacct tctgtggcag aaaggagacag tgcagatgta tgtaagttaa ggactttgag			1501
atagagaggt tattcttgct gattcaggtg ggccccaaat atcaccacaa gggtcctcat			1561
aagaaagagg ccagaaggtc aaagaggtag agacaaagtg atgatggaag tggacgtggg			1621
tgtgacgtga gcagggggcca tgaatgccgc agccttcaga tgccagaaag ggaaaggaat			1681
ggattcccct gcctggagcc tccaaaagaa accagccctg cccacgcctt gacttgagcc			1741
cattgaaact gatcttgagc tcctggcctc cagaattgca ggagaataaa tttgtgttgt			1801
ttttaatgag aaaaaaaaaa			1821

<210> 3

<211> 305

<212> PRT

<213> Homo sapiens

WO 01/55335

PCT/US01/02570

<400> 3

```

Met Pro Leu Leu Thr Leu Tyr Leu Leu Leu Phe Trp Leu Ser Gly Tyr
 1          5          10          15
Ser Ile Ala Thr Gln Ile Thr Gly Pro Thr Thr Val Asn Gly Leu Glu
          20          25          30
Arg Gly Ser Leu Thr Val Gln Cys Val Tyr Arg Ser Gly Trp Glu Thr
          35          40          45
Tyr Leu Lys Trp Trp Cys Arg Gly Ala Ile Trp Arg Asp Cys Lys Ile
          50          55          60
Leu Val Lys Thr Ser Gly Ser Glu Gln Glu Val Lys Arg Asp Arg Val
          65          70          75          80
Ser Ile Lys Asp Asn Gln Lys Asn Arg Thr Phe Thr Val Thr Met Glu
          85          90          95
Asp Leu Met Lys Thr Asp Ala Asp Thr Tyr Trp Cys Gly Ile Glu Lys
          100          105          110
Thr Gly Asn Asp Leu Gly Val Thr Val Gln Val Thr Ile Asp Pro Ala
          115          120          125
Ser Thr Pro Ala Pro Thr Thr Pro Thr Ser Thr Thr Phe Thr Ala Pro
          130          135          140
Val Thr Gln Glu Glu Thr Ser Ser Ser Pro Thr Leu Thr Gly His His
          145          150          155          160
Leu Asp Asn Arg His Lys Leu Leu Lys Leu Ser Val Leu Leu Pro Leu
          165          170          175
Ile Phe Thr Ile Leu Leu Leu Leu Leu Val Ala Ala Ser Leu Leu Ala
          180          185          190
Trp Arg Met Met Lys Tyr Gln Gln Lys Ala Ala Gly Met Ser Pro Glu
          195          200          205
Gln Val Leu Gln Pro Leu Glu Gly Asp Leu Cys Tyr Ala Asp Leu Thr
          210          215          220
Leu Gln Leu Ala Gly Thr Ser Pro Gln Lys Ala Thr Thr Lys Leu Ser
          225          230          235          240
Ser Ala Gln Val Asp Gln Val Glu Val Glu Tyr Val Thr Met Ala Ser
          245          250          255
Leu Pro Lys Glu Asp Ile Ser Tyr Ala Ser Leu Thr Leu Gly Ala Glu
          260          265          270
Asp Gln Glu Pro Thr Tyr Cys Asn Met Gly His Leu Ser Ser His Leu
          275          280          285
Pro Gly Arg Gly Pro Glu Glu Pro Thr Glu Tyr Ser Thr Ile Ser Arg
          290          295          300
Pro
305

```

<210> 4

<211> 918

<212> DNA

<213> Homo sapiens

<400> 4

```

atgccctgc tgacactcta cctgctcctc ttctggctct caggctactc cattgccact 60
caaatcaccg gtccaacaac agtgaatggc ttggagcggg gctccttgac cgtgcagtgt 120
gtttacagat caggctggga gacctacttg aagtgggtgg gtcgaggagc tatttggcgt 180
gactgcaaga tccttggttaa aaccagtggg tcagagcagg aggtgaagag ggaccgggtg 240
tccatcaagg acaatcagaa aaaccgcacg ttcactgtga ccatggagga tctcatgaaa 300
actgatgctg acacttactg gtgtggaatt gagaaaactg gaaatgacct tggggtcaca 360
gttcaagtga ccattgaccc agcgtcgact cctgccccca ccacgcctac ctccactacg 420
tttacagcac cagtcaccca agaagaaact agcagctccc caactctgac cggccaccac 480
ttggacaaca ggcacaagct cctgaagctc agtgtcctcc tgcccctcat cttcaccata 540
ttgctgctgc ttttggtggc cgcctcactc ttggcttgga ggatgatgaa gtaccagcag 600
aaagcagccg ggatgtcccc agagcaggta ctgcagcccc tggagggcga cctctgctat 660
gcagacctga ccctgcagct ggccggaacc tccccgcaaa aggctaccac gaagctttcc 720
tctgcccagg ttgaccaggt ggaagtggaa tatgtcacca tggcttcctt gccgaaggag 780

```

<400> 5																	
cccgggtcga	ccatttcgtg	gcaaaagtgg	ctccaggtgc	agaaggttgg	agttcagtgg											60	
tgcgatctgg	gttcactgca	acctctgccg	cctggggttca	agtgattctc	ctacctcggc											120	
ctccccgagtc	actgggatta	cagtctcttt	cacccatggg	aagtgactga	aggaggaagt											180	
tcaagggcgca	gagtgagtac	cagcagaagg	ctgggagttct	gtagtttggt	cctgctgcca											240	
ggctccactg	aggggaacgg	ggacctgtct	gaagagaag	atg	ccc	ctg	ctg	aca								294	
				Met	Pro	Leu	Leu	Thr									
				1					5								
ctc	tac	ctg	ctc	ctc	ttc	tgg	ctc	tca	ggc	tac	tcc	att	gcc	act	caa	342	
Leu	Tyr	Leu	Leu	Leu	Phe	Trp	Leu	Ser	Gly	Tyr	Ser	Ile	Ala	Thr	Gln		
				10					15					20			
atc	acc	ggc	cca	aca	aca	gtg	aat	ggc	ttg	gag	cgg	ggc	tcc	ttg	acc	390	
Ile	Thr	Gly	Pro	Thr	Thr	Val	Asn	Gly	Leu	Glu	Arg	Gly	Ser	Leu	Thr		
				25					30					35			
gtg	cag	tgt	gtt	tac	aga	tca	ggc	tgg	gag	acc	tac	ttg	aag	tgg	tgg	438	
Val	Gln	Cys	Val	Tyr	Arg	Ser	Gly	Trp	Glu	Thr	Tyr	Leu	Lys	Trp	Trp		
				40					45					50			
tgt	cga	gga	gct	att	tgg	cgt	gac	tgc	aag	atc	ctt	gtt	aaa	acc	agt	486	
Cys	Arg	Gly	Ala	Ile	Trp	Arg	Asp	Cys	Lys	Ile	Leu	Val	Lys	Thr	Ser		
				55					60					65			
ggg	tca	gag	cag	gag	gtg	aag	agg	gac	cgg	gtg	tcc	atc	aag	gac	aat	534	
Gly	Ser	Glu	Gln	Glu	Val	Lys	Arg	Asp	Arg	Val	Ser	Ile	Lys	Asp	Asn		
				70					75					80			
gag	aaa	aac	cgc	acg	ttc	act	gtg	acc	atg	gag	gat	ctc	atg	aaa	act	582	
Gln	Lys	Asn	Arg	Thr	Phe	Thr	Val	Thr	Met	Glu	Asp	Leu	Met	Lys	Thr		
				90					95					100			
gat	gct	gac	act	tac	tgg	tgt	gga	att	gag	aaa	act	gga	aat	gac	ctt	630	
Asp	Ala	Asp	Thr	Tyr	Trp	Cys	Gly	Ile	Glu	Lys	Thr	Gly	Asn	Asp	Leu		
				105					110					115			
ggg	gtc	aca	gtt	caa	gtg	acc	att	gac	cca	gca	cca	gtc	acc	caa	gaa	678	
Gly	Val	Thr	Val	Gln	Val	Thr	Ile	Asp	Pro	Ala	Pro	Val	Thr	Gln	Glu		
				120					125					130			
gaa	act	agc	agc	tcc	cca	act	ctg	acc	ggc	cac	cac	ttg	gac	aac	agg	726	
Glu	Thr	Ser	Ser	Ser	Pro	Thr	Leu	Thr	Gly	His	His	Leu	Asp	Asn	Arg		
				135					140					145			
tac	tgc	agc	ccc	tgg	aqq	gcg	acc	tct	gct	atg	cag	acc	tga			768	

WO 01/55335

PCT/US01/02570

Tyr Cys Ser Pro Trp Arg Ala Thr Ser Ala Met Gln Thr
 150 155 160

ccctgcagct ggccggaacc tccccgcaaa aggctaccac gaagctttcc tctgcccagg 828
 ttgaccaggt ggaagtggaa tatgtcacca tggcttcctt gccgaaggag gacatttcct 888
 atgcattctt gaccttgggt gctgaggatc aggaaccgac ctactgcaac atggggccacc 948
 tcagtagcca cctccccggc agggggcctg aggagcccac ggaatacagc accatcagca 1008
 ggccttagcc tgcactccag gctccttctt ggaccccagg ctgtgagcac actcctgcct 1068
 catcgaccgt ctgccccctg ctcccctcat caggaccaac ccgggggactg gtgcctctgc 1128
 ctgatcagcc agcattgccc ctagctctgg gttgggcttg gggccaagtc tcaggggggct 1188
 tctaggagtt ggggttttct aaacgtcccc tctctccta catagttgag gagggggcta 1248
 gggatatgct ctggggcttt catgggaatg atgaagatga taatgagaaa aatgttatca 1308
 ttattatcat gaagtacat tatcgtaata caatgaacct ttatttattg cctaccacat 1368
 gttatgggct gaataatggc ccccaaagat atctgtgtcc taatcctcag aacctgtgac 1428
 tgttaccttc tgtggcagaa agggacagtg cagatgtatg taagttaagg actttgagat 1488
 agagagggtta ttcttgctga ttcaggtggg cccaaaatat caccacaagg gtcctcataa 1548
 gaaagaggcc agaaggtcaa agaggtagag acaaagtgat gatggaagtg gacgtgggtg 1608
 tgacgtgagc agggggccatg aatgccgcag ccttcagatg ccagaaaggg aaaggaatgg 1668
 attcccctgc ctggagcctc caaaagaaac cagccctgcc cacgccttga cttgagccca 1728
 ttgaaactga tcttgagctc ctggcctcca gaattgcagg agaataaatt tgtgttggtt 1788
 ttaatgaaaa aaaaaa 1804

<210> 6

<211> 162

<212> PRT

<213> Homo sapiens

<400> 6

Met Pro Leu Leu Thr Leu Tyr Leu Leu Leu Phe Trp Leu Ser Gly Tyr
 1 5 10 15
 Ser Ile Ala Thr Gln Ile Thr Gly Pro Thr Thr Val Asn Gly Leu Glu
 20 25 30
 Arg Gly Ser Leu Thr Val Gln Cys Val Tyr Arg Ser Gly Trp Glu Thr
 35 40 45
 Tyr Leu Lys Trp Trp Cys Arg Gly Ala Ile Trp Arg Asp Cys Lys Ile
 50 55 60
 Leu Val Lys Thr Ser Gly Ser Glu Gln Glu Val Lys Arg Asp Arg Val
 65 70 75 80
 Ser Ile Lys Asp Asn Gln Lys Asn Arg Thr Phe Thr Val Thr Met Glu
 85 90 95
 Asp Leu Met Lys Thr Asp Ala Asp Thr Tyr Trp Cys Gly Ile Glu Lys
 100 105 110
 Thr Gly Asn Asp Leu Gly Val Thr Val Gln Val Thr Ile Asp Pro Ala
 115 120 125
 Pro Val Thr Gln Glu Glu Thr Ser Ser Ser Pro Thr Leu Thr Gly His
 130 135 140

His Leu Asp Asn Arg Tyr Cys Ser Pro Trp Arg Ala Thr Ser Ala Met
 145 150 155 160
 Gln Thr

<210> 7
 <211> 489
 <212> DNA
 <213> Homo sapiens

<400> 7
 atgcccctgc tgacactcta cctgctcctc ttctggctct caggctactc cattgtcact 60
 caaatcaccg gtccaacaac agtgaatggc ttggagcggg gtccttgac cgtgcagtgt 120
 gtttacagat caggctggga gacctacttg aagtgggtgg gtcgaggagc tatttggcgt 180
 gactgcaaga tccttggttaa aaccagtggg tcagagcagg aggtgaagag ggaccgggtg 240
 tccatcaagg acaatcagaa aaaccgcacg ttcactgtga ccatggagga tctcatgaaa 300
 actgatgctg acacttactg gtgtggaatt gagaaaactg gaaatgacct tggggtcaca 360
 gttcaagtga ccattgaccc agcaccagtc acccaagaag aaactagcag ctccccaact 420
 ctgaccggcc accacttgga caacaggtac tgcagcccct ggagggcgac ctctgctatg 480
 cagacctga 489

<210> 8
 <211> 48
 <212> PRT
 <213> Homo sapiens

<400> 8
 Ile Lys Asp Asn Gln Lys Asn Arg Thr Phe Thr Val Thr Met Glu Asp
 1 5 10 15
 Leu Met Lys Thr Asp Ala Asp Thr Tyr Trp Cys Gly Ile Glu Lys Thr
 20 25 30
 Gly Asn Asp Leu Gly Val Thr Val Gln Val Thr Ile Asp Pro Ala Ser
 35 40 45

<210> 9
 <211> 48
 <212> PRT
 <213> Homo sapiens

<400> 9
 Ile Lys Asp Asn Gln Lys Asn Arg Thr Phe Thr Val Thr Met Glu Asp
 1 5 10 15
 Leu Met Lys Thr Asp Ala Asp Thr Tyr Trp Cys Gly Ile Glu Lys Thr
 20 25 30
 Gly Asn Asp Leu Gly Val Thr Val Gln Val Thr Ile Asp Pro Ala Pro
 35 40 45

<210> 10
 <211> 30
 <212> PRT

WO 01/55335

PCT/US01/02570

<213> Homo sapiens

<400> 10

Met	Pro	Leu	Leu	Thr	Leu	Tyr	Leu	Leu	Leu	Phe	Trp	Leu	Ser	Gly	Tyr
1				5					10					15	

Ser	Ile	Ala	Thr	Gln	Ile	Thr	Gly	Pro	Thr	Thr	Val	Asn	Gly
			20					25					30

<210> 11

<211> 24

<212> PRT

<213> Homo sapiens

<400> 11

Leu	Ser	Val	Leu	Leu	Pro	Leu	Ile	Phe	Thr	Ile	Leu	Leu	Leu	Leu	Leu
1				5					10					15	

Val	Ala	Ala	Ser	Leu	Leu	Ala	Trp
				20			

<210> 12

<211> 275

<212> PRT

<213> Homo sapiens

<400> 12

Leu	Glu	Arg	Gly	Ser	Leu	Thr	Val	Gln	Cys	Val	Tyr	Arg	Ser	Gly	Trp
1				5					10					15	

Glu	Thr	Tyr	Leu	Lys	Trp	Trp	Cys	Arg	Gly	Ala	Ile	Trp	Arg	Asp	Cys
			20					25						30	

Lys	Ile	Leu	Val	Lys	Thr	Ser	Gly	Ser	Glu	Gln	Glu	Val	Lys	Arg	Asp
		35					40					45			

Arg	Val	Ser	Ile	Lys	Asp	Asn	Gln	Lys	Asn	Arg	Thr	Phe	Thr	Val	Thr
	50					55					60				

Met	Glu	Asp	Leu	Met	Lys	Thr	Asp	Ala	Asp	Thr	Tyr	Trp	Cys	Gly	Ile
65					70					75					80

Glu	Lys	Thr	Gly	Asn	Asp	Leu	Gly	Val	Thr	Val	Gln	Val	Thr	Ile	Asp
				85					90					95	

Pro	Ala	Ser	Thr	Pro	Ala	Pro	Thr	Thr	Pro	Thr	Ser	Thr	Thr	Phe	Thr
			100					105						110	

Ala	Pro	Val	Thr	Gln	Glu	Glu	Thr	Ser	Ser	Ser	Pro	Thr	Leu	Thr	Gly
		115					120					125			

His	His	Leu	Asp	Asn	Arg	His	Lys	Leu	Leu	Lys	Leu	Ser	Val	Leu	Leu
	130					135					140				

Pro	Leu	Ile	Phe	Thr	Ile	Leu	Leu	Leu	Leu	Leu	Val	Ala	Ala	Ser	Leu
145					150					155					160

Leu	Ala	Trp	Arg	Met	Met	Lys	Tyr	Gln	Gln	Lys	Ala	Ala	Gly	Met	Ser
				165					170					175	

Pro	Glu	Gln	Val	Leu	Gln	Pro	Leu	Glu	Gly	Asp	Leu	Cys	Tyr	Ala	Asp
			180					185					190		

WO 01/55335

PCT/US01/02570

Leu Thr Leu Gln Leu Ala Gly Thr Ser Pro Gln Lys Ala Thr Thr Lys
 195 200 205
 Leu Ser Ser Ala Gln Val Asp Gln Val Glu Val Glu Tyr Val Thr Met
 210 215 220
 Ala Ser Leu Pro Lys Glu Asp Ile Ser Tyr Ala Ser Leu Thr Leu Gly
 225 230 235 240
 Ala Glu Asp Gln Glu Pro Thr Tyr Cys Asn Met Gly His Leu Ser Ser
 245 250 255
 His Leu Pro Gly Arg Gly Pro Glu Glu Pro Thr Glu Tyr Ser Thr Ile
 260 265 270
 Ser Arg Pro
 275

<210> 13
 <211> 132
 <212> PRT
 <213> Homo sapiens

<400> 13
 Gly Ala Ile Met Ile Pro Lys Leu Leu Ser Leu Leu Cys Phe Arg Leu
 1 5 10 15
 Arg Val Gly Gln Gly Asp Thr Arg Gly Asp Gly Ser Leu Pro Lys Pro
 20 25 30
 Ser Leu Ile Ala Trp Pro Thr Ser Val Val Pro Ala Asn Ser Asn Val
 35 40 45
 Thr Leu Arg Cys Trp Thr Pro Ala Arg Gly Val Ser Cys Val Leu Arg
 50 55 60
 Lys Gly Gly Ile Ile Leu Glu Ser Pro Lys Pro Leu Asp Ser Thr Glu
 65 70 75 80
 Gly Ala Asp Glu Cys His Leu Tyr Asn Leu Lys Val Arg Asn Ala Gly
 85 90 95
 Glu Tyr Thr Cys Glu Tyr Tyr Arg Lys Ala Cys Pro His Ile Leu Ser
 100 105 110
 Gln Ser Ser Asp Asp Leu Leu Leu Met Val Thr Gly His Leu Cys Lys
 115 120 125
 Pro Leu Leu Arg
 130

<210> 14
 <211> 292
 <212> PRT
 <213> Homo sapiens

<400> 14
 Leu Leu Leu Leu Trp Val Pro Gly Cys Phe Ala Leu Ser Lys Cys Arg
 1 5 10 15
 Thr Val Ala Gly Pro Val Gly Gly Ser Leu Ser Val Gln Cys Pro Tyr

```
<400> 15
Leu Leu Leu Leu Ser Leu Ser Gly Cys Phe Ser Ile Gln Gly Pro Glu
  1             5             10             15
Ser Val Arg Ala Pro Glu Gln Gly Ser Leu Thr Val Gln Cys His Tyr
```

WO 01/55335

PCT/US01/02570

20								25				30					
Lys	Gln	Gly	Trp	Glu	Thr	Tyr	Ile	Lys	Trp	Trp	Cys	Arg	Gly	Val	Arg		
35				40				45									
Trp	Asp	Thr	Cys	Lys	Ile	Leu	Ile	Glu	Thr	Arg	Gly	Ser	Glu	Gln	Gly		
50				55				60									
Glu	Lys	Ser	Asp	Arg	Val	Ser	Ile	Lys	Asp	Asn	Gln	Lys	Asp	Arg	Thr		
65				70				75				80					
Phe	Thr	Val	Thr	Met	Glu	Gly	Leu	Arg	Arg	Asp	Asp	Ala	Asp	Val	Tyr		
				85				90				95					
Trp	Cys	Gly	Ile	Glu	Arg	Arg	Gly	Pro	Asp	Leu	Gly	Thr	Gln	Val	Lys		
100				105				110									
Val	Ile	Val	Asp	Pro	Glu	Gly	Ala	Ala	Ser	Thr	Thr	Ala	Ser	Ser	Pro		
115				120				125									
Thr	Asn	Ser	Asn	Met	Ala	Val	Phe	Ile	Gly	Ser	His	Lys	Arg	Asn	His		
130				135				140									
Tyr	Met	Leu	Leu	Val	Phe	Val	Lys	Val	Pro	Ile	Leu	Leu	Ile	Leu	Val		
145				150				155				160					
Thr	Ala	Ile	Leu	Trp	Leu												
				165													

<210> 16
 <211> 437
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)..(437)
 <223> n = A, T, G, or C

<400> 16
 tgagaatctc cgggcgaccc acgnacggaa actggggagt ggggcagaga accagagtgt 60
 cagagctaaa cctcctctat ctgcacatcg gggggacgaa ccgggcagcc ggagagctgc 120
 ggccggccca atcccgcctcc gcctttgaag ggtaaaaccc aaggcggggc cttgggttctg 180
 gcagaaggga cgctatgacc gcagaattcc tctccctgct ttgcctcggg ctgtgtcttg 240
 gctacgaaga tgagaaaaag aatgagaaac cgcccaagcc ctccctccac gcctggccca 300
 gctcgggtgt tgaagctgag agcaatgtga ccctgaagtg tcaggctcat tcccagaatg 360
 tgacatttgt gctgcgcaag gtgaacgact ctgggtacaa gcaggaacag agctcggcag 420
 aaaacgaagc tgaattc 437

<210> 17
 <211> 1026
 <212> DNA
 <213> Homo sapiens

<400> 17
 gaaactgcaa gagtggggca gagaaccaga gtgtcagagc aaaacctcct ctatctgcac 60
 atcctgggga cgaaccgggc agccggagag ctgcggccgg ccagatcccg ctccgccttt 120
 gaagggtaaa acccaaggcg gggccttggt tctggcagaa gggacgctat gaccgcagaa 180
 ttctctccc tgctttgcct cgggctgtgt ctgggctacg aagatgagaa aaagaatgag 240
 aaaccgcca agccctccct ccacgcctgg ccagctcggg tggttgaagc cgagagcaat 300
 gtgaccctga agtgtcaggc tcattcccag aatgtgacat ttgtgctgcg caaggtgaac 360
 gactctgggt acaagcagga acagagctcg gcagaaaacg aagctgaatt ccccttcacg 420

```

gacctgaagc ctaaggatgc tgggaggtac ttttgtgcct acaagacaac agcctcccat 480
gagtggtcag aaagcagtga acacttgacg ctggtgggtca cagataaaca cgatgaactt 540
gaagctccct caatgaaaac agacaccaga accatctttg tcgccatctt cagctgcac 600
tccatccttc tctctctcct ctcagtcttc atcatctaca gatgcagcca gcacagttca 660
tcctctgagg aatccaccaa gagaaccagc cattccaaac ttccggagca ggaggctgcc 720
gaggcagatt tatccaatat ggaaagggta tctctctcga cggcagaccc ccaaggagt 780
acctatgctg agctaagcac cagcgccctg tctgaggcag cttcagacac caccaggag 840
ccccaggat ctcataata tgcggcactg aaagtgtagc aagaagacag ccctggccac 900
taaaagaggg gggatcgtgc tggccaaggt tatcggaat ctggagatgc agatactgtg 960
tttcttgct cttcgtccat atcaataaaa ttaagtttct cgtcttaaaa agaaaaaaaa 1020
aaaaaa 1026

```

<210> 18
 <211> 1016
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (169)..(879)

```

<400> 18
gaaactgcaa gagtggggca gagaaccaga gtgtcagagc aaaacctcct ctatctgcac 60
atcctgggga cgaaccgggc agccggagag ctgcgggcgg cccagtcccg ctccgccttt 120
gaagggtaaa acccaaggcg gggccttggt tctggcagaa gggacgct atg acc gca 177
                                   Met Thr Ala
                                   1

```

```

gaa ttc ctc tcc ctg ctt tgc ctc ggg ctg tgt ctg ggc tac gaa gat 225
Glu Phe Leu Ser Leu Leu Cys Leu Gly Leu Cys Leu Gly Tyr Glu Asp
      5                10                15

```

```

gag aaa aag aat gag aaa ccg ccc aag ccc tcc ctc cac gcc tgg ccc 273
Glu Lys Lys Asn Glu Lys Pro Pro Lys Pro Ser Leu His Ala Trp Pro
      20                25                30                35

```

```

agc tcg gtg gtt gaa gct gag agc aat gtg acc ctg aag tgt cag gct 321
Ser Ser Val Val Glu Ala Glu Ser Asn Val Thr Leu Lys Cys Gln Ala
                40                45                50

```

```

cat tcc cag aat gtg aca ttt gtg ctg cgc aag gtg aac gac tct ggg 369
His Ser Gln Asn Val Thr Phe Val Leu Arg Lys Val Asn Asp Ser Gly
                55                60                65

```

```

tac aag cag gaa cag agc tcg gca gaa aac gaa gct gaa ttc ccc ttc 417
Tyr Lys Gln Glu Gln Ser Ser Ala Glu Asn Glu Ala Glu Phe Pro Phe
                70                75                80

```

```

acg gac ctg aag cct aag gat gct ggg agg tac ttt tgt gcc tac aag 465
Thr Asp Leu Lys Pro Lys Asp Ala Gly Arg Tyr Phe Cys Ala Tyr Lys
                85                90                95

```

```

aca aca gcc tcc cat gag tgg tca gaa agc agt gaa cac ttg cag ctg 513
Thr Thr Ala Ser His Glu Trp Ser Glu Ser Ser Glu His Leu Gln Leu
      100                105                110                115

```

```

gtg gtc aca gat aaa cac gat gaa ctt gaa gct ccc tca atg aaa aca 561
Val Val Thr Asp Lys His Asp Glu Leu Glu Ala Pro Ser Met Lys Thr
                120                125                130

```

```

gac acc aga acc ata ttt gtc gcc atc ttc agc tgc atc tcc atc ctt 609

```

```

Asp Thr Arg Thr Ile Phe Val Ala Ile Phe Ser Cys Ile Ser Ile Leu
      135                      140                      145

ctc ctc ttc ctc tca gtc ttc atc atc tac aga tgc agc cag cac agt 657
Leu Leu Phe Leu Ser Val Phe Ile Ile Tyr Arg Cys Ser Gln His Ser
      150                      155                      160

tca tca tct gag gaa tcc acc aag aga acc agc cat tcc aaa ctt ccg 705
Ser Ser Ser Glu Glu Ser Thr Lys Arg Thr Ser His Ser Lys Leu Pro
      165                      170                      175

gag cag gag gct gcc gag gca gat tta tcc aat atg gaa agg gta tct 753
Glu Gln Glu Ala Ala Glu Ala Asp Leu Ser Asn Met Glu Arg Val Ser
180                      185                      190                      195

ctc tcg acg gca gac ccc caa gga gtg acc tat gct gag cta agc acc 801
Leu Ser Thr Ala Asp Pro Gln Gly Val Thr Tyr Ala Glu Leu Ser Thr
      200                      205                      210

agc gcc ctg ttt gag gca gct tca gac ccc acc cag gag ccc cca gga 849
Ser Ala Leu Phe Glu Ala Ala Ser Asp Pro Thr Gln Glu Pro Pro Gly
      215                      220                      225

ttt cat gaa tat gcg gca ctg aaa gtg tag caaaaagaca gccctggcca 899
Phe His Glu Tyr Ala Ala Leu Lys Val
      230                      235

ctaaaggagg ggggatcgtg ctggccaagg ttatcggaaa tctggagatg cagatactgt 959

gtttccttgc tcttcgtcca tatcaataaa attaagtttc tcgtcttaaa aaaaaaa 1016

```

<210> 19
 <211> 236
 <212> PRT
 <213> Homo sapiens

<400> 19
 Met Thr Ala Glu Phe Leu Ser Leu Leu Cys Leu Gly Leu Cys Leu Gly
 1 5 10 15
 Tyr Glu Asp Glu Lys Lys Asn Glu Lys Pro Pro Lys Pro Ser Leu His
 20 25 30
 Ala Trp Pro Ser Ser Val Val Glu Ala Glu Ser Asn Val Thr Leu Lys
 35 40 45
 Cys Gln Ala His Ser Gln Asn Val Thr Phe Val Leu Arg Lys Val Asn
 50 55 60
 Asp Ser Gly Tyr Lys Gln Glu Gln Ser Ser Ala Glu Asn Glu Ala Glu
 65 70 75 80
 Phe Pro Phe Thr Asp Leu Lys Pro Lys Asp Ala Gly Arg Tyr Phe Cys
 85 90 95
 Ala Tyr Lys Thr Thr Ala Ser His Glu Trp Ser Glu Ser Ser Glu His
 100 105 110
 Leu Gln Leu Val Val Thr Asp Lys His Asp Glu Leu Glu Ala Pro Ser
 115 120 125
 Met Lys Thr Asp Thr Arg Thr Ile Phe Val Ala Ile Phe Ser Cys Ile
 130 135 140
 Ser Ile Leu Leu Leu Phe Leu Ser Val Phe Ile Ile Tyr Arg Cys Ser
 145 150 155 160
 Gln His Ser Ser Ser Ser Glu Glu Ser Thr Lys Arg Thr Ser His Ser
 165 170 175
 Lys Leu Pro Glu Gln Glu Ala Ala Glu Ala Asp Leu Ser Asn Met Glu
 180 185 190
 Arg Val Ser Leu Ser Thr Ala Asp Pro Gln Gly Val Thr Tyr Ala Glu
 195 200 205

Leu Ser Thr Ser Ala Leu Phe Glu Ala Ala Ser Asp Pro Thr Gln Glu
 210 215 220
 Pro Pro Gly Phe His Glu Tyr Ala Ala Leu Lys Val
 225 230 235

<210> 20
 <211> 711
 <212> DNA
 <213> Homo sapiens

<400> 20
 atgaccgcag aattcctctc cctgctttgc ctcgggctgt gtctgggcta cgaagatgag 60
 aaaaagaatg agaaaccgcc caagccctcc ctccacgcct ggcccagctc ggtgggtgaa 120
 gctgagagca atgtgaccct gaagtgtcag gctcattccc agaatgtgac atttgtgctg 180
 cgcaaggatga acgactctgg gtacaagcag gaacagagct cggcagaaaa cgaagctgaa 240
 ttccccttca cggacctgaa gcctaaggat gctgggaggt acttttgtgc ctacaagaca 300
 acagcctccc atgagtgggtc agaaagcagt gaacacttgc agctgggtggc cacagataaa 360
 cagcatgaac ttgaagctcc ctcaatgaaa acagacacca gaaccatatt tgtcgccatc 420
 ttcagctgca tctccatcct tctcctcttc ctctcagtct tcatcatcta cagatgcagc 480
 cagcacagtt catcatctga ggaatccacc aagagaacca gccattccaa acttccggag 540
 caggaggctg ccgagggcaga tttatccaat atggaaaggg tatctctctc gacggcagac 600
 cccaaggag tgacctatgc tgagctaagc accagcgccc tgtttgaggc agcttcagac 660
 cccacccagg agccccagg atttcatgaa tatgcggcac tgaaagtgtg g 711

<210> 21
 <211> 1332
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (176)..(775)

<220>
 <221> misc_feature
 <222> (1)..(1332)
 <223> n = A, T, G, or C

<400> 21
 gggtcgaccc acgcgtccgg tggggcagag aaccagagtg tcagagcaaa acctcctcta 60
 tctgcacatc ctggggacga accgggcagc cggagagctg cggccggccc agtcccgcctc 120
 cgcctttgaa gggtaaaacc caaggcgggg ccttggttct ggcagaaggg acgct atg 178
 Met
 1

acc gca gaa ttc ctc tcc ctg ctt tgc ctc ggg ctg tgt ctg ggc tac 226
 Thr Ala Glu Phe Leu Ser Leu Leu Cys Leu Gly Leu Cys Leu Gly Tyr
 5 10 15

gaa gat gag aaa aag aat gag aaa ccg ccc aag ccc tcc ctc cac gcc 274
 Glu Asp Glu Lys Lys Asn Glu Lys Pro Pro Lys Pro Ser Leu His Ala
 20 25 30

tgg ccc agc tcg gtg gtt gaa gcc gag agc aat gtg acc ctg aag tgt 322
 Trp Pro Ser Ser Val Val Glu Ala Glu Ser Asn Val Thr Leu Lys Cys
 35 40 45

cag gct cat tcc cag aat gtg aca ttt gtg ctg cgc aag gtg aac gac 370
 Gln Ala His Ser Gln Asn Val Thr Phe Val Leu Arg Lys Val Asn Asp

WO 01/55335

PCT/US01/02570

50	55	60	65	
tct ggg tac aag cag gaa cag agc tcg gca gaa aac gaa gct gaa ttc				418
Ser Gly Tyr Lys Gln Glu Gln Ser Ser Ala Glu Asn Glu Ala Glu Phe				
	70	75	80	
ccc ttc acg gac ctg aag cct aag gat gct ggg agg tac ttt tgt gcc				466
Pro Phe Thr Asp Leu Lys Pro Lys Asp Ala Gly Arg Tyr Phe Cys Ala				
	85	90	95	
tac aag aca aca gcc tcc cat gag tgg tca gaa agc agt gaa cac ttg				514
Tyr Lys Thr Thr Ala Ser His Glu Trp Ser Glu Ser Ser Glu His Leu				
	100	105	110	
cag ctg gtg gtc aca gga tca ctc cca gaa cct ttg ctc tca gtc aat				562
Gln Leu Val Val Thr Gly Ser Leu Pro Glu Pro Leu Leu Ser Val Asn				
	115	120	125	
gta gac cct ggg atg act cca ggt ctc agg aca ctt cga tgt ctc act				610
Val Asp Pro Gly Met Thr Pro Gly Leu Arg Thr Leu Arg Cys Leu Thr				
	130	135	140	145
cca tac aat gga acc gaa tgt att gta att gct ctg tgg aaa atg ggg				658
Pro Tyr Asn Gly Thr Glu Cys Ile Val Ile Ala Leu Trp Lys Met Gly				
	150	155	160	
atc cca gaa cca tta caa gtc agg caa gta aga aaa aac cag act gat				706
Ile Pro Glu Pro Leu Gln Val Arg Gln Val Arg Lys Asn Gln Thr Asp				
	165	170	175	
ttc atg ctc tgg aac gtg aca ggt aat gac agt gga aac tac agc tgt				754
Phe Met Leu Trp Asn Val Thr Gly Asn Asp Ser Gly Asn Tyr Ser Cys				
	180	185	190	
gtg tat tac ctg agc aac taa tcacacttgg cctccttccc cagcaacaag				805
Val Tyr Tyr Leu Ser Asn				
	195			
ctggagatct gggtgacaga taaacacgat gaacttgaag ctccttcaat gaaaacagac				865
accagaacca tctttgtggc catcttcagc tgcattctcca tccttctcct cttcctctca				925
gtcttcatca tctacagatg cagccagcac agtgagctca gagaacgcaa agggagagag				985
ggggagtgaa ggattttctc gaaccagcca ttccaaactt ncggagcagn aggctgccga				1045
ggcagattta atccaatatg ggaaaggat ctcttctcga cggcagaccc cccaaggagt				1105
gacctatgct gagctaagca ccagcgcct gtctgaggca gcttcagaca ccaccagga				1165
gccccaggat ctcataata tgcggcactg aaaagtgagc aagaagacag ccctgccact				1225
aaaggagggg gatctgctgg ccaagttatc ggaaactgga gagcagatac tgtgttcctt				1285
gctcttcgtc atatcataaa ataagttctc gtctaaaaaa aaaaaa				1332
<210> 22				
<211> 199				
<212> PRT				
<213> Homo sapiens				
<400> 22				
Met Thr Ala Glu Phe Leu Ser Leu Leu Cys Leu Gly Leu Cys Leu Gly				

WO 01/55335

PCT/US01/02570

```

      1           5           10           15
Tyr Glu Asp Glu Lys Lys Asn Glu Lys Pro Pro Lys Pro Ser Leu His
      20           25           30
Ala Trp Pro Ser Ser Val Val Glu Ala Glu Ser Asn Val Thr Leu Lys
      35           40           45
Cys Gln Ala His Ser Gln Asn Val Thr Phe Val Leu Arg Lys Val Asn
      50           55           60
Asp Ser Gly Tyr Lys Gln Glu Gln Ser Ser Ala Glu Asn Glu Ala Glu
      65           70           75           80
Phe Pro Phe Thr Asp Leu Lys Pro Lys Asp Ala Gly Arg Tyr Phe Cys
      85           90           95
Ala Tyr Lys Thr Thr Ala Ser His Glu Trp Ser Glu Ser Ser Glu His
      100          105          110
Leu Gln Leu Val Val Thr Gly Ser Leu Pro Glu Pro Leu Leu Ser Val
      115          120          125
Asn Val Asp Pro Gly Met Thr Pro Gly Leu Arg Thr Leu Arg Cys Leu
      130          135          140
Thr Pro Tyr Asn Gly Thr Glu Cys Ile Val Ile Ala Leu Trp Lys Met
      145          150          155          160
Gly Ile Pro Glu Pro Leu Gln Val Arg Gln Val Arg Lys Asn Gln Thr
      165          170          175
Asp Phe Met Leu Trp Asn Val Thr Gly Asn Asp Ser Gly Asn Tyr Ser
      180          185          190
Cys Val Tyr Tyr Leu Ser Asn
      195

```

<210> 23
 <211> 600
 <212> DNA
 <213> Homo sapiens

```

<400> 23
atgaccgcag aattcctctc cctgctttgc ctcgggctgt gtctgggcta cgaagatgag 60
aaaaagaatg agaaaccgcc caagccctcc ctccacgcct ggcccagctc ggtgggttgaa 120
gccgagagca atgtgaccct gaagtgtcag gctcattccc agaatgtgac atttgtgctg 180
cgcaagggtga acgactctgg gtacaagcag gaacagagct cggcagaaaa cgaagctgaa 240
ttccccctca cggacctgaa gcctaaggat gctgggaggt acttttgtgc ctacaagaca 300
acagcctccc atgagtggtc agaaagcagt gaacacttgc agctggtggt cacaggatca 360
ctcccagaac ctttgctctc agtcaatgta gacctggga tgactccagg tctcaggaca 420
cttcgatgtc tctactccata caatggaacc gaatgtattg taattgctct gtggaaaatg 480
gggatcccag aaccattaca agtcaggcaa gtaagaaaaa accagactga tttcatgctc 540
tggaacgtga caggtaatga cagtggaaac tacagctgtg tgtattacct gagcaactaa 600

```

<210> 24
 <211> 72
 <212> PRT
 <213> Homo sapiens

```

<400> 24
Pro Pro Lys Pro Ser Leu His Ala Trp Pro Ser Ser Val Val Glu Ala
      1           5           10           15
Glu Ser Asn Val Thr Leu Lys Cys Gln Ala His Ser Gln Asn Val Thr
      20           25           30
Phe Val Leu Arg Lys Val Asn Asp Ser Gly Tyr Lys Gln Glu Gln Ser
      35           40           45
Ser Ala Glu Asn Glu Ala Glu Phe Pro Phe Thr Asp Leu Lys Pro Lys
      50           55           60

```

Asp Ala Gly Arg Tyr Phe Cys Ala
65 70

<210> 25
<211> 16
<212> PRT
<213> Homo sapiens

<400> 25
Met Thr Ala Glu Phe Leu Ser Leu Leu Cys Leu Gly Leu Cys Leu Gly
1 5 10 15

<210> 26
<211> 23
<212> PRT
<213> Homo sapiens

<400> 26
Thr Ile Phe Val Ala Ile Phe Ser Cys Ile Ser Ile Leu Leu Leu Phe
1 5 10 15

Leu Ser Val Phe Ile Ile Tyr
20

<210> 27
<211> 220
<212> PRT
<213> Homo sapiens

<400> 27
Tyr Glu Asp Glu Lys Lys Asn Glu Lys Pro Pro Lys Pro Ser Leu His
1 5 10 15

Ala Trp Pro Ser Ser Val Val Glu Ala Glu Ser Asn Val Thr Leu Lys
20 25 30

Cys Gln Ala His Ser Gln Asn Val Thr Phe Val Leu Arg Lys Val Asn
35 40 45

Asp Ser Gly Tyr Lys Gln Glu Gln Ser Ser Ala Glu Asn Glu Ala Glu
50 55 60

Phe Pro Phe Thr Asp Leu Lys Pro Lys Asp Ala Gly Arg Tyr Phe Cys
65 70 75 80

Ala Tyr Lys Thr Thr Ala Ser His Glu Trp Ser Glu Ser Ser Glu His
85 90 95

Leu Gln Leu Val Val Thr Asp Lys His Asp Glu Leu Glu Ala Pro Ser
100 105 110

Met Lys Thr Asp Thr Arg Thr Ile Phe Val Ala Ile Phe Ser Cys Ile
115 120 125

Ser Ile Leu Leu Leu Phe Leu Ser Val Phe Ile Ile Tyr Arg Cys Ser
130 135 140

Gln His Ser Ser Ser Ser Glu Glu Ser Thr Lys Arg Thr Ser His Ser
145 150 155 160

Lys Leu Pro Glu Gln Glu Ala Ala Glu Ala Asp Leu Ser Asn Met Glu

WO 01/55335

PCT/US01/02570

165 170 175

Arg Val Ser Leu Ser Thr Ala Asp Pro Gln Gly Val Thr Tyr Ala Glu
180 185 190

Leu Ser Thr Ser Ala Leu Phe Glu Ala Ala Ser Asp Pro Thr Gln Glu
195 200 205

Pro Pro Gly Phe His Glu Tyr Ala Ala Leu Lys Val
210 215 220

<210> 28
<211> 183
<212> PRT
<213> Homo sapiens

<400> 28

Tyr Glu Asp Glu Lys Lys Asn Glu Lys Pro Pro Lys Pro Ser Leu His
1 5 10 15

Ala Trp Pro Ser Ser Val Val Glu Ala Glu Ser Asn Val Thr Leu Lys
20 25 30

Cys Gln Ala His Ser Gln Asn Val Thr Phe Val Leu Arg Lys Val Asn
35 40 45

Asp Ser Gly Tyr Lys Gln Glu Gln Ser Ser Ala Glu Asn Glu Ala Glu
50 55 60

Phe Pro Phe Thr Asp Leu Lys Pro Lys Asp Ala Gly Arg Tyr Phe Cys
65 70 75 80

Ala Tyr Lys Thr Thr Ala Ser His Glu Trp Ser Glu Ser Ser Glu His
85 90 95

Leu Gln Leu Val Val Thr Gly Ser Leu Pro Glu Pro Leu Leu Ser Val
100 105 110

Asn Val Asp Pro Gly Met Thr Pro Gly Leu Arg Thr Leu Arg Cys Leu
115 120 125

Thr Pro Tyr Asn Gly Thr Glu Cys Ile Val Ile Ala Leu Trp Lys Met
130 135 140

Gly Ile Pro Glu Pro Leu Gln Val Arg Gln Val Arg Lys Asn Gln Thr
145 150 155 160

Asp Phe Met Leu Trp Asn Val Thr Gly Asn Asp Ser Gly Asn Tyr Ser
165 170 175

Cys Val Tyr Tyr Leu Ser Asn
180

<210> 29
<211> 145
<212> PRT
<213> Homo sapiens

<400> 29

Met Thr Pro Ile Leu Thr Val Leu Ile Cys Leu Gly Leu Ser Leu Gly
1 5 10 15

WO 01/55335

PCT/US01/02570

Pro Arg Thr His Val Gln Ala Gly His Leu Pro Lys Pro Thr Leu Trp
 20 25 30

Ala Glu Pro Gly Ser Val Ile Ile Gln Gly Ser Pro Val Thr Leu Arg
 35 40 45

Cys Gln Gly Ser Leu Gln Ala Glu Glu Tyr His Leu Tyr Arg Glu Asn
 50 55 60

Lys Ser Ala Ser Trp Val Arg Arg Ile Gln Glu Pro Gly Lys Asn Gly
 65 70 75 80

Gln Phe Pro Ile Pro Ser Ile Thr Trp Glu His Ala Gly Arg Tyr His
 85 90 95

Cys Gln Tyr Tyr Ser His Asn His Ser Ser Glu Tyr Ser Asp Pro Leu
 100 105 110

Glu Leu Val Val Thr Gly Ala Tyr Ser Lys Pro Thr Leu Ser Ala Leu
 115 120 125

Pro Ser Pro Val Val Thr Leu Gly Gly Asn Val Thr Leu Gln Cys Val
 130 135 140

Ser
 145

<210> 30
 <211> 123
 <212> PRT
 <213> Homo sapiens

<400> 30
 Met Ile Pro Thr Phe Thr Ala Leu Leu Cys Leu Gly Leu Ser Leu Gly
 1 5 10 15

Pro Arg Thr His Met Gln Ala Gly Pro Leu Pro Lys Pro Thr Leu Trp
 20 25 30

Ala Glu Pro Gly Ser Val Ile Ser Trp Gly Asn Ser Val Thr Ile Trp
 35 40 45

Cys Gln Gly Thr Leu Glu Ala Arg Glu Tyr Arg Leu Asp Lys Glu Glu
 50 55 60

Ser Pro Ala Pro Trp Asp Arg Gln Asn Pro Leu Glu Pro Lys Asn Lys
 65 70 75 80

Ala Arg Phe Ser Ile Pro Ser Met Thr Glu Asp Tyr Ala Gly Arg Tyr
 85 90 95

Arg Cys Tyr Tyr Arg Ser Pro Val Gly Trp Ser Gln Pro Ser Asp Pro
 100 105 110

Leu Glu Leu Val Met Thr Gly Ala Tyr Ser Lys
 115 120

<210> 31
 <211> 205
 <212> PRT
 <213> Homo sapiens

WO 01/55335

PCT/US01/02570

<400> 31

Pro Lys Pro Trp Leu Phe Ala Glu Pro Ser Ser Val Val Pro Met Gly
 1 5 10 15

Gln Asn Val Thr Leu Trp Cys Arg Gly Pro Val His Gly Val Gly Tyr
 20 25 30

Ile Leu His Lys Glu Gly Glu Ala Thr Ser Met Gln Leu Trp Gly Ser
 35 40 45

Thr Ser Asn Asp Gly Ala Phe Pro Ile Thr Asn Ile Ser Gly Thr Ser
 50 55 60

Met Gly Arg Tyr Ser Cys Cys Tyr His Pro Asp Trp Thr Ser Ser Ile
 65 70 75 80

Lys Ile Gln Pro Ser Asn Thr Leu Glu Leu Leu Val Thr Gly Leu Leu
 85 90 95

Pro Lys Pro Ser Leu Leu Ala Gln Pro Gly Pro Met Val Ala Pro Gly
 100 105 110

Glu Asn Met Thr Leu Gln Cys Gln Gly Glu Leu Pro Asp Ser Thr Phe
 115 120 125

Val Leu Leu Lys Glu Gly Ala Gln Glu Pro Leu Glu Gln Gln Arg Pro
 130 135 140

Ser Gly Tyr Arg Ala Asp Phe Trp Met Pro Ala Val Arg Gly Glu Asp
 145 150 155 160

Ser Gly Ile Tyr Ser Cys Val Tyr Tyr Leu Asp Ser Thr Pro Phe Ala
 165 170 175

Ala Ser Asn His Ser Asp Ser Leu Glu Ile Trp Val Thr Asp Lys Pro
 180 185 190

Pro Lys Pro Ser Leu Ser Ala Trp Pro Ser Thr Met Phe
 195 200 205

<210> 32

<211> 236

<212> PRT

<213> Homo sapiens

<400> 32

Met Thr Pro Ile Leu Thr Val Leu Ile Cys Leu Gly Leu Ser Leu Gly
 1 5 10 15

Pro Arg Thr His Val Gln Ala Gly Thr Leu Pro Lys Pro Thr Leu Trp
 20 25 30

Ala Glu Pro Gly Ser Val Ile Thr Gln Gly Ser Pro Val Thr Leu Trp
 35 40 45

Cys Gln Gly Ile Leu Glu Thr Gln Glu Tyr Arg Leu Tyr Arg Glu Lys
 50 55 60

Lys Thr Ala Pro Trp Ile Thr Arg Ile Pro Gln Glu Ile Val Lys Lys
 65 70 75 80

Gly Gln Phe Pro Ile Pro Ser Ile Thr Trp Glu His Thr Gly Arg Tyr
 85 90 95

WO 01/55335

PCT/US01/02570

Arg Cys Phe Tyr Gly Ser His Thr Ala Gly Trp Ser Glu Pro Ser Asp
 100 105 110
 Pro Leu Glu Leu Val Val Thr Gly Ala Tyr Ile Lys Pro Thr Leu Ser
 115 120 125
 Ala Leu Pro Ser Pro Val Val Thr Ser Gly Gly Asn Val Thr Leu His
 130 135 140
 Cys Val Ser Gln Val Ala Phe Gly Ser Phe Ile Leu Cys Lys Glu Gly
 145 150 155 160
 Glu Asp Glu His Pro Gln Cys Leu Asn Ser Gln Pro Arg Thr His Gly
 165 170 175
 Trp Ser Arg Ala Ile Phe Ser Val Gly Pro Val Ser Pro Ser Arg Arg
 180 185 190
 Trp Ser Tyr Arg Cys Tyr Ala Tyr Asp Ser Asn Ser Pro His Val Trp
 195 200 205
 Ser Leu Pro Ser Asp Leu Leu Glu Leu Leu Val Pro Gly Ala Ala Glu
 210 215 220
 Thr Leu Ser Pro Pro Gln Asn Lys Ser Asp Ser Lys
 225 230 235

<210> 33
 <211> 45
 <212> PRT
 <213> Homo sapiens

<400> 33
 Met Pro Leu Leu Thr Leu Tyr Leu Leu Leu Phe Trp Leu Ser Gly Tyr
 1 5 10 15
 Ser Ile Ala Thr Gln Ile Thr Gly Pro Thr Thr Val Asn Gly Leu Glu
 20 25 30
 Arg Gly Ser Leu Thr Val Gln Cys Val Tyr Arg Ser Gly
 35 40 45

<210> 34
 <211> 249
 <212> PRT
 <213> Homo sapiens

<400> 34
 Asn Pro Arg Arg Gly Leu Gly Ser Gly Arg Arg Asp Ala Met Thr Ala
 1 5 10 15
 Glu Phe Leu Ser Leu Leu Cys Leu Gly Leu Cys Leu Gly Tyr Glu Asp
 20 25 30
 Glu Lys Lys Asn Glu Lys Pro Pro Lys Pro Ser Leu His Ala Trp Pro
 35 40 45
 Ser Ser Val Val Glu Ala Glu Ser Asn Val Thr Leu Lys Cys Gln Ala
 50 55 60
 His Ser Gln Asn Val Thr Phe Val Leu Arg Lys Val Asn Asp Ser Gly

WO 01/55335

PCT/US01/02570

65		70		75		80									
Tyr	Lys	Gln	Glu	Gln	Ser	Ser	Ala	Glu	Asn	Glu	Ala	Glu	Phe	Pro	Phe
				85					90					95	
Thr	Asp	Leu	Lys	Pro	Lys	Asp	Ala	Gly	Arg	Tyr	Phe	Cys	Ala	Tyr	Lys
			100					105					110		
Thr	Thr	Ala	Ser	His	Glu	Trp	Ser	Glu	Ser	Ser	Glu	His	Leu	Gln	Leu
		115					120					125			
Val	Val	Thr	Asp	Lys	His	Asp	Glu	Leu	Glu	Ala	Pro	Ser	Met	Lys	Thr
		130				135					140				
Asp	Thr	Arg	Thr	Ile	Phe	Val	Ala	Ile	Phe	Ser	Cys	Ile	Ser	Ile	Leu
145					150					155					160
Leu	Leu	Phe	Leu	Ser	Val	Phe	Ile	Ile	Tyr	Arg	Cys	Ser	Gln	His	Ser
				165					170					175	
Ser	Ser	Ser	Glu	Glu	Ser	Thr	Lys	Arg	Thr	Ser	His	Ser	Lys	Leu	Pro
			180					185					190		
Glu	Gln	Glu	Ala	Ala	Glu	Ala	Asp	Leu	Ser	Asn	Met	Glu	Arg	Val	Ser
		195					200					205			
Leu	Ser	Thr	Ala	Asp	Pro	Gln	Gly	Val	Thr	Tyr	Ala	Glu	Leu	Ser	Thr
		210				215					220				
Ser	Ala	Leu	Ser	Glu	Ala	Ala	Ser	Asp	Thr	Thr	Gln	Glu	Pro	Pro	Gly
225					230				235						240
Ser	His	Glu	Tyr	Ala	Ala	Leu	Lys	Val							
				245											

<210> 35
 <211> 482
 <212> DNA
 <213> Homo sapiens

<400> 35
 ctccagtttg gacgaggcct tagaggcatc agcgtatcac tttcctcgta agtcgggagt 60
 gatggaacga ccaccctgta gtgcggttgt gagaattgag atgaggcttg gttcatattg 120
 agtgctcagc tttcctggct tatagacagt ggaggggctg ggccccacca tgcaccccaa 180
 ggggtctcaga ctcaagggcc accaggagga gttggcgggg agccttgggc ccctctggcc 240
 tcagccggat ttcccagcca aacgcagaga gagatgccct ggaccatctt gctctttgca 300
 gctggctcct tggcgatccc agcaccatcc atccggctgg tgccccgta cccaagcagc 360
 caagaggacc ccatccacat cgcatgcatg gcccttgga acttcccggg ggcgaatttc 420
 aactgtatc gaggggggca ggtggtccag ctctgcagg ccccccagga ccagcgcggg 480
 gg 482

<210> 36
 <211> 1398
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (263)..(955)

<400> 36
 acgaggcctt agaggcatca gcgtatcact ttcctcgtaa gtcgggagtg atggaacgac 60

23

WO 01/55335

PCT/US01/02570

Glu Thr Pro Glu Phe Ser Thr Phe Arg Ala Cys Gln
 220 225 230

tgggggaccc ctctgtctcc aggcattcgg gggcctgagg tccctccagc tacttctggg 1025
 ggggctctgt cagccacttt ctcagggaat tggacagagg aaaggaaggg gaaccctggc 1085
 cttgggattt tcatcacaga ggagtgggag aggggacaca ggcattgggccc tggcactata 1145
 cagacaacag gaagttcccc tctcgacctt cggctcctca ggaccaccag agaaggagat 1205
 gtcaggaccc cttcttgtcc ccagctggg ccataagacg tcccagggtct ctgcacaccc 1265
 gtggaattcc tcccttcccc agtggggttt tgagcatagg gtgcccttgg gtgtgttgtg 1325
 tgtctgcctg ctggcttgct taagttatta attataacac gggtaaggt gttcccaggg 1385
 aaaaaaaaaa aaa 1398

<210> 37
 <211> 230
 <212> PRT
 <213> Homo sapiens

<400> 37
 Met Pro Trp Thr Ile Leu Leu Phe Ala Ala Gly Ser Leu Ala Ile Pro
 1 5 10 15
 Ala Pro Ser Ile Arg Leu Val Pro Pro Tyr Pro Ser Ser Gln Glu Asp
 20 25 30
 Pro Ile His Ile Ala Cys Met Ala Pro Gly Asn Phe Pro Gly Ala Asn
 35 40 45
 Phe Thr Leu Tyr Arg Gly Gly Gln Val Val Gln Leu Leu Gln Ala Pro
 50 55 60
 Thr Asp Gln Arg Gly Val Thr Phe Asn Leu Ser Gly Gly Ser Ser Lys
 65 70 75 80
 Ala Pro Gly Gly Pro Phe His Cys Gln Tyr Gly Val Leu Gly Glu Leu
 85 90 95
 Asn Gln Ser Gln Leu Ser Asp Leu Ser Glu Pro Val Asn Val Ser Phe
 100 105 110
 Pro Val Pro Thr Trp Ile Leu Val Leu Ser Leu Ser Leu Ala Gly Ala
 115 120 125
 Leu Phe Leu Leu Ala Gly Leu Val Ala Val Ala Leu Val Val Arg Lys
 130 135 140
 Val Lys Leu Arg Asn Leu Gln Lys Lys Arg Asp Arg Glu Ser Cys Trp
 145 150 155 160
 Ala Gln Ile Asn Phe Asp Ser Thr Asp Met Ser Phe Asp Asn Ser Leu
 165 170 175
 Phe Thr Val Ser Ala Lys Thr Met Pro Glu Glu Asp Pro Ala Thr Leu
 180 185 190
 Asp Asp His Ser Gly Thr Thr Ala Thr Pro Ser Asn Ser Arg Thr Arg
 195 200 205
 Lys Arg Pro Thr Ser Thr Ser Ser Ser Pro Glu Thr Pro Glu Phe Ser
 210 215 220
 Thr Phe Arg Ala Cys Gln
 225 230

<210> 38
 <211> 693
 <212> DNA
 <213> Homo sapiens

```

<400> 38
atgccctgga ccattcttgct ctttgcagct ggctccttgg cgatcccagc accatccatc 60
cggctggtgc ccccgtagcc aagcagccaa gaggacccca tccacatcgc atgcatggcc 120
cctgggaact tcccgggggc gaatttcaca ctgtatcgag gggggcaggt ggtccagctc 180
ctgcaggccc ccacggacca gcgcggggtg acatttaacc tgagcggcgg cagcagcaag 240
gctccagggg gacccttcca ctgccagtat ggagtgttag gtgagctcaa ccagtcccag 300
ctgtcagacc tcagcgagcc cgtgaacgtc tccttcccag tgcccacttg gatcttgggtg 360
ctctccctga gcctggctgg tgccctcttc ctcttctgtg ggctgggtggc tgttgccctg 420
gtggtcagaa aagttaaact cagaaattta cagaagaaaa gagatcgaga atcctgctgg 480
gccagatta acttcgacag cacagacatg tccttcgata actccctgtt taccgtctcc 540
gcgaaaacga tgccagaaga agacccggcc accttggatg atcactcagg caccactgcc 600
acccccagca actccaggac ccggaagagg ccacttcca cgtcctcttc gcctgagacc 660
cccgaattca gcactttccg ggctgcccag tga                                     693

```

```

<210> 39
<211> 1455
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> CDS
<222> (274)..(966)

```

```

<220>
<221> misc_feature
<222> (1)..(1455)
<223> n = A, T, G, or C

```

```

<400> 39
ctccagtttg gacgaggcct tagaggcatc agcgtatcac tttcctcgta agtcgggagt 60

gatggaacga ccaccctgta gtgcgggttg gagaattgag atgaggcttg gctcatattg 120

agtgctcagc tttcctggct tatagacagt ggagggggcgt ggccccacca tgcaccccaa 180

gggtctcaga ctcaagggcc agcaggagga gttggcgggg agccttgggc ccctctggcc 240

tcagccggat ttcccagcca aacgcagaga gag atg ccc tgg acc atc ttg ctc 294
                Met Pro Trp Thr Ile Leu Leu
                1                5

ttt gca gct ggc tcc ttg gcg atc cca gca cca tcc atc cgg ctg gtg 342
Phe Ala Ala Gly Ser Leu Ala Ile Pro Ala Pro Ser Ile Arg Leu Val
        10                15                20

ccc ccg tac cca agc agc caa gag gac ccc atc cac atc gca tgc atg 390
Pro Pro Tyr Pro Ser Ser Gln Glu Asp Pro Ile His Ile Ala Cys Met
        25                30                35

gcc cct ggg aac ttc ccg ggg gcg aat ttc aca ctg tat cga ggg ggg 438
Ala Pro Gly Asn Phe Pro Gly Ala Asn Phe Thr Leu Tyr Arg Gly Gly
        40                45                50                55

cag gtg gtc cag ctc ctg cag gcc ccc acg gac cag cgc ggg gtg aca 486
Gln Val Val Gln Leu Leu Gln Ala Pro Thr Asp Gln Arg Gly Val Thr
        60                65                70

ttt aac ctg agc ggc ggc agc agc aag gct cca ggg gga ccc ttc cac 534
Phe Asn Leu Ser Gly Gly Ser Ser Lys Ala Pro Gly Gly Pro Phe His
        75                80                85

tgc cag tat gga gtg tta ggt gag ctc aac cag tcc cag ctg tca gac 582
Cys Gln Tyr Gly Val Leu Gly Glu Leu Asn Gln Ser Gln Leu Ser Asp

```

WO 01/55335

PCT/US01/02570

90	95	100	
ctc agc gag ccc gtg aac gtc tcc ttc cca gtg ccc act tgg atc ttg			630
Leu Ser Glu Pro Val Asn Val Ser Phe Pro Val Pro Thr Trp Ile Leu			
105	110	115	
gtg ctc tcc ctg agc ctg gct ggt gcc ctc ttc ctc ctt gct ggg ctg			678
Val Leu Ser Leu Ser Leu Ala Gly Ala Leu Phe Leu Leu Ala Gly Leu			
120	125	130	135
gtg gct gtt gcc ctg gtg gtc aga aaa gtt aaa ctc aga aat tta cag			726
Val Ala Val Ala Leu Val Val Arg Lys Val Lys Leu Arg Asn Leu Gln			
	140	145	150
aag aaa aga gat cga gaa tcc tgc tgg gcc cag att aac ttc gac agc			774
Lys Lys Arg Asp Arg Glu Ser Cys Trp Ala Gln Ile Asn Phe Asp Ser			
	155	160	165
aca gac atg tcc ttc gat aac tcc ctg ttt acc gtc tcc gcg aaa acg			822
Thr Asp Met Ser Phe Asp Asn Ser Leu Phe Thr Val Ser Ala Lys Thr			
	170	175	180
atg cca gaa gaa gac ccg gcc acc ttg gat gat cac tca ggc acc act			870
Met Pro Glu Glu Asp Pro Ala Thr Leu Asp Asp His Ser Gly Thr Thr			
	185	190	195
gcc acc ccc agc aac tcc agg acc cgg aag agg ccc act tcc acg tcc			918
Ala Thr Pro Ser Asn Ser Arg Thr Arg Lys Arg Pro Thr Ser Thr Ser			
200	205	210	215
tcc tcg cct gag acc ccc gaa ttc agc act ttc cgg gcc tgc cag tga			966
Ser Ser Pro Glu Thr Pro Glu Phe Ser Thr Phe Arg Ala Cys Gln			
	220	225	230
ggctgaggac tgggggaccc ctctgtctcc aggcattcgg gggcctgagg tccctccagc			1026
tacttctggg ggggctctgt cagccacttt ctccagggaat tggacagagg aaaggaaggg			1086
gaaccctggc cttgggattt tcatcacaga ggagtgggag aggggacaca ggcattgggccc			1146
tggcactata cagacaacag gaagtcccc tctcgacctt cggctcctca ggaccaccag			1206
agaaggagat gtcaggaccc cttcttgtcc ccagctggg ccataagacg tcccaggtct			1266
ctgcacaccc gtggaattcc tcccttcccc agtggggttt tgagcatagg gtgcccttgg			1326
gtgtgttgtg tgtctgcctg ctggcttgct taagttatta atctcagaac aacgacagcg			1386
gccgctctag aggatccaag cttacgtacg cgtgcatgcc catgaactta atngnangag			1446
cggggggcg			1455

<210> 40

<211> 230

<212> PRT

<213> Homo sapiens

<400> 40

Met	Pro	Trp	Thr	Ile	Leu	Leu	Phe	Ala	Ala	Gly	Ser	Leu	Ala	Ile	Pro
1				5				10					15		
Ala	Pro	Ser	Ile	Arg	Leu	Val	Pro	Pro	Tyr	Pro	Ser	Ser	Gln	Glu	Asp
			20				25						30		
Pro	Ile	His	Ile	Ala	Cys	Met	Ala	Pro	Gly	Asn	Phe	Pro	Gly	Ala	Asn

WO 01/55335

PCT/US01/02570

		35					40				45						
Phe	Thr	Leu	Tyr	Arg	Gly	Gly	Gln	Val	Val	Gln	Leu	Leu	Gln	Ala	Pro		
	50					55					60						
Thr	Asp	Gln	Arg	Gly	Val	Thr	Phe	Asn	Leu	Ser	Gly	Gly	Ser	Ser	Lys		
65					70					75					80		
Ala	Pro	Gly	Gly	Pro	Phe	His	Cys	Gln	Tyr	Gly	Val	Leu	Gly	Glu	Leu		
				85				90						95			
Asn	Gln	Ser	Gln	Leu	Ser	Asp	Leu	Ser	Glu	Pro	Val	Asn	Val	Ser	Phe		
			100					105						110			
Pro	Val	Pro	Thr	Trp	Ile	Leu	Val	Leu	Ser	Leu	Ser	Leu	Ala	Gly	Ala		
		115					120						125				
Leu	Phe	Leu	Leu	Ala	Gly	Leu	Val	Ala	Val	Ala	Leu	Val	Val	Arg	Lys		
130						135						140					
Val	Lys	Leu	Arg	Asn	Leu	Gln	Lys	Lys	Arg	Asp	Arg	Glu	Ser	Cys	Trp		
145				150					155						160		
Ala	Gln	Ile	Asn	Phe	Asp	Ser	Thr	Asp	Met	Ser	Phe	Asp	Asn	Ser	Leu		
			165						170					175			
Phe	Thr	Val	Ser	Ala	Lys	Thr	Met	Pro	Glu	Glu	Asp	Pro	Ala	Thr	Leu		
		180						185						190			
Asp	Asp	His	Ser	Gly	Thr	Thr	Ala	Thr	Pro	Ser	Asn	Ser	Arg	Thr	Arg		
		195					200					205					
Lys	Arg	Pro	Thr	Ser	Thr	Ser	Ser	Ser	Pro	Glu	Thr	Pro	Glu	Phe	Ser		
	210					215					220						
Thr	Phe	Arg	Ala	Cys	Gln												
225					230												

<210> 41
 <211> 693
 <212> DNA
 <213> Homo sapiens

<400> 41
 atgccctgga ccattcttgc ttttgcagct ggctccttgg cgatcccagc accatccatc 60
 cggctggtgc ccccgtagcc aagcagccaa gaggacccca tccacatcgc atgcatggcc 120
 cctgggaact tcccgggggc gaatttcaca ctgtatcgag gggggcaggt ggtccagctc 180
 ctgcaggccc ccacggacca gcgcggggtg acattttaacc tgagcggcgg cagcagcaag 240
 gctccagggg gacccttcca ctgccagtat ggagtgttag gtgagctcaa ccagtcccag 300
 ctgtcagacc tcagcgagcc cgtgaacgct tccttcccag tgcccacttg gatcttggtg 360
 ctctccctga gcctggctgg tgccctcttc ctcttgctg ggctgggtggc tgttgccctg 420
 gtggtcagaa aagttaaact cagaaattta cagaagaaaa gagatcgaga atcctgctgg 480
 gccagatta acttcgacag cacagacatg tccttcgata actccctgtt taccgtctcc 540
 gcgaaaacga tgccagaaga agaccgggcc accttggtatg atcactcagg caccactgcc 600
 acccccagca actccaggac ccggaagagg cccacttcca cgtcctctc gcctgagacc 660
 cccgaattca gcactttccg ggccctgccag tga 693

<210> 42
 <211> 102
 <212> PRT
 <213> Homo sapiens

<400> 42
 Pro Ser Ile Arg Leu Val Pro Pro Tyr Pro Ser Ser Gln Glu Asp Pro
 1 5 10 15
 Ile His Ile Ala Cys Met Ala Pro Gly Asn Phe Pro Gly Ala Asn Phe
 20 25 30
 Thr Leu Tyr Arg Gly Gly Gln Val Val Gln Leu Leu Gln Ala Pro Thr
 35 40 45
 Asp Gln Arg Gly Val Thr Phe Asn Leu Ser Gly Gly Ser Ser Lys Ala

50 55 60
 Pro Gly Gly Pro Phe His Cys Gln Tyr Gly Val Leu Gly Glu Leu Asn
 65 70 75 80
 Gln Ser Gln Leu Ser Asp Leu Ser Glu Pro Val Asn Val Ser Phe Pro
 85 90 95
 Val Pro Thr Trp Ile Leu
 100

<210> 43
 <211> 15
 <212> PRT
 <213> Homo sapiens

<400> 43
 Met Pro Trp Thr Ile Leu Leu Phe Ala Ala Gly Ser Leu Ala Ile
 1 5 10 15

<210> 44
 <211> 27
 <212> PRT
 <213> Homo sapiens

<400> 44
 Thr Trp Ile Leu Val Leu Ser Leu Ser Leu Ala Gly Ala Leu Phe Leu
 1 5 10 15

Leu Ala Gly Leu Val Ala Val Ala Leu Val Val
 20 25

<210> 45
 <211> 215
 <212> PRT
 <213> Homo sapiens

<400> 45
 Pro Ala Pro Ser Ile Arg Leu Val Pro Pro Tyr Pro Ser Ser Gln Glu
 1 5 10 15

Asp Pro Ile His Ile Ala Cys Met Ala Pro Gly Asn Phe Pro Gly Ala
 20 25 30

Asn Phe Thr Leu Tyr Arg Gly Gly Gln Val Val Gln Leu Leu Gln Ala
 35 40 45

Pro Thr Asp Gln Arg Gly Val Thr Phe Asn Leu Ser Gly Gly Ser Ser
 50 55 60

Lys Ala Pro Gly Gly Pro Phe His Cys Gln Tyr Gly Val Leu Gly Glu
 65 70 75 80

Leu Asn Gln Ser Gln Leu Ser Asp Leu Ser Glu Pro Val Asn Val Ser
 85 90 95

Phe Pro Val Pro Thr Trp Ile Leu Val Leu Ser Leu Ser Leu Ala Gly
 100 105 110

Ala Leu Phe Leu Leu Ala Gly Leu Val Ala Val Ala Leu Val Val Arg
 115 120 125

WO 01/55335

PCT/US01/02570

Lys Val Lys Leu Arg Asn Leu Gln Lys Lys Arg Asp Arg Glu Ser Cys
 130 135 140
 Trp Ala Gln Ile Asn Phe Asp Ser Thr Asp Met Ser Phe Asp Asn Ser
 145 150 155 160
 Leu Phe Thr Val Ser Ala Lys Thr Met Pro Glu Glu Asp Pro Ala Thr
 165 170 175
 Leu Asp Asp His Ser Gly Thr Thr Ala Thr Pro Ser Asn Ser Arg Thr
 180 185 190
 Arg Lys Arg Pro Thr Ser Thr Ser Ser Ser Pro Glu Thr Pro Glu Phe
 195 200 205
 Ser Thr Phe Arg Ala Cys Gln
 210 215

<210> 46
 <211> 103
 <212> PRT
 <213> Homo sapiens

<400> 46
 Pro Ser Leu Leu Ala His Pro Gly Pro Leu Val Lys Ser Glu Glu Thr
 1 5 10 15
 Val Ile Leu Gln Cys Trp Ser Asp Val Arg Phe Gln His Phe Leu Leu
 20 25 30
 His Arg Glu Gly Lys Phe Lys Asp Thr Leu His Leu Ile Gly Glu His
 35 40 45
 His Asp Gly Val Ser Lys Ala Asn Phe Ser Ile Gly Pro Met Met Gln
 50 55 60
 Asp Leu Ala Gly Thr Tyr Arg Cys Tyr Gly Ser Val Thr His Ser Pro
 65 70 75 80
 Tyr Gln Leu Ser Ala Pro Ser Asp Pro Leu Asp Ile Val Ile Thr Gly
 85 90 95
 Leu Tyr Glu Lys Pro Ser Leu
 100

<210> 47
 <211> 698
 <212> DNA
 <213> Homo sapiens

<400> 47
 ccggtggggt tcaatgtcag aaggaaaaag agcctgagac cctgctgcca caagggttttt 60
 ccatgctggc tgtctgactg tgaggggccc cagcaccgtg atgggcgccg tggtggaatc 120
 cctgagtgtt cagtgtcggg atgaagagaa atacaagacg tttaacaaat actggtgcag 180
 acaaccatgc ttgccaattt gcatgaaatg gtggagaccg gaggtctgag ggagtgggtga 240
 ggagtgacca agtgatcatc acggaccatc ctggagacct caccttcacc gtgaccttgg 300
 agaacctcac ggcagacgat gcaggaaaat accgatgtgg gattgcaaca atactgcagg 360
 aagatggcct gtctgggtttc ctgcccgate ccttcttcca ggttcaagtg ctggtctcat 420
 cggcctccag tactgagaac tttgtgaaga cacctgcac tcccaccagg cccagccaat 480
 gccaaagggtc cttgcccagc agcacctgct tcttgcttct cccactcctg aagggtgcctt 540
 tgctcctgag catactcggg gctatcctct gggggaacag gctttggagg actccttggc 600

WO 01/55335

PCT/US01/02570

```

cct gga gac ctc acc ttc acc gtg acc ttg gag aac ctc acg gca gac 521
Pro Gly Asp Leu Thr Phe Thr Val Thr Leu Glu Asn Leu Thr Ala Asp
    90                      95                      100

gat gca gga aaa tac cga tgt ggg att gca aca ata ctg cag gaa gat 569
Asp Ala Gly Lys Tyr Arg Cys Gly Ile Ala Thr Ile Leu Gln Glu Asp
105                      110                      115                      120

ggc ctg tct ggt ttc ctg ccc gat ccc ttc ttc cag gtt caa gtg ctg 617
Gly Leu Ser Gly Phe Leu Pro Asp Pro Phe Phe Gln Val Gln Val Leu
                      125                      130                      135

gtc tca tcg gcc tcc agt act gag aac tct gtg aag aca cct gca tct 665
Val Ser Ser Ala Ser Ser Thr Glu Asn Ser Val Lys Thr Pro Ala Ser
                      140                      145                      150

ccc acc agg ccc agc caa tgc caa ggg tcc ctg ccc agc agc acc tgc 713
Pro Thr Arg Pro Ser Gln Cys Gln Gly Ser Leu Pro Ser Ser Thr Cys
                      155                      160                      165

ttc ctg ctt ctc cca ctc ctg aag gtg cct ctg ctc ctg agc ata ctc 761
Phe Leu Leu Leu Pro Leu Leu Lys Val Pro Leu Leu Leu Ser Ile Leu
    170                      175                      180

ggg gct atc ctc tgg gtg aac agg cct tgg agg act cct tgg aca gag 809
Gly Ala Ile Leu Trp Val Asn Arg Pro Trp Arg Thr Pro Trp Thr Glu
185                      190                      195                      200

tca tga acaggagaac ttgcaacacc ccatgcccat tggaaccctg tccagagaca 865
Ser

cagcccctct gactgcaaaa aggacttctg accctgaccc tcatatttct ttccatctta 925

tcaccggata cttttttaaaa gttaaaaaaaa aatgtaggcc ggggtgcggtg gcttacacct 985

gcaatcccag cactttggga ggccaaggca ggtggatcac ttgagtccag gagtttgaga 1045

gcagcctggg cagcatgggc agacctcatc tctacaaaaa aatacaaaaa ttagcagggt 1105

gtgggtggtgt atgcctgtga tcccagctac ttgggaagct gagacaggag gatcgcttga 1165

gccccggagt ggaggttgca ttgagtcgag attgtgccac tgcactccag cctgggtgac 1225

agagggagac cctgtctcag ataaacaaat aaataaataa aatacatccc atacacaaga 1285

gtatgtatat gaggtatcta tacagttcaa ggactaaaaa taaacatgtg taccaccat 1345

tcg 1348

<210> 50
<211> 201
<212> PRT
<213> Homo sapiens

<400> 50
Met Thr Gln Arg Ala Gly Ala Ala Met Leu Pro Ser Ala Leu Leu Leu
  1                      5                      10                      15
Leu Cys Val Pro Gly Cys Leu Thr Val Ser Gly Pro Ser Thr Val Met
                      20                      25                      30
Gly Ala Val Gly Glu Ser Leu Ser Val Gln Cys Arg Tyr Glu Glu Lys
                      35                      40                      45
Tyr Lys Thr Phe Asn Lys Tyr Trp Cys Arg Gln Pro Cys Leu Pro Ile

```

WO 01/55335

PCT/US01/02570

50	55	60
Trp His Glu Met Val Glu Thr Gly Gly Ser Glu Gly Val Val Arg Ser		
65	70	75
Asp Gln Val Ile Ile Thr Asp His Pro Gly Asp Leu Thr Phe Thr Val		80
	85	90
Thr Leu Glu Asn Leu Thr Ala Asp Asp Ala Gly Lys Tyr Arg Cys Gly		95
	100	105
Ile Ala Thr Ile Leu Gln Glu Asp Gly Leu Ser Gly Phe Leu Pro Asp		110
	115	120
Pro Phe Phe Gln Val Gln Val Leu Val Ser Ser Ala Ser Ser Thr Glu		125
	130	135
Asn Ser Val Lys Thr Pro Ala Ser Pro Thr Arg Pro Ser Gln Cys Gln		140
145	150	155
Gly Ser Leu Pro Ser Ser Thr Cys Phe Leu Leu Leu Pro Leu Leu Lys		160
	165	170
Val Pro Leu Leu Leu Ser Ile Leu Gly Ala Ile Leu Trp Val Asn Arg		175
	180	185
Pro Trp Arg Thr Pro Trp Thr Glu Ser		190
	195	200

<210> 51

<211> 606

<212> DNA

<213> Homo sapiens

<400> 51

```

atgacccaga gggctggggc tgccatgctg ccttcagctc tgctccttct ctgtgtccca 60
ggctgtctga ctgtgagtgg ccccagcacc gtgatgggcg ccgtggggga atccctgagt 120
gttcagtgtc ggtatgaaga gaaatacaag acgtttaaca aatactggtg cagacaacca 180
tgcttgccaa tttggcatga aatggtggag accggagggt ctgagggagt ggtgaggagt 240
gaccaagtga tcatcacgga ccatcctgga gacctcacct tcaccgtgac cttggagaac 300
ctcacggcag acgatgcagg aaaataccga tgtgggattg caacaatact gcaggaagat 360
ggcctgtctg gtttcctgcc cgatcccttc ttccagggtc aagtgtctgt ctcacgggcc 420
tccagtactg agaactctgt gaagacacct gcattctcca ccaggcccag ccaatgccaa 480
gggtccctgc ccagcagcac ctgcttcctg cttctccac tctgaagggt gcctctgtctc 540
ctgagcatac tcggtgctat cctctgggtg aacaggcctt ggaggactcc ttggacagag 600
tcatga 606

```

<210> 52

<211> 119

<212> PRT

<213> Homo sapiens

<400> 52

Leu Thr Val Ser Gly Pro Ser Thr Val Met Gly Ala Val Gly Glu Ser	
1	15
Leu Ser Val Gln Cys Arg Tyr Glu Glu Lys Tyr Lys Thr Phe Asn Lys	
20	30
Tyr Trp Cys Arg Gln Pro Cys Leu Pro Ile Trp His Glu Met Val Glu	
35	45
Thr Gly Gly Ser Glu Gly Val Val Arg Ser Asp Gln Val Ile Ile Thr	
50	60
Asp His Pro Gly Asp Leu Thr Phe Thr Val Thr Leu Glu Asn Leu Thr	
65	80
Ala Asp Asp Ala Gly Lys Tyr Arg Cys Gly Ile Ala Thr Ile Leu Gln	
85	95

WO 01/55335

PCT/US01/02570

Glu Asp Gly Leu Ser Gly Phe Leu Pro Asp Pro Phe Phe Gln Val Gln
 100 105 110

Val Leu Val Ser Ser Ala Ser
 115

<210> 53
 <211> 48
 <212> PRT
 <213> Homo sapiens

<400> 53
 Ile Thr Asp His Pro Gly Asp Leu Thr Phe Thr Val Thr Leu Glu Asn
 1 5 10 15

Leu Thr Ala Asp Asp Ala Gly Lys Tyr Arg Cys Gly Ile Ala Thr Ile
 20 25 30

Leu Gln Glu Asp Gly Leu Ser Gly Phe Leu Pro Asp Pro Phe Phe Gln
 35 40 45

<210> 54
 <211> 37
 <212> PRT
 <213> Homo sapiens

<400> 54
 Met Gly Ala Val Gly Glu Ser Leu Ser Val Gln Cys Arg Tyr Glu Glu
 1 5 10 15

Lys Tyr Lys Thr Phe Asn Lys Tyr Trp Cys Arg Gln Pro Cys Leu Pro
 20 25 30

Ile Trp His Glu Met
 35

<210> 55
 <211> 20
 <212> PRT
 <213> Homo sapiens

<400> 55
 Met Thr Gln Arg Ala Gly Ala Ala Met Leu Pro Ser Ala Leu Leu Leu
 1 5 10 15

Leu Cys Val Pro
 20

<210> 56
 <211> 24
 <212> PRT
 <213> Homo sapiens

<400> 56
 Thr Cys Phe Leu Leu Leu Pro Leu Leu Lys Val Pro Leu Leu Leu Ser
 1 5 10 15

WO 01/55335

PCT/US01/02570

Ile Leu Gly Ala Ile Leu Trp Val
20

<210> 57
<211> 181
<212> PRT
<213> Homo sapiens

<400> 57
Gly Cys Leu Thr Val Ser Gly Pro Ser Thr Val Met Gly Ala Val Gly
1 5 10 15
Glu Ser Leu Ser Val Gln Cys Arg Tyr Glu Glu Lys Tyr Lys Thr Phe
20 25 30
Asn Lys Tyr Trp Cys Arg Gln Pro Cys Leu Pro Ile Trp His Glu Met
35 40 45
Val Glu Thr Gly Gly Ser Glu Gly Val Val Arg Ser Asp Gln Val Ile
50 55 60
Ile Thr Asp His Pro Gly Asp Leu Thr Phe Thr Val Thr Leu Glu Asn
65 70 75 80
Leu Thr Ala Asp Asp Ala Gly Lys Tyr Arg Cys Gly Ile Ala Thr Ile
85 90 95
Leu Gln Glu Asp Gly Leu Ser Gly Phe Leu Pro Asp Pro Phe Phe Gln
100 105 110
Val Gln Val Leu Val Ser Ser Ala Ser Ser Thr Glu Asn Ser Val Lys
115 120 125
Thr Pro Ala Ser Pro Thr Arg Pro Ser Gln Cys Gln Gly Ser Leu Pro
130 135 140
Ser Ser Thr Cys Phe Leu Leu Leu Pro Leu Leu Lys Val Pro Leu Leu
145 150 155 160
Leu Ser Ile Leu Gly Ala Ile Leu Trp Val Asn Arg Pro Trp Arg Thr
165 170 175
Pro Trp Thr Glu Ser
180

<210> 58
<211> 123
<212> PRT
<213> Homo sapiens

<400> 58
Val Gly Ser Phe Gln Ile Gly Phe Leu Leu Leu Leu Trp Leu Arg Asp
1 5 10 15
Ser Thr Gly Glu Ile Val Lys Thr Gln Ser Pro Ser Thr Leu Ser Gly
20 25 30
Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val
35 40 45
Ser Ile Ile Leu Ala Trp Asp Gln Gln Lys Pro Gly Gln Ala Pro Met

WO 01/55335

PCT/US01/02570

50 55 60
 Leu Leu Met Tyr Arg Ala Cys Thr Arg Ala Ile Asp Ile Pro Ala Arg
 65 70 75 80
 Phe Ser Gly Gly Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser
 85 90 95
 Leu Gln Ser Gly Asp Cys Ala Val Tyr Phe Trp Gln His Tyr Asn Asn
 100 105 110
 Trp Pro Pro Trp Thr Phe Gly Gln Gly Thr Arg
 115 120

<210> 59
 <211> 112
 <212> PRT
 <213> Homo sapiens

<400> 59
 Gln Val Arg Gln Ser Pro Gln Ser Leu Thr Val Trp Glu Gly Glu Thr
 1 5 10 15
 Ala Ile Leu Asn Cys Ser Tyr Glu Asn Ser Ala Phe Asp Tyr Phe Pro
 20 25 30
 Trp Tyr Gln Gln Phe Pro Gly Glu Gly Pro Ala Leu Leu Ile Ser Ile
 35 40 45
 Leu Ser Val Ser Asn Lys Lys Glu Asp Gly Arg Phe Thr Ile Phe Phe
 50 55 60
 Asn Lys Arg Glu Lys Lys Leu Ser Leu His Ile Ala Asp Ser Gln Pro
 65 70 75 80
 Gly Asp Ser Ala Thr Tyr Phe Cys Ala Ala Ser Ala Ser Phe Gly Asp
 85 90 95
 Asn Ser Lys Leu Ile Trp Gly Leu Gly Thr Ser Leu Val Val Asn Pro
 100 105 110

<210> 60
 <211> 211
 <212> PRT
 <213> Homo sapiens

<400> 60
 Met Thr Ala Arg Ala Trp Ala Ser Trp Arg Ser Ser Ala Leu Leu Leu
 1 5 10 15
 Leu Leu Val Pro Gly Tyr Phe Pro Leu Ser His Pro Met Thr Val Ala
 20 25 30
 Gly Pro Val Gly Gly Ser Leu Ser Val Gln Cys Arg Tyr Glu Lys Glu
 35 40 45
 His Arg Thr Leu Asn Lys Phe Trp Cys Arg Pro Pro Gln Ile Leu Arg
 50 55 60

WO 01/55335

PCT/US01/02570

Cys Asp Lys Ile Val Glu Thr Lys Gly Ser Ala Gly Lys Arg Asn Gly
 65 70 75 80
 Arg Val Ser Ile Arg Asp Ser Pro Ala Asn Leu Ser Phe Thr Val Thr
 85 90 95
 Leu Glu Asn Leu Thr Glu Glu Asp Ala Gly Thr Tyr Trp Cys Gly Val
 100 105 110
 Asp Thr Pro Trp Leu Arg Asp Phe His Asp Pro Ile Val Glu Val Glu
 115 120 125
 Val Ser Val Phe Pro Ala Gly Thr Thr Thr Ala Ser Ser Pro Gln Ser
 130 135 140
 Ser Met Gly Thr Ser Gly Pro Pro Thr Lys Leu Pro Val His Thr Trp
 145 150 155 160
 Pro Ser Val Thr Arg Lys Asp Ser Pro Glu Pro Ser Pro His Pro Gly
 165 170 175
 Ser Leu Phe Ser Asn Val Arg Phe Leu Leu Leu Val Leu Leu Glu Leu
 180 185 190
 Pro Leu Leu Leu Ser Met Leu Gly Ala Val Leu Trp Val Asn Arg Pro
 195 200 205
 Gln Arg Ser
 210

<210> 61
 <211> 135
 <212> PRT
 <213> Homo sapiens

<400> 61
 Leu Pro Trp Ala Leu Leu Leu Leu Trp Val Pro Gly Cys Phe Ala Leu
 1 5 10 15
 Ser Lys Cys Arg Thr Val Ala Gly Pro Val Gly Gly Ser Leu Ser Val
 20 25 30
 Gln Cys Pro Tyr Glu Lys Glu His Arg Thr Leu Asn Lys Tyr Trp Cys
 35 40 45
 Arg Pro Pro Gln Ile Phe Leu Cys Asp Lys Ile Val Glu Thr Lys Gly
 50 55 60
 Ser Ala Gly Lys Arg Asn Gly Arg Val Ser Ile Arg Asp Ser Pro Ala
 65 70 75 80
 Asn Leu Ser Phe Thr Val Thr Leu Glu Asn Leu Thr Glu Glu Asp Ala
 85 90 95
 Gly Thr Tyr Trp Cys Gly Val Asp Thr Pro Trp Leu Gln Asp Phe His
 100 105 110
 Asp Pro Val Val Glu Val Glu Val Ser Val Phe Pro Ala Ser Thr Ser
 115 120 125
 Met Thr Pro Ala Ser Ile Thr
 130 135

WO 01/55335

PCT/US01/02570

<210> 62
 <211> 201
 <212> PRT
 <213> Homo sapiens

<400> 62
 Leu Leu Pro Ala Leu Leu Leu Leu Cys Leu Ser Gly Cys Leu Ser Leu
 1 5 10 15
 Lys Gly Pro Gly Ser Val Thr Gly Thr Ala Gly Asp Ser Leu Thr Val
 20 25 30
 Trp Cys Gln Tyr Glu Ser Met Tyr Lys Gly Tyr Asn Lys Tyr Trp Cys
 35 40 45
 Arg Gly Gln Tyr Asp Thr Ser Cys Glu Ser Ile Val Glu Thr Lys Gly
 50 55 60
 Glu Glu Lys Val Glu Arg Asn Gly Arg Val Ser Ile Arg Asp His Pro
 65 70 75 80
 Glu Ala Leu Ala Phe Thr Val Thr Met Gln Asn Leu Asn Glu Asp Asp
 85 90 95
 Ala Gly Ser Tyr Trp Cys Lys Ile Gln Thr Val Trp Val Leu Asp Ser
 100 105 110
 Trp Ser Arg Asp Pro Ser Asp Leu Val Arg Val Tyr Val Ser Pro Ala
 115 120 125
 Ile Thr Thr Pro Arg Arg Thr Thr His Pro Ala Thr Pro Pro Ile Phe
 130 135 140
 Leu Val Val Asn Pro Gly Arg Asn Leu Ser Thr Arg Glu Val Leu Thr
 145 150 155 160
 Gln Asn Ser Gly Phe Arg Leu Ser Ser Pro His Phe Leu Leu Val Val
 165 170 175
 Leu Leu Lys Leu Pro Leu Leu Leu Ser Met Leu Gly Ala Val Phe Trp
 180 185 190
 Val Asn Arg Pro Gln Trp Ala Pro Pro
 195 200

<210> 63
 <211> 438
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)..(438)
 <223> n = A, T, G, or C

<400> 63
 ttctgctcctg ccaacagcaa tgtgacgctg cgatgttgga ctctgccag aggtgtgagc 60
 ttgtttctca ggaagggagg aattattctg gagtccccga agccccttga ttctacagag 120
 ggcgcggccg aatttcacct caataatcta aaagtcagaa atgctggaga gtacacctgt 180
 gaatactaca gaaaagcatc cccccacatc ctttcacagc gcagtgcagt ctttctactg 240
 ttggtgacag gacatttatc taaacctttc ctccgaacct accaaagggg tacagtgacc 300
 gcaggtggaa ggggtgactct gcagtgccag aagcgagacc aattgtttgt gcctatcatg 360

WO 01/55335

PCT/US01/02570

120	125	130	135	
gtg acc gca ggt gga agg gtg act ctg cag tgc cag aag cga gac caa				487
Val Thr Ala Gly Gly Arg Val Thr Leu Gln Cys Gln Lys Arg Asp Gln				
	140	145	150	
ttg ttt gtg cct atc atg ttc gct cta ctg aag gca ggg acg cca tca				535
Leu Phe Val Pro Ile Met Phe Ala Leu Leu Lys Ala Gly Thr Pro Ser				
	155	160	165	
ccc atc cag ctg cag agt cca gcg ggg aag gag ata gac ttc tct ctg				583
Pro Ile Gln Leu Gln Ser Pro Ala Gly Lys Glu Ile Asp Phe Ser Leu				
	170	175	180	
gtg gac gtg aca gcc ggc gat gct ggg aac tac agc tgc atg tac tac				631
Val Asp Val Thr Ala Gly Asp Ala Gly Asn Tyr Ser Cys Met Tyr Tyr				
	185	190	195	
cag aca aag tct ccc ttc tgg gcc tca gaa ccc agt gat cag ctt gag				679
Gln Thr Lys Ser Pro Phe Trp Ala Ser Glu Pro Ser Asp Gln Leu Glu				
	200	205	210	215
ata ttg gtg aca gtt ccc cca ggt acc aca tcg agc aac tac tcc ctg				727
Ile Leu Val Thr Val Pro Pro Gly Thr Thr Ser Ser Asn Tyr Ser Leu				
	220	225	230	
ggt aac ttc gta cga ctg ggt ctg gct gcc gta att gtg gtt atc atg				775
Gly Asn Phe Val Arg Leu Gly Leu Ala Ala Val Ile Val Val Ile Met				
	235	240	245	
gga gct ttc ctg gtg gag gcc tgg tac agc cgg aat gtg tct cca ggt				823
Gly Ala Phe Leu Val Glu Ala Trp Tyr Ser Arg Asn Val Ser Pro Gly				
	250	255	260	
gaa tca gag gcc ttc aaa cca gag tga				850
Glu Ser Glu Ala Phe Lys Pro Glu				
	265	270		

<210> 66

<211> 271

<212> PRT

<213> Homo sapiens

<400> 66

Met	Ile	Pro	Lys	Leu	Leu	Ser	Leu	Leu	Cys	Phe	Arg	Leu	Cys	Val	Gly
1				5					10					15	
Gln	Gly	Asp	Thr	Arg	Gly	Asp	Gly	Ser	Leu	Pro	Lys	Pro	Ser	Leu	Ser
			20					25					30		
Ala	Trp	Pro	Ser	Ser	Val	Val	Pro	Ala	Asn	Ser	Asn	Val	Thr	Leu	Arg
			35				40					45			
Cys	Trp	Thr	Pro	Ala	Arg	Gly	Val	Ser	Phe	Val	Leu	Arg	Lys	Gly	Gly
	50					55					60				
Ile	Ile	Leu	Glu	Ser	Pro	Lys	Pro	Leu	Asp	Ser	Thr	Glu	Gly	Ala	Ala
65					70					75					80
Glu	Phe	His	Leu	Asn	Asn	Leu	Lys	Val	Arg	Asn	Ala	Gly	Glu	Tyr	Thr
				85					90					95	
Cys	Glu	Tyr	Tyr	Arg	Lys	Ala	Ser	Pro	His	Ile	Leu	Ser	Gln	Arg	Ser
			100					105					110		
Asp	Val	Leu	Leu	Leu	Leu	Val	Thr	Gly	His	Leu	Ser	Lys	Pro	Phe	Leu
		115					120					125			
Arg	Thr	Tyr	Gln	Arg	Gly	Thr	Val	Thr	Ala	Gly	Gly	Arg	Val	Thr	Leu
	130					135					140				
Gln	Cys	Gln	Lys	Arg	Asp	Gln	Leu	Phe	Val	Pro	Ile	Met	Phe	Ala	Leu

WO 01/55335

PCT/US01/02570

145		150		155		160									
Leu	Lys	Ala	Gly	Thr	Pro	Ser	Pro	Ile	Gln	Leu	Gln	Ser	Pro	Ala	Gly
		165		170		175									
Lys	Glu	Ile	Asp	Phe	Ser	Leu	Val	Asp	Val	Thr	Ala	Gly	Asp	Ala	Gly
		180		185		190									
Asn	Tyr	Ser	Cys	Met	Tyr	Tyr	Gln	Thr	Lys	Ser	Pro	Phe	Trp	Ala	Ser
		195		200		205									
Glu	Pro	Ser	Asp	Gln	Leu	Glu	Ile	Leu	Val	Thr	Val	Pro	Pro	Gly	Thr
		210		215		220									
Thr	Ser	Ser	Asn	Tyr	Ser	Leu	Gly	Asn	Phe	Val	Arg	Leu	Gly	Leu	Ala
		225		230		235									
Ala	Val	Ile	Val	Val	Ile	Met	Gly	Ala	Phe	Leu	Val	Glu	Ala	Trp	Tyr
		245		250		255									
Ser	Arg	Asn	Val	Ser	Pro	Gly	Glu	Ser	Glu	Ala	Phe	Lys	Pro	Glu	
		260		265		270									

<210> 67
 <211> 816
 <212> DNA
 <213> Homo sapiens

<400> 67
 atgatcccta agctgctttc cctcctctgt ttcagactgt gcgtgggcca aggagacaca 60
 aggggagatg ggtcactgcc caagccgtcc ctcaagtgcct ggcccagctc ggtgggttcct 120
 gccaacagca atgtgacgct gcgatgttgg actcctgccca gaggtgtgag ctttggttctc 180
 aggaaggag gaattattct ggagtcctccg aagccccttg attctacaga gggcgcgggcc 240
 gaatttcacc tcaataatct aaaagtcaga aatgctggag agtacacctg tgaatactac 300
 agaaaagcat cccccacat cctttcacag cgcagtgcg tccttctact gttgggtgaca 360
 ggacatttat ctaaaccctt cctccgaacc taccaaagg gtacagtgc cgcagggtgga 420
 aggggtgactc tgcagtgcc gaagcgagac caattgtttg tgcctatcat gttcgctcta 480
 ctgaaggcag ggacgccatc acccatccag ctgcagagtc cagcggggaa ggagatagac 540
 ttctctctgg tggacgtgac agccggcgat gctgggaact acagctgcat gtactaccag 600
 acaaagtctc ccttctgggc ctcagaaccc agtgatcagc ttgagatatt ggtgacagtt 660
 cccccaggta ccacatcgag caactactcc ctgggtaact tcgtacgact gggctctggct 720
 gccgtaattg tggttatcat gggagctttc ctgggtggagg cctgggtacag ccggaatgtg 780
 tctccagggtg aatcagaggc cttcaaacca gagtga 816

<210> 68
 <211> 36
 <212> PRT
 <213> Homo sapiens

<400> 68
 Gly Ser Leu Pro Lys Pro Ser Leu Ser Ala Trp Pro Ser Ser Val Val
 1 5 10 15
 Pro Ala Asn Ser Asn Val Thr Leu Arg Cys Trp Thr Pro Ala Arg Gly
 20 25 30
 Val Ser Phe Val
 35

<210> 69
 <211> 52
 <212> PRT
 <213> Homo sapiens

<400> 69
 Cys Val Gly Gln Gly Asp Thr Arg Gly Asp Gly Ser Leu Pro Lys Pro
 1 5 10 15

WO 01/55335

PCT/US01/02570

Ser Leu Ser Ala Trp Pro Ser Ser Val Val Pro Ala Asn Ser Asn Val
 20 25 30

Thr Leu Arg Cys Trp Thr Pro Ala Arg Gly Val Ser Phe Val Leu Arg
 35 40 45

Lys Gly Gly Ile
 50

<210> 70

<211> 52

<212> PRT

<213> Homo sapiens

<400> 70

Arg Ser Asp Val Leu Leu Leu Leu Val Thr Gly His Leu Ser Lys Pro
 1 5 10 15

Phe Leu Arg Thr Tyr Gln Arg Gly Thr Val Thr Ala Gly Gly Arg Val
 20 25 30

Thr Leu Gln Cys Gln Lys Arg Asp Gln Leu Phe Val Pro Ile Met Phe
 35 40 45

Ala Leu Leu Lys
 50

<210> 71

<211> 16

<212> PRT

<213> Homo sapiens

<400> 71

Met Ile Pro Lys Leu Leu Ser Leu Leu Cys Phe Arg Leu Cys Val Gly
 1 5 10 15

<210> 72

<211> 255

<212> PRT

<213> Homo sapiens

<400> 72

Gln Gly Asp Thr Arg Gly Asp Gly Ser Leu Pro Lys Pro Ser Leu Ser
 1 5 10 15

Ala Trp Pro Ser Ser Val Val Pro Ala Asn Ser Asn Val Thr Leu Arg
 20 25 30

Cys Trp Thr Pro Ala Arg Gly Val Ser Phe Val Leu Arg Lys Gly Gly
 35 40 45

Ile Ile Leu Glu Ser Pro Lys Pro Leu Asp Ser Thr Glu Gly Ala Ala
 50 55 60

Glu Phe His Leu Asn Asn Leu Lys Val Arg Asn Ala Gly Glu Tyr Thr
 65 70 75 80

Cys Glu Tyr Tyr Arg Lys Ala Ser Pro His Ile Leu Ser Gln Arg Ser
 85 90 95

WO 01/55335

PCT/US01/02570

Asp Val Leu Leu Leu Leu Val Thr Gly His Leu Ser Lys Pro Phe Leu
 100 105 110
 Arg Thr Tyr Gln Arg Gly Thr Val Thr Ala Gly Gly Arg Val Thr Leu
 115 120 125
 Gln Cys Gln Lys Arg Asp Gln Leu Phe Val Pro Ile Met Phe Ala Leu
 130 135 140
 Leu Lys Ala Gly Thr Pro Ser Pro Ile Gln Leu Gln Ser Pro Ala Gly
 145 150 155 160
 Lys Glu Ile Asp Phe Ser Leu Val Asp Val Thr Ala Gly Asp Ala Gly
 165 170 175
 Asn Tyr Ser Cys Met Tyr Tyr Gln Thr Lys Ser Pro Phe Trp Ala Ser
 180 185 190
 Glu Pro Ser Asp Gln Leu Glu Ile Leu Val Thr Val Pro Pro Gly Thr
 195 200 205
 Thr Ser Ser Asn Tyr Ser Leu Gly Asn Phe Val Arg Leu Gly Leu Ala
 210 215 220
 Ala Val Ile Val Val Ile Met Gly Ala Phe Leu Val Glu Ala Trp Tyr
 225 230 235 240
 Ser Arg Asn Val Ser Pro Gly Glu Ser Glu Ala Phe Lys Pro Glu
 245 250 255

<210> 73
 <211> 24
 <212> PRT
 <213> Homo sapiens

<400> 73
 Leu Gly Asn Phe Val Arg Leu Gly Leu Ala Ala Val Ile Val Val Ile
 1 5 10 15

Met Gly Ala Phe Leu Val Glu Ala
 20

<210> 74
 <211> 132
 <212> PRT
 <213> Homo sapiens

<400> 74
 Gly Ala Ile Met Ile Pro Lys Leu Leu Ser Leu Leu Cys Phe Arg Leu
 1 5 10 15

Arg Val Gly Gln Gly Asp Thr Arg Gly Asp Gly Ser Leu Pro Lys Pro
 20 25 30

Ser Leu Ile Ala Trp Pro Thr Ser Val Val Pro Ala Asn Ser Asn Val
 35 40 45

Thr Leu Arg Cys Trp Thr Pro Ala Arg Gly Val Ser Cys Val Leu Arg
 50 55 60

Lys Gly Gly Ile Ile Leu Glu Ser Pro Lys Pro Leu Asp Ser Thr Glu
 65 70 75 80

WO 01/55335

PCT/US01/02570

Gly Ala Asp Glu Cys His Leu Tyr Asn Leu Lys Val Arg Asn Ala Gly
85 90 95

Glu Tyr Thr Cys Glu Tyr Tyr Arg Lys Ala Cys Pro His Ile Leu Ser
100 105 110

Gln Ser Ser Asp Asp Leu Leu Leu Met Val Thr Gly His Leu Cys Lys
115 120 125

Pro Leu Leu Arg
130

<210> 75

<211> 203

<212> PRT

<213> Homo sapiens

<400> 75

Met Ser Pro Ser Pro Thr Ala Leu Phe Cys Leu Gly Leu Cys Leu Gly
1 5 10 15

Arg Val Pro Ala Gln Ser Gly Pro Leu Pro Lys Pro Ser Leu Gln Ala
20 25 30

Leu Pro Ser Ser Leu Val Pro Leu Glu Lys Pro Val Thr Leu Arg Cys
35 40 45

Gln Gly Pro Pro Gly Val Asp Leu Tyr Arg Leu Glu Lys Leu Ser Ser
50 55 60

Ser Arg Tyr Gln Asp Gln Ala Val Leu Phe Ile Pro Ala Met Lys Arg
65 70 75 80

Ser Leu Ala Gly Arg Tyr Arg Cys Ser Tyr Gln Asn Gly Ser Leu Trp
85 90 95

Ser Leu Pro Ser Asp Gln Leu Glu Leu Val Ala Thr Gly Val Phe Ala
100 105 110

Lys Pro Ser Leu Ser Ala Gln Pro Gly Pro Ala Val Ser Ser Gly Gly
115 120 125

Asp Val Thr Leu Gln Cys Gln Thr Arg Tyr Gly Phe Asp Gln Phe Ala
130 135 140

Leu Tyr Lys Glu Gly Asp Pro Ala Pro Tyr Lys Asn Pro Glu Arg Trp
145 150 155 160

Tyr Arg Ala Ser Phe Pro Ile Ile Thr Val Thr Ala Ala His Ser Gly
165 170 175

Thr Tyr Arg Cys Tyr Ser Phe Ser Ser Arg Asp Pro Tyr Leu Trp Ser
180 185 190

Ala Pro Ser Asp Pro Leu Glu Leu Val Val Thr
195 200

<210> 76

<211> 228

<212> PRT

<213> Homo sapiens

WO 01/55335

PCT/US01/02570

<400> 76

```

Pro Lys Pro Trp Leu Gly Ala Gln Pro Ala Thr Val Val Thr Pro Gly
 1           5           10           15

Val Asn Val Thr Leu Arg Cys Arg Ala Pro Gln Pro Ala Trp Arg Phe
          20           25           30

Gly Leu Phe Lys Pro Gly Glu Ile Ala Pro Leu Leu Phe Arg Asp Val
          35           40           45

Ser Ser Glu Leu Ala Glu Phe Phe Leu Glu Glu Val Thr Pro Ala Gln
          50           55           60

Gly Gly Ser Tyr Arg Cys Cys Tyr Arg Arg Pro Asp Trp Gly Pro Gly
 65           70           75           80

Val Trp Ser Gln Pro Ser Asp Val Leu Glu Leu Leu Val Thr Glu Glu
          85           90           95

Leu Pro Arg Pro Ser Leu Val Ala Leu Pro Gly Pro Val Val Gly Pro
          100          105          110

Gly Ala Asn Val Ser Leu Arg Cys Ala Gly Arg Leu Arg Asn Met Ser
          115          120          125

Phe Val Leu Tyr Arg Glu Gly Val Ala Ala Pro Leu Gln Tyr Arg His
          130          135          140

Ser Ala Gln Pro Trp Ala Asp Phe Thr Leu Leu Gly Ala Arg Ala Pro
145           150           155           160

Gly Thr Tyr Ser Cys Tyr Tyr His Thr Pro Ser Ala Pro Tyr Val Leu
          165           170           175

Ser Gln Arg Ser Glu Val Leu Val Ile Ser Trp Glu Asp Ser Gly Ser
          180           185           190

Ser Asp Tyr Thr Arg Gly Asn Leu Val Arg Leu Gly Leu Ala Gly Leu
          195           200           205

Val Leu Ile Ser Leu Gly Ala Leu Val Thr Phe Asp Trp Arg Ser Gln
          210          215          220

Asn Arg Ala Pro
225

```

<210> 77

<211> 6

<212> PRT

<213> Homo sapiens

<220>

<221> DOMAIN

<222> (1)..(6)

<223> X1 = I, L or V; X2 = any amino acid; X4 = any
amino acid; X5 = any amino acid; and X6 = L or V

<400> 77

```

Xaa Xaa Tyr Xaa Xaa Xaa
 1           5

```

WO 01/55335**PCT/US01/02570**

<210> 78
<211> 4
<212> PRT
<213> Homo sapiens

<220>
<221> DOMAIN
<222> (1)..(4)
<223> X = any amino acid

<400> 78
Tyr Xaa Xaa Leu
1

CLAIMS

WE CLAIM:

- 5 1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 2, 4-5, 7, 17-18, 20-21, 23, 36, 38-39, 41, 48-49, 51, 64-65 and 67, the translated protein coding portion thereof, the mature protein coding portion thereof, the extracellular portion thereof, or the active domain thereof.
- 10 2. An isolated polynucleotide encoding a polypeptide with biological activity, said polynucleotide having greater than about 98% sequence identity with the polynucleotide of claim 1.
3. The polynucleotide of claim 1 which is a DNA sequence.
- 15 4. An isolated polynucleotide which comprises the complement of the polynucleotide of claim 1.
5. A vector comprising the polynucleotide of claim 1.
- 20 6. An expression vector comprising the polynucleotide of claim 1.
7. A host cell genetically engineered to express the polynucleotide of claim 1.
- 25 8. The host cell of claim 7 wherein the polynucleotide is in operative association with a regulatory sequence that controls expression of the polynucleotide in the host cell.
- 30 9. An isolated polypeptide comprising an amino acid sequence which is at least 95% identical to the amino acid sequence selected from the group consisting of SEQ ID NO: 3, 6, 8-13, 19, 22, 24-28, 33-34, 37, 42-45, 50, 52-58, 66, 68-73, and 74 the translated protein coding portion thereof, the mature protein coding portion thereof, the extracellular portion thereof, or the active domain thereof.

10. A composition comprising the polypeptide of claim 9 and a carrier.
11. A polypeptide, having LIR-like activity, comprising at least ten
5 consecutive amino acids from the polypeptide sequences selected from the group consisting of
SEQ ID NO: 3, 6, 8-13, 19, 22, 24-28, 33-34, 37, 42-45, 50, 52-58, 66, 68-73 and 74.
12. The polypeptide of claim 11, comprising at least five consecutive amino
acids from the polypeptide sequences selected from the group consisting of SEQ ID NO: 3, 6,
10 8-13, 19, 22, 24-28, 33-34, 37, 42-45, 50, 52-58, 66, 68-73, and 74.
13. A polynucleotide encoding a polypeptide according to claim 11.
14. A polynucleotide encoding a polypeptide according to claim 12.
15
15. A polynucleotide encoding a polypeptide according to claim 9.
16. An antibody specific for the polypeptide of claim 9.
17. A method for detecting the polynucleotide of claim 1 in a sample,
20 comprising:
a) contacting the sample with a compound that binds to and forms a complex
with the polynucleotide of claim 1 for a period sufficient to form the complex; and
b) detecting the complex, so that if a complex is detected, the polynucleotide
25 claim 1 is detected.
18. A method for detecting the polynucleotide of claim 1 in a sample,
comprising:
a) contacting the sample under stringent hybridization conditions with
30 nucleic acid primers that anneal to the polynucleotide of claim 1 under such conditions;
b) amplifying a product comprising at least a portion of the polynucleotide
of claim 1; and

c) detecting said product and thereby the polynucleotide of claim 1 in the sample.

19. The method of claim 18, wherein the polynucleotide comprises an RNA molecule and the method further comprises reverse transcribing an annealed RNA molecule into a cDNA polynucleotide.

20. A method for detecting the polypeptide of claim 9 in a sample. comprising:

10 a) contacting the sample with a compound that binds to and forms a complex with the polypeptide under conditions and for a period sufficient to form the complex; and

b) detecting formation of the complex, so that if a complex formation is detected, the polypeptide of claim 9 is detected.

15

21. A method for identifying a compound that binds to the polypeptide of claim 9, comprising:

a) contacting the compound with the polypeptide of claim 9 under conditions and for a time sufficient to form a polypeptide/compound complex; and

20 b) detecting the complex, so that if the polypeptide/compound complex is detected, a compound that binds to the polypeptide of claim 9 is identified.

22. A method for identifying a compound that binds to the polypeptide of claim 9, comprising:

25 a) contacting the compound with the polypeptide of claim 9, in a cell, for a time sufficient to form a polypeptide/compound complex, wherein the complex drives expression of a reporter gene sequence in the cell; and

b) detecting the complex by detecting reporter gene sequence expression, so that if the polypeptide/compound complex is detected, a compound that binds to the polypeptide of claim 9 is identified.

30

23. A method of producing an LIR-like polypeptide, comprising.

a) culturing the host cell of claim 7 under conditions sufficient to express the polypeptide in said cell; and

- b) isolating the polypeptide from the cell culture or cells of step (a).

24. A kit comprising the polypeptide of claim 9.

5 25. A nucleic acid array comprising the polynucleotide of claim 1 or a unique segment of the polynucleotide of claim 1 attached to a surface.

 26. The array of claim 25, wherein the array detects full-matches to the polynucleotide or a unique segment of the polynucleotide of claim 1.

10

 27. The array of claim 25, wherein the array detects mismatches to the polynucleotide or a unique segment of the polynucleotide of claim 1.

 28. A method of treatment of a subject in need of enhanced activity or expression of LIR-like polypeptide of claim 9 comprising administering to the subject a composition selected from the group consisting of:

15

- (a) a therapeutic amount of a agonist of said polypeptide;
 - (b) a therapeutic amount of the polypeptide; and
 - (c) a therapeutic amount of a polynucleotide encoding the polypeptide in
- 20 a form and under conditions such that the polypeptide is produced, and a pharmaceutically acceptable carrier.

20

 29. A method of treatment of a subject having need to inhibit activity or expression of LIR-like polypeptide comprising administering to the subject a composition selected from the group consisting of:

25

- (a) a therapeutic amount of an antagonist to said polypeptide;
 - (b) a therapeutic amount of a nucleic acid molecule that inhibits the expression of the nucleotide sequence encoding said polypeptide; and
 - (c) a therapeutic amount of a polypeptide that competes with the LIR-
- 30 like polypeptide for its ligand and a pharmaceutically acceptable carrier.

30

BLASTX ALIGNMENT OF SEQ ID NO: 3 LEUKOCYTE IMMUNOGLOBULIN RECEPTOR-LIKE POLYPEPTIDE (IDENTIFIED AS "LIR-LIKE") WITH HUMAN IRC1A HOMOLOG SEQ ID NO: 14

Query: Leukocyte immunoglobulin receptor-like polypeptide (SEQ ID 3)
Subject: Human IRC1a homolog (SEQ ID NO: 14)

emb|CAB52291.1| (AJ010101) IRC1a [Homo sapiens] >emb|CAB55347.1| (AJ224864)
IRC1 [Homo sapiens]
Length = 299

Score = 331 (116.5 bits), Expect = 2.4e-28, P = 2.4e-28
Identities = 110/297 (37%), Positives = 164/297 (55%)

Query:	135	LLFWLSGYSIATQITGPTTVNGLERGLTVQCVYRSGWETYLKWCRCGAIWRDCKILVK	314
		LLL W+ G ++ TV G GSL+VQC Y T K+WCR C +V+	
Sbjct:	7	LLLLWPGCFALSKCR---TVAGPVGGSLSVQCPYEKEHRTLKNKYWCRPPQIFLCDKIVE	63
Query:	315	TSGSEQEVKRDVSIKDNQKNRTFTVTMEDLMKTDADTYWCGIE-----KTGNDLGVTVQV	482
		T GS + + RVSI+D+ N +FTVT+E+L + DA TYWCG++ + +D V V+V	
Sbjct:	64	TKGSAGK-RNGRVSIKRDSPANLSFTVTLENLTEEDAGTYWCGVDTPWLRDHFDPVVEVEV	122
Query:	483	TIDPAST---PAPTP--TSTTFTA--PVTQEE--SSSPTLTGHHLDNRHKLL--KLSVL	632
		++ PAST PA T TST TA PV+ + T + + +++ +L +L	
Sbjct:	123	SVFPASTSMTPASITAAKTSTITTAFFPVSSSTTLFAVGATHSASIQEETEVEVNSQLPLL	182
Query:	633	LPLIFTILLLLVAAASLLAWRMKYYQQAAG---MSPEQVLQPLEGDLQVADLTQLAGT	803
		L L+ +LLLLLV ASLLAWRM + KA +S + +L YA+L L +	
Sbjct:	183	LSLL-ALLLLVGASLLAWRMFQKWIKAGDHSELSQNPQKAATQSELHYANLELLMWPL	241
Query:	804	SPQKATTKLSSAQVDQVEVEYVTMASLPKEDISYASLTGAEDEQPTCYCNMGHLSHLP	983
		+ A + +VEVEY T+AS P+E++ YAS+ + N +++ P	
Sbjct:	242	QEKPAFPR-----EVEVEYSTVAS-PREELHYASVVFDSE-----NTNRIAAQRP-	284
Query:	984	RGPEEPTTEYSTISR	1025
		R E ++YS I +	
Sbjct:	285	REEEPDSDYSVIRK	298

FIG. 1

BLASTX ALIGNMENT OF SEQ ID NO: 3 LEUKOCYTE IMMUNOGLOBULIN RECEPTOR-LIKE POLYPEPTIDE (IDENTIFIED AS "LIR-LIKE") WITH HUMAN PIGR-1 SEQ ID NO: 15

Query: Leukocyte immunoglobulin receptor-like polypeptide (SEQ ID 3)
Subject: Human PIGR-1 (SEQ ID NO: 15)

sp|W99070|W99070 Human PIGR-1.
Length = 201

Score = 435 (153.1 bits), Expect = 2.5e-40, P = 2.5e-40
Identities = 95/176 (53%), Positives = 112/176 (63%)

Query:	135	LLFWLSGYSIATQITGPTTVNGLERGLTVQCVYRSGWETYLKWWCRGAIWRDCKILVK	314
		LLL LSG I GP +V E+GSLTVQC Y+ GWETY+KWWCRG W CKIL++	
Sbjct:	7	LLLLSLSG---CFSIQGPESVRAPEQGSLTVQCHYKQGWETIYKWWCRGVRWDTCKILIE	63
Query:	315	TSGSEQEVKRDVRSIKDNQKNRFTVTMEDLMKTDADTYWCGIEKTGNDLGVTVQVTIDP	494
		T GSEQ K DRVSIKDNQK+RTFTVTME L + DAD YWCGIE+ G DLG V+V +DP	
Sbjct:	64	TRGSEQGEKSDRVSIKDNQKDRFTFTVTMEGLRRDDADVWCGIERRGPDGLGTQVKVIVDP	123
Query:	495	ASTPAPTPTSTTFTAPVTQEETSSSPTLTGHHLDNRHKL---KLSVLLPLIFTILL	662
		A TT +S T S+ G H N + LL K+ +LL L+ IL L	
Sbjct:	124	EGA-ASTTASSPT-----NSNMAVFIGSHKRNHYMLLVFVKVPILLILVTAILWL	172

FIG. 2

BLASTX ALIGNMENT OF SEQ ID NO: 6 LEUKOCYTE IMMUNOGLOBULIN RECEPTOR-LIKE POLYPEPTIDE (IDENTIFIED AS "LIR-LIKE") WITH HUMAN IRC1A HOMOLOG SEQ ID NO: 14

Query: Leukocyte immunoglobulin receptor-like polypeptide (SEQ ID 6)
Sbjct: Human IRC1a homolog (SEQ ID NO: 14)

emb|CAB52291.1| (AJ010101) IRC1a [Homo sapiens] >emb|CAB55347.1| (AJ224864)
IRC1 [Homo sapiens]
Length = 299

Score = 210 (73.9 bits), Expect = 2.8e-18, Sum P(2) = 2.8e-18
Identities = 52/135 (38%), Positives = 77/135 (57%)

Query: 129 LLLFWLSGYSIVTQITGPTTVNGLERGS�TVQCVRSGWETYLKWWCRGAIWRDCKILVK 308
 LLL W+ G +++ TV G GSL+VQC Y T K+WCR C +V+
Sbjct: 7 LLLWVPGCFALSKCR---TVAGPVGGSLSVQCPYEKEHRTLNKYWCRRPPQIFLCKIVE 63

Query: 309 TSGSEQEVKRDVSIKDNQKNRFTVTMEDLMKTDADTYWCGIE----KTGNDLGVTVQV 476
 T GS + + RVSI+D+ N +FTVT+E+L + DA TYWCG++ + +D V V+V
Sbjct: 64 TKGSAGK-RNGRVSIIRDSPANLSFTVTLENLTEEDAGTYWCGVDTPWLRDFHDPVVEVEV 122

Query: 477 TIDPAPVTQEETSSSPTLT 533
 ++ PA + S + T
Sbjct: 123 SVFPASTSMTTPASITAAKT 141

FIG. 3

BLASTX ALIGNMENT OF SEQ ID NO: 6 LEUKOCYTE IMMUNOGLOBULIN RECEPTOR-LIKE POLYPEPTIDE (IDENTIFIED AS "LIR-LIKE") WITH HUMAN PIGR-1 SEQ ID NO: 15

Query: Leukocyte immunoglobulin receptor-like polypeptide (SEQ ID 6)
Sbjct: Human PIGR-1 (SEQ ID NO: 15)

sp|W99070|W99070 Human PIGR-1.
Length = 201

Score = 422 (148.6 bits), Expect = 5.9e-39, P = 5.9e-39
Identities = 86/145 (59%), Positives = 98/145 (67%)

Query:	129	LLFLWLSGYSIVTQITGPTTVNGLERGLTVQCVYRSGWETYLKWWCRGAIWRDCKILVK	308
		LLL LSG I GP +V E+GSLTVQC Y+ GWETY+KWWCRG W CKIL++	
Sbjct:	7	LLLLSLG---CFSIQGPESVRAP EQGSLTVQCHYKQGWETIYIKWWCRGVVRWDTCKILIE	63
Query:	309	TSGSEQEVKRDVSIKDNQKNRFTFTVMTEDLMKTDADTYWCGIEKTGNDLGVTVQVTIDP	488
		T GSEQ K DRVSIKDNQK+RTFTVTME L + DAD YWCGIE+ G DLG V+V +DP	
Sbjct:	64	TRGSEQGEKSDRVSIKDNQKDRFTFTVMEGLRRDDADVWCGIERRGPD LGTQVKVIVDP	123
Query:	489	APVTQEETSSSPT-----LTGHLDNRY	557
		T+SSPT G H N Y	
Sbjct:	124	EGAAST-TASSPTNSNMAVFIGSHKRNY	151

BLASTP ALIGNMENT OF SEQ ID NO: 19 LEUKOCYTE IMMUNOGLOBULIN RECEPTOR-LIKE POLYPEPTIDE (IDENTIFIED AS "LIR-LIKE") WITH PUTATIVE INHIBITORY RECEPTOR SEQ ID NO: 29

Query: Leukocyte immunoglobulin receptor-like polypeptide (SEQ ID NO: 19)
Sbjct: Putative inhibitory receptor (SEQ ID NO: 29)

gb|AAC50928.1| (U70665) putative inhibitory receptor [Homo sapiens]
Length = 151

Score = 164 (57.7 bits), Expect = 9.0e-11, P = 9.0e-11
Identities = 49/145 (33%), Positives = 74/145 (51%)

Query: 1 MTAEFLSLCLGLCLGDEKKEKPPKPSLHAWPSSVVEAESNVTLKCAHSQNVTFVL 60
MT L+CLGL LG + PKP+L A P SV+ S VTL+CQ Q + L
Sbjct: 1 MTPILTVLICLGLSLGPRTHVQAGHLPKPTLWAEPPGSVLIQSPVTLRCQGSQAEEYHL 60

Query: 61 RKVNDG--YKQEQSSAENEAEFFFTDLKPKDAGRYFCAYKTTASHEWSESSEHLQLVVT 118
+ N S ++ Q +N +FP + + AGRY C Y + +H SE S+ L+LVVT
Sbjct: 61 YRENKSASWVRRRIQEPGN-GQFPISITWEHAGRYHCQYYSH-NHS-SEYSDPLELVVT 117

Query: 119 DKHDELEAPSMKTDTRTIFVAI-FSCIS 146
+ + ++ + T+ + C+S
Sbjct: 118 GAYSKPTLSALPSPVVTLGNNVTLCQVS 145

FIG. 5

BLASTP ALIGNMENT OF SEQ ID NO: 19 LEUKOCYTE IMMUNOGLOBULIN RECEPTOR-LIKE POLYPEPTIDE (IDENTIFIED AS "LIR-LIKE") WITH HUMAN GP49 HM18 POLYPEPTIDE SEQ ID NO: 30

Query: Leukocyte immunoglobulin receptor-like polypeptide (SEQ ID NO: 19)
Sbjct: Human gp49 HM18 polypeptide (SEQ ID NO: 30)

sp|W53463|W53463 Human gp49 HM18 polypeptide.
Length = 448

Score = 160 (56.3 bits), Expect = 2.2e-10, Sum P(2) = 2.2e-10
Identities = 42/123 (34%), Positives = 62/123 (50%)

Query: 1 MTAEFLSLCLGLCLGYEDEKKNEKPKPSLHAWPSSVVEAESNVTLKCAHSQNVTFVL 60
M F +LLCLGL LG + PKP+L A P SV+ ++VT+ CQ + + L
Sbjct: 1 MIPTFTALLCLGLSLGPRTHMQAGPLPKPTLWAEPGSVISWGNSTIWCQGTLEAREYRL 60

Query: 61 RKNVDSGYKQEQSSAE--NEAEFPFTDLKPKDAGRYFCAYKTTASHEWSESSEHLQLVVT 118
K Q+ E N+A F + AGRY C Y++ WS+ S+ L+LV+T
Sbjct: 61 DKEESPAPWDRQNPLEPKNKARFSPMTEDYAGRYRCYRSPVG--WSQSPDPLELVMT 118

Query: 119 DKHDE 123
+ +
Sbjct: 119 GAYSK 123

FIG. 6

BLASTP ALIGNMENT OF SEQ ID NO: 22 LEUKOCYTE IMMUNOGLOBULIN RECEPTOR-LIKE POLYPEPTIDE (IDENTIFIED AS "LIR-LIKE") WITH IMMUNOGLOBULIN-LIKE PROTEIN IGSF1
SEQ ID NO: 31

Query: Leukocyte immunoglobulin receptor-like polypeptide (SEQ ID NO: 22)
Sbjct: Immunoglobulin-like protein IGSF1 (SEQ ID NO: 31)

pir||T09402 immunoglobulin-like protein IGSF1 - human >dbj|BAA20819.1|
(AB002362) KIAA0364 [Homo sapiens] >gb|AAC52057.1| (AF034198) IGSF1 [Homo sapiens]
Length = 1327

Score = 308 (108.4 bits), Expect = 7.3e-24, Sum P(2) = 7.3e-24
Identities = 81/209 (38%), Positives = 111/209 (53%)

Query: 31 PKPSLHAWPSSVVEAESNVTLCQAHSQNVTFVLRKVNDSGYKQEQSSAENEAEFPFTDL 86
PKP L A PSSV V NVTLC + V ++L K ++ Q S N+ FP T++
Sbjct: 960 PKPWLFAEPSSVVPMPGQNVTLWCRGPVHGVGYYLHKEGEATSMQLWGSTSDGAFPTNI 1019

Query: 87 KPKDAGRYFCAYKT--TASHEWSESSEHLQLVVTGSLPEPLLSNVNDPGMTPGLR-TLRC 143
GRY C Y T+S + + S L+L+VTG LP+P L P + PG TL+C
Sbjct: 1020 SGTSMGRYSCCYHPDWTSSIK-IQPSNTLELLVTGLLPKPSLLAQPGPMVAPGENMTLQC 1078

Query: 144 LTPYNGTECIVIALWKMGIPQLQVRQVRKNQTDFFMLWNVTGNDSGNYSCVYVLSN 199
+ +++ K G EPL+ ++ + DF + V G DSG YSCVYVYL +
Sbjct: 1079 QGELPDSTFVLL---KEGAQEPLEQQRPSPGYRADFWMPAVRGEDSGIYSCVYVYLD 1131

Query: *SHLASFPSNKLKLEIWTDKHDELEAPSMKTDRTIF
AS S+ LEIWTDK + PS+ T+F
Sbjct: 1132 TPFAASNHSDSLEIWTDKPPK---PSLSAWPSTMF 1164

NOTE: * = stop codon at position 199 in Seq No 3 geneseq blastp alignment.

FIG. 7

BLASTP ALIGNMENT OF SEQ ID NO: 22 LEUKOCYTE IMMUNOGLOBULIN RECEPTOR-LIKE POLYPEPTIDE (IDENTIFIED AS "LIR-LIKE") WITH HUMAN LIR-PBM36-2 PROTEIN SEQ ID NO: 32

Query: Leukocyte immunoglobulin receptor-like polypeptide (SEQ ID NO: 22)
Sbjct: Human LIR-pbm36-2 protein (SEQ ID NO: 32)

sp|W82548|W82548 Human LIR-pbm36-2 protein.
Length = 289

Score = 232 (81.7 bits), Expect = 3.1e-18, P = 3.1e-18
Identities = 76/236 (32%), Positives = 110/236 (46%)

Query: 1 MTAEFLLCLGLCLGYEDEKKNEKPPKPSLHAWPSSVVEAESNVTLCQA--HSQNVTF 58
MT L+CLGL LG + PKP+L A P SV+ S VTL CQ +Q
Sbjct: 1 MTPILTVLICLGLSLGPRTHVQAGTLPKPRTLWAEFGSVITQGSPTLWCQGILETQEYRL 60

Query: 59 VLRKVNDSGYKQEQSSAENEAEFFPTDLKPKDAGRYFCAYKT-TASHEWSESSEHLQLVV 117
K + +FP + + GRY C Y + TA WSE S+ L+LVV
Sbjct: 61 YREKKTAPWITRIPQEIYKKGQFPISITWEHTGRYRCFYGSHTAG--WSEPSDPLELVV 118

Query: 118 TGSLEPELLSVNVDPGMPGLR-TLRCLTPYNGTECIVIALWKMGIPEPL--QVRQVRKN 174
TG+ +P LS P +T G TL C++ I+ + P+ L Q R +
Sbjct: 119 TGAYIKPTLSALPSPVVTSGGNVTLHCVSQVAFGSFILCKEGEDHPQCLNSQPRTHGWS 178

Query: 175 QTDFMLWNVTGNDSGNYSCVYLSN 199
+ F + V+ + +Y C Y SN
Sbjct: 179 RAIFSVGPFVSPSRRWSYRCYAYDSN 203

Query: *SHLASFPSNKLFIWTDKHDELEAPSMKTDTR
H+ S PS+ LE+ V + L P K+D++
Sbjct: 204 SPHVWSLPSDLLLELLVPGAAETLSPPPQNKSDSK 236

NOTE: * = stop codon at position 199 in Seq No 22 geneseq blastp alignment.

FIG. 8

MOLECULAR SIMULATIONS INC (MSI) GENEATLAS ALIGNMENT OF SEQ ID NO: 37 AND 40,
LEUKOCYTE IMMUNOGLOBULIN RECEPTOR-LIKE POLYPEPTIDE (IDENTIFIED AS "LIR-
LIKE") WITH HUMAN P58 KILLER CELL INHIBITORY RECEPTOR, 1B6U (PDB NO) SEQ ID
NO: 46

QUERY : Leukocyte immunoglobulin receptor-like polypeptide (SEQ ID 37 and 40)
Subject: P58 Killer cell inhibitory receptor, 1b6u (pdb number) (SEQ ID NO: 46)

Score = 0.45

Identities = 20/103(19.4%), Positives = 34/103(33.0%)

Sbjct: 4 PSLLAHPGPLVKSEETVILQCWSDVRFQ--HFLHREGKFKDTHLHIGEHDGVSKANFS 61
PS+ P E+ + + C + F +F L+R G+ L N S
Query: 18 PSIRLVPPYPSSQEDPIHIACMAPGNFPGANFTLYRGGQVVQLLQAP--TDQRGVTFNLS 75

Sbjct: 62 IGPMMQDLAGTYRCYGSVTHSPYQLSAPSDPLD-IVITGLYEKPSL 106
G + G + C S SD + + ++ L
Query: 76 -GGSSKAPGGPFHCQ-YGVLGELNQSLSDLSEPVNVSFVPVTWIL 119

FIG. 9

BLASTX ALIGNMENT OF SEQ ID NO: 50 LEUKOCYTE IMMUNOGLOBULIN RECEPTOR-LIKE POLYPEPTIDE (IDENTIFIED AS "LIR-LIKE") WITH HUMAN CMRF 35 ANTIGEN SEQ ID NO: 60

Query : Leukocyte immunoglobulin receptor-like polypeptide (SEQ ID 50)
Subject: CMRF35 antigen
gi|5729776 ref|NP_006669.1| CMRF35 antigen >sp|Q08708|CM35_HUMAN CMRF35 ANTIGEN PRECURSOR >pir||I37243 CMRF-35 antigen - human >emb|CAA46948.1| (X66171) CMRF-35 antigen [Homo sapiens] (SEQ ID NO: 60)
Length = 224

Score = 421 (153.3 bits), Expect = 1.6e-38, P = 1.6e-38
Identities = 105/217 (48%), Positives = 135/217 (62%)

Query: 210 MTQRAGAAMLPSALLLLCVPGCLTVSGPSTVMGAVGESLSVQCRYEKTKFNKYWCRQP 389
MT RA A+ SALLLL VPG +S P TV G VG SLSVQCRYE+++T NK+WCR P
Sbjct: 1 MTARAWASWRSSALLLLVPGYFFPLSHPMTVAGPVGGSLSVQCRYEKEHRTLKFWCRPP 60

Query: 390 CLPIWHEMVETGGSEGVVRSQDQVIITDHPGDLTFTVTLENLTADDAGKYRCGIATILQED 569
+ ++VET GS G R+ +V I D P +L+FTVTLENLT +DAG Y CG+ T D
Sbjct: 61 QILRCDKIVETKGSAGK-RNGRVSIRDSPANLSFTVTLENLTTEEDAGTYWCGVDTPWLRD 119

Query: 570 GLSGFLPDPPFFQVQLV-----SSASSTENSVKTPASPTR-----PSQC 686
DP +V+V V ++ASS ++S+ T PT+ PS
Sbjct: 120 -----FHDPIVEVEVSVPFAGTTASSPQSSMGTSGPPTKLPVHTWPSVTRKDSPEPSPH 174

Query: 687 QGSLPSSTCFLLLLPLLLKVPLLLLSILGAILWVNRPWRT 797
GSL S+ FLLL LL++PLLLS+LGA+LWVNRP R+
Sbjct: 175 PGSLSNVRFLLLVLELPLLLSMLGAVLWVNRPQRS 211

FIG. 10

BLASTX ALIGNMENT OF SEQ ID NO: 50 LEUKOCYTE IMMUNOGLOBULIN RECEPTOR-LIKE
POLYPEPTIDE (IDENTIFIED AS "LIR-LIKE") WITH HUMAN NK CELL INHIBITORY
RECEPTOR PROTEIN SEQ ID NO: 61

Query : Leukocyte immunoglobulin receptor-like polypeptide (SEQ ID 50)
Subject: Natural Killer (NK) inhibitory receptor (SEQ ID NO: 61)
>emb|CAB66145.1| (AJ238323) NK inhibitory receptor [Homo sapiens]
Length = 299

Score = 318 (117.0 bits), Expect = 1.3e-27, P = 1.3e-27
Identities = 74/145 (51%), Positives = 94/145 (64%)

Query: 237 LPSALLLLCVPGLTVSGPSTVMGAVGESLSVQCRYEKTKFNKYWCRCQPCLPWHMV 416
LP ALLLL VPGC +S TV G VG SLSVQC YE+++T NKYWCRC P + + ++V
Sbjct: 3 LPWALLLLWVPGCFALSKCRTVAGPVGSGLSVQCPYEKEHRTLNKYWCRCPPQIFLCDKIV 62

Query: 417 ETGGSEGVVRSQVVIITDHPGDLTFTVTLENLTADDAGKYRCGIATILQEDGLSGFLPDP 596
ET GS G R+ +V I D P +L+FTVTLENLT +DAG Y CG+ T +D DP
Sbjct: 63 ETKGSAGK-RNGRVSI RDS PANLSFTVTLENLT EEDAGTYWCGVDT PWLQD-----FHDP 116

Query: 597 FFQVQVLVSSASSSTENSVKTPASPT 671
+V+V V AS++ TPAS T
Sbjct: 117 VVEVEVSVPASTS-----MTPASIT 137

FIG. 11

BLASTX ALIGNMENT OF SEQ ID NO: 50 LEUKOCYTE IMMUNOGLOBULIN RECEPTOR-LIKE POLYPEPTIDE (IDENTIFIED AS "LIR-LIKE") WITH HUMAN PIGR-2 PROTEIN SEQ ID NO: 62

Query : Leukocyte immunoglobulin receptor-like polypeptide (SEQ ID 50)
Subject: Human PIGR-2 protein (SEQ ID NO: 62)

>sp|Y05069|Y05069 Human PIGR-2 protein sequence.

Score = 400 (145.9 bits), Expect = 1.3e-36, P = 1.3e-36
Identities = 97/205 (47%), Positives = 120/205 (58%)

Query: 234 MLPSALLLLCVPGCLTVSGPSTVMGAVGESLSVQCRYEEKYKTFNKYWCRCQPCLPIWHEM 413
+LP ALLLLC+ GCL++ GP +V G G+SL+V C+YE YK +NKYWCR +
Sbjct: 3 LLP-ALLLLCLSGCLSLKPGSVTGTAGDSLTVWCQYESMYKGYNKYWCRCGQYDTSCEI 61

Query: 414 VETGGSEGVVRSQVVIITDHPGDLTFTVTLENLTADDAGKYRCGIATILQEDGLSGFLPD 593
VET G E V R+ +V I DHP L FTVT++NL DDAG Y C I T+ D S D
Sbjct: 62 VETKGEKVERNGRVSIRDHPEALAFVTVMQNLNEDDAGSYWCKIQITVWVLDWSR---D 118

Query: 594 PFFQVQVLVSSASSTENSVKTPASP-----TRP--SQCGSLPSS'CFLLLP 728
P V+V VS A +T PA+P TR +Q G SS FLL+
Sbjct: 119 PSDLVRVYVSPAITTPRRRTHPATPPIFLVVNPGRNLSTREVLTONSGFRLSSPHFLLV 178

Query: 729 LLKVPLLLSILGAILWVNRP-WRTP 800
LLK+PLLLS+LGA+ WVNRP W P
Sbjct: 179 LLKLPLLLSMLGAVFWVNRPQWAPP 203

FIG. 12

MOLECULAR SIMULATIONS INC (MSI) GENEATLAS ALIGNMENT OF SEQ ID NO: 50,
LEUKOCYTE IMMUNOGLOBULIN RECEPTOR-LIKE POLYPEPTIDE (IDENTIFIED AS "LIR-
LIKE") WITH T CELL RECEPTOR, 1b88 (PDB NO) SEQ ID NO: 59

QUERY : Leukocyte immunoglobulin receptor-like polypeptide (SEQ ID 50)
Subject: T-cell receptor, 1b88 (pdb number) (SEQ ID NO: 59)

Score = 0.30

Identities = 13/112(11.6%), Positives = 33/112(29.5%)

Sbjct: 3 QVRQSPQSLTVWEGETAAILNCSYENSADFYP-WYQQFPGEGPALLISILSVSNKKEDGR 61
P ++ GE+ + C YE + W +Q ++ +
Query: 23 LTVSGPSTVMGAVGESLSVQCRYEKKYKTFNKYWCRCPLPIWHEMVEGTGGSEGVVRSDQ 82

Sbjct: 62 FTIFFNKREKKLSLHIADSQPGDSATYFCAASAS-----FGDNSKLIWGLGTSLVVNP 114
I + + ++ + + D+ Y C + G + + +
Query: 83 VIITDHPGDLTFTVTLENLTADDAGKYRCGIATILQEDGLSGFLPDPPFFQVQVLVSSAS 141

FIG. 13

BLASTP ALIGNMENT OF SEQ ID NO: 66, LEUKOCYTE IMMUNOGLOBULIN RECEPTOR-LIKE POLYPEPTIDE (IDENTIFIED AS "LIR-LIKE") WITH HUMAN PLATELET GLYCOPROTEIN VI-2 PROTEIN SEQ ID NO: 75

Query: Leukocyte immunoglobulin receptor-like polypeptide (SEQ ID NO: 66)
Sbjct: dbj|BAB12246.1| (AB043820) platelet glycoprotein VI-2 (SEQ ID NO: 75)
Length = 321

Score = 288 (106.4 bits), Expect = 1.5e-33, Sum P(2) = 1.5e-33
Identities = 83/220 (37%), Positives = 110/220 (50%)

Query: 1 MIPKLLSLLCFRLCVGQDTRGDGSLPKPSLSAWPSSVVPANSNVTLCWTPARGVS-FV 59
M P +L C LC+G+ + G LPKPSL A PSS+VP VTLRC P GV +
Sbjct: 1 MSPSPTALFCLGLCLGRVPAQS-GPLPKPSLQALPSSLVPLEKPVTLRCQGPP-GVDLYR 58

Query: 60 LRKGGIILESPKPLDSTEGAAEFHLNNLKVRNAGEYTCYYRKASPHILSQRSDVLLLV 119
L K L S + D A + +K AG Y C Y + + S SD L L+
Sbjct: 59 LEK-----LSSRYQDQ-----AVLFIPAMKRSLAGRYRCSYQNGS---LWSLPSDQLELVA 107

Query: 120 TGHLSKPFRLRTYQRGTVTAGGRVTLQCQKRDQLFVPIMFALLKAGTPSPIQLQSPAGKEI 179
TG +KP L V++GG VTLQCQ R + FAL K G P+P +
Sbjct: 108 TGVFAKPSLSAQPGPAVSSGGDVTLQCQTR---YGFDDQFALYKEGDPAPYK-NPERWYRA 163

Query: 180 DFSLVDVVTAGDAGNYSCMYYYQTKSPFWASEPSDQLEILVT 219
F ++ VTA +G Y C + ++ P+ S PSD LE++VT
Sbjct: 164 SFPIITVFAAHSGTYRCYSFSSRDPYLWSAPSDPLELVVT 203

FIG. 14

BLASTP ALIGNMENT OF SEQ ID NO: 66, LEUKOCYTE IMMUNOGLOBULIN RECEPTOR-LIKE POLYPEPTIDE (IDENTIFIED AS "LIR-LIKE") WITH HUMAN FCRII PROTEIN SEQ ID NO: 76

Query: Leukocyte immunoglobulin receptor-like polypeptide (SEQ ID NO: 66)
Sbjct: sp|W69232|W69232 FcR-II protein sequence (SEQ ID NO: 76)
Length = 263

Score = 318 (117.0 bits), Expect = 1.4e-28, P = 1.4e-28
Identities = 89/238 (37%), Positives = 122/238 (51%)

Query: 27 PKPSLSAWPSSVVPANSNVTLCWTPARGVSFVLRKGGIILESPKPL-DSTEGAAEFHLN 85
PKP L A P++VV NVTLCRC P F L K G I +P D + AEF L
Sbjct: 31 PKPWLGAQPATVVTGPNVTLRCRAPQPAPWRFGFLFKPGEI--APLLFRDVSSELAEEFFLE 88

Query: 86 NLKVRNAGEYTCYRKA-SPHILSQRSDDLVLVLTGHLSPFLRTYQRTVTAGGRVTL 144
+ G Y C Y R P + SQ SDVL LLVT L +P L V G V+L
Sbjct: 89 EVTPAQGGSYRCCYRRPDWGPGVWSQPSDVLELLVTEELPRPSLVALPGPVVGPANVSL 148

Query: 145 QCQKRDQLFVPIMFALLKAGTPSPIQLQSPAGKEIDFSLVDVTTAGDAGNYSCMYQTKSP 204
+C R + + F L + G +P+Q + A DF+L+ A G YSC Y+ +P
Sbjct: 149 RCAGRLLR---NMSFVLYREGVAAPLQYRHSAPQPWADFTLLGARA--PGTYSYCYHTPSAP 203

Query: 205 FWASEPSDQLEILVTVPPTSSNYSLGNFVRLGLAAVIVIMGAFLVEAWYSRNVSP 262
+ S+ S E+LV + SS+Y+ GN VRLGLA +++ +GA + W S+N +P
Sbjct: 204 YVLSQRS---EVLVISWEDSGSSDYTRGNLVRLGLAGLVLSLGALVTFDWRSQNRAP 258

FIG. 15